Pre-clinical assessment of genetic and neurobiochemical markers for depressive behavior and antidepressant response by Benton, Cristina S.
i 
 
 
 
 
 
 
 
 
PRE-CLINICAL ASSESSMENT OF GENETIC AND NEUROBIOCHEMICAL MARKERS 
FOR DEPRESSIVE BEHAVIOR AND ANTIDEPRESSANT RESPONSE  
 
 
 
Cristina S. Benton 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the School of 
Pharmacy 
 
 
 
 
 
Chapel Hill 
2011 
 
 
 
 
 
         
         
     Approved by: 
 
     Tim Wiltshire, PhD  
      
     Howard McLeod, PharmD 
 
     Patrick Sullivan, PhD   
         
     J.Heyward Hull, PharmD  
         
     Oscar Alzate, PhD   
 
 
ii 
 
 
 
 
 
ABSTRACT 
 
CRISTINA S. BENTON: Pre-clinical Assessment of Genetic and Neurobiochemical Markers for 
Depressive Behavior and Antidepressant Response  
 (Under the direction of Dr. Tim Wiltshire) 
 
 
Feeling sad and blue, 
Is there a marker for you? 
Tell me, am I blue? 
 
Identification of biomarkers that can establish diagnosis or treatment response is critical 
to the advancement of research and management of patients with major depressive disorder. 
Biomarkers can be used objectively to evaluate clinical progression and response to 
antidepressant therapy. To identify genetic and neurobiochemical biomarkers of antidepressant 
response, we compared  behavior, gene expression, and levels of  thirty-six neurobiochemical 
analytes proposed to affect anxiety and mood disorders between water and fluoxetine-treated 
mice in a panel of genetically diverse mouse inbred lines. While responses in the open field (OF) 
and tail suspension test (TST) contribute to baseline inter-strain differences, chronic fluoxetine 
treatment predominantly affected behavior in the TST, indicating that the TST is sensitive to the 
antidepressive effects of fluoxetine. We found that levels of glyoxylase1 (GLO1) and guanine 
nucleotide binding protein (GNB1) account for most of the covariance in baseline anxiety-like 
and depressive-like behavior. Overall difference in neurobiochemical levels were observed for 
positive and negative responders. Biochemical alterations following chronic fluoxetine treatment 
discriminated positive responders, while baseline neurobiochemical differences differentiated 
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negative responders. Results show that glial fibrillary acidic protein (GFAP), S100 beta protein 
(S100β), GLO1, and histone deacytelase 5 (HDAC5) contributed most to fluoxetine response. 
These proteins are linked within a cellular growth/proliferation pathway, suggesting that positive 
responses to antidepressants are likely due to increased cellular genesis. In addition, a candidate 
genetic locus that associates with baseline depressive-like behavior contains a gene that encodes 
for cellular proliferation/adhesion molecule (Cadm1), supporting a genetic basis for the role of 
neuro/gliogenesis in depression. By using a multi-faceted approach that investigates connections 
on genetic, neurobiochemical, and behavioral levels, we were able to identify genetic and 
neurobiochemical markers that can potentially assess risk for despair and poor treatment 
outcome. Importantly, our research study provides an innovative and powerful platform for pre-
clinical assessment of antidepressant drugs in depressive-like susceptible strains and non-
responsive lines.   
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This dissertation is dedicated to Mrs. C and her family. 
I still remember! 
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CHAPTER 1 
BIOLOGICAL ALTERATIONS IN DEPRESSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work will be published in Psychiatric Disorders - Trends and Developments, Biological 
Alterations in Depression, Toru Uehara (Ed.), ISBN: 978-953-307-716-1, InTech 
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 1. Introduction 
According to the World Health Organization, depression is among the leading cause of 
disability worldwide with approximately 121 million people affected (http://www.who.int). It is 
estimated that 5% of men and 9% of women will experience depression in a given year (Kessler 
et al. 2005). Major Depressive Disorder (MDD) is characterized by persistent depressed mood or 
loss of interest or pleasure from daily activities.  Additionally, patients may experience feelings 
of guilt or worthlessness, as well as psychomotor, physiological, and cognitive disturbances 
(DSM IV). Given that the etiology of depression is unclear, current antidepressant treatments are 
ineffective for most patients. Presently, less than 30% of patients achieve response or remission 
(Trivedi et al. 2006).  Depression is a clinically and genetically heterogeneous disorder, which 
complicates efforts to identify causative factors of disease and replicate findings. In addition, 
diagnosis and therapeutic assessment are primarily based on subjective measures, making patient 
selection and outcome measures amenable to inconsistencies and irreproducibility.  
Biomarkers that objectively establish diagnosis, prognosis, and antidepressant response 
can facilitate research and clinical management of patients with depression. Many analytes, 
including brain-derived neurotrophic factor (BDNF), serotonin transporter, and monoamines, 
have been linked with depressive symptoms and response to antidepressant therapy (Manji et al. 
2001; Nestler et al. 2002; Thase 2007). Although much progress has been made in identifying 
neurobiological correlates of depression, it is unclear whether these alterations are causally 
linked or are due to disease and/or treatment.  With the goal of facilitating the search for 
depression biomarkers, this chapter will discuss several key molecular and neurochemical 
alterations that have been linked with depressive disorder.       
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2. Genetic Studies 
 
The role of genetics in the development of MDD is supported by findings from family, 
twin, and adoption studies. Studies that compared the prevalence of depression in monozygotic 
versus dizygotic twins indicate a heritability estimate of 35-50% (Bierut et al. 1999; Kendler et 
al. 1993; Sullivan et al. 2000). There is a two-to-threefold increased risk of developing MDD 
among first degree relatives of depressed individuals (Kelsoe 2004; Sullivan et al. 2000), 
indicating that genetic variants can be used as prognostic and diagnostic biomarkers.  There are 
two widely used approaches to determine genetic markers of depression. Candidate gene analysis 
examines the frequency of genetic alleles between cases and controls. Hypotheses are generated 
a priori based on the likelihood that the gene affects the risk of depression. Alternatively, 
advances in genotyping capabilities and more recently, gene sequencing, have enabled scientists 
to look for unbiased genome-wide associations between common single nucleotide 
polymorphisms (SNPs) and behavior.  Genes that confer risk to depression have been primarily 
identified using candidate gene analysis approach, while recent efforts to uncover genetic 
markers of antidepressant response include the Sequenced Treatment Alternatives to Relieve 
Depression (STAR*D) trial and Genome-Based Therapeutic Drugs for Depression (GENDEP) 
study, which looked at genome-wide associations of common variants with antidepressant 
response. Genetic studies of depression (Levinson 2006; Lohoff 2010; Shyn and Hamilton 2010) 
and antidepressant response (Crisafulli et al. 2011; Kato and Serretti 2010; Porcelli et al. 2010)  
are reviewed in this chapter with a focus on several genes.  
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2.1 Genetic Predictors of Depression and Antidepressant Response 
Antidepressant medications primarily work on altering neurotransmitters in the brain, 
thus much attention has been given to genes within the monoaminergic pathway (Kato and 
Serretti 2010). An insertion/deletion polymorphism on the 5‟ promoter region of the serotonin 
transporter gene (5-HTTLPR) produces a long (L) allele or a short (S) lower-expressing allele. 
The 5-HTTLPR variant alters expression of the serotonin transporter in vitro (Lesch et al. 1996) 
and has been linked with MDD (Caspi et al. 2010; Goldman et al. 2010; Uher and McGuffin 
2010), neuroticism (Lesch et al. 1996), affective disorder (Collier et al. 1996; Lasky-Su et al. 
2005), suicidality (Anguelova et al. 2003; Lin and Tsai 2004), and anxiety related personality 
traits (Schinka et al. 2004; Sen et al. 2004). Patients with the low expressing allele exhibited 
increased amygdala activation in response to sad faces (Hariri et al. 2002), reduced gray matter 
volume in amygdala and perigenual cingulate cortex (Pezawas et al. 2005), as well as altered 
functional coupling in both regions (Pezawas et al. 2005), thus supporting the role of the 
serotonin transporter in the development of the amygdala-cingulate feedback circuitry. Carriers 
of the S allele who experienced stressful life events in the past were more vulnerable to 
depression and suicidality (Caspi et al. 2003; Kendler et al. 2005). However, several groups did 
not find an association between depression and 5-HTTLPR alone (Middeldorp et al. 2010; 
Munafo and Flint 2009; Risch et al. 2009) or in interaction with stressful life events (Risch et al. 
2009).  Homozygous carriers of the L allele showed higher response and remission rates (Serretti 
et al. 2005) and more favorable side effect profiles (Kato and Serretti 2010; Kraft et al. 2007; 
Murphy et al. 2004), which did not replicate in a recent large clinical trial (Kraft et al. 2007). 
Altogether, these findings indicate that environment must be taken into account when evaluating 
the potential use of 5-HTTLPR as a genetic marker of depression.   
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Other genes in the monoamine pathway have been studied for their link with depressive 
behavior. The serotonin-1A receptor (HTR1A) is located in the serotonergic neurons and on their 
post-synaptic targets. In the pre-synaptic neuron, 5HT1A auto-inhibits raphe firing and 5-HT 
synthesis. The -1019C/G variant (rs6295) found in the promoter region of HTR1A results in 
higher expression of serotonin-1A auto-receptor (5-HT1A), which leads to reduction in 
serotonergic neurotransmission (Stahl 1994). The -1019C/G mutation is correlated with anxiety 
and depression (Gross et al. 2002; Lemonde et al. 2004; Strobel et al. 2003). In Asians, the G 
allele is associated with improved treatment outcomes (Hong et al. 2006; Kato et al. 2009).  
However, this finding was not observed in Caucasians (Lemonde et al. 2004; Serretti et al. 
2004), suggesting a confounding effect of race. The relationship between HTR2A and 
antidepressant response is unclear due to conflicting results (reviewed in Kato 2010). A recent 
meta-analysis did not find any association between HTR1A and HTR2A and treatment response; 
however, a polymorphism within HTR2A was correlated with tolerability (Kato and Serretti 
2010).  No association has been established between HTR2A and MDD (Anguelova et al. 2003).  
The tryptophan hydroxylases 1 and 2 (TPH1 and TPH2) catalyze the rate-limiting step in 
5-HT biosynthesis. A functional variant in TPH2 (Arg441His) results in 80% reduction of 5-HT 
in the brain (Zhang et al. 2004) and was found to be more frequent in patients with MDD (Zhang 
et al. 2005). However, other studies failed to replicate this finding (Delorme et al. 2006). 
Furthermore, the TPH 218A allele is associated with poor antidepressant response (Serretti et al. 
2001a; Serretti et al. 2001b), a finding that was supported by a meta-analysis study (Kato and 
Serretti 2010). Patients with the 218 C/C genotype were more likely to respond to antidepressant 
therapy (Kato and Serretti 2010). Interestingly, the significant pooled odds ratio score (OR) was 
primarily influenced by the sum of the three studies that looked at the association between 
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remission rates and the 218 genotype, suggesting that the TPH gene may be important in 
regulating long-term antidepressant response. Of interest is the recent correlation between TPH2 
haplotype markers and suicidality (De Luca et al. 2004; Lopez et al. 2007), suggesting that TPH2 
may mediate a subset of depressive symptoms like suicidal thoughts and feelings of guilt and 
worthlessness.  
Enzymes that mediate clearance of catecholamines, including monoamine oxidase A 
(MAO-A) and catechol-O-methyl transferase (COMT) have been linked to antidepressant 
response. Higher transcription efficiency is observed with the variable number tandem repeat 
(VNTR) sequence located 1.2kb upstream of the MAO-A gene (Sabol et al. 1998). Alternatively, 
the Val to Met substitution at codon 158 for membrane-bound COMT protein (codon 108 for 
soluble COMT) has been linked to lower enzymatic activity (Mannisto and Kaakkola 1999) and 
improved response to citalopram (Arias et al. 2006) and mirtazapine (Szegedi et al. 2005) but not 
paroxetine (Arias et al. 2006; Szegedi et al. 2005).  
A locus on Chr. 12 has been linked with MDD (Abkevich et al. 2003; McGuffin et al. 
2005) and anxiety (Erhardt et al. 2007). Within this putative region lies the purinergic ATP-
binding calcium channel gene (P2X7). A non-synonymous coding SNP within P2X7 
(Gln460Arg) is associated with MDD risk (Lucae et al. 2006). P2X7 protein is required for IL-1 
(interleukin-1) processing and secretion (Ferrari et al. 2006), highlighting the potential role of 
immune function in depressive behavior. Moreover, the FK506 binding protein 5 (FKBP5) in 
complex with Hsp90 regulates glucocorticoid receptor sensitivity. A functional variant within 
FKBP5 that results in increased intracellular concentration of FKBP5 has been linked with 
recurrence of depressive episodes (Binder et al. 2004) and antidepressant response (Binder et al. 
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2004; Lekman et al. 2008b). FKBP5 activates glucocorticoid receptors and the hypothalamic-
pituitary-adrenal axis, which regulate response to stress (Binder et al. 2004). Additionally, the 
corticotropin releasing hormone 1 (CRH1) variant is correlated with early onset of depressive 
symptoms (Papiol et al. 2007). CRH activates the HPA axis, thus supporting the role of the HPA 
axis in mediating depressive behavior.  
Small low-powered studies were combined in a meta-analysis to clarify the associations 
of several genes with depression, which were unclear due to inconsistent or non-replicated 
findings. Lopez-Leon et al. found a protective effect for the APOE 2 allele (combined OR, 0.51; 
95% CI, 0.27-0.97) with no evidence of between-study heterogeneity (Lopez-Leon et al. 2008).  
Alternatively, an increased risk was found for the methylenetetrahydrofolate reductase MTHFR 
C677T polymorphism (pooled OR, 1.36),  the guanine nucleotide binding protein 3 GNB3 
C825T variant (pooled OR, 1.38; 95% CI, 1.13-1.69), and the dopamine transporter SLC6A3 40 
bp VNTR (pooled OR, 2.06; 95% CI, 1.25-3.40)  (Lopez-Leon et al. 2008).   
 
Pharmacogenetic studies of antidepressants in the STAR*D trial have identified genes 
associated with treatment response (Hu et al. 2007; Lekman et al. 2008a; McMahon et al. 2006; 
Paddock 2008), treatment resistance (Perlis et al. 2008), and treatment-emergent suicidal ideation 
(Laje et al. 2009; Laje et al. 2007; Perlis et al. 2007). In addition, polymorphisms in genes that 
encode drug-metabolizing enzymes and transporters have been tested for correlation with 
treatment response (Peters et al. 2008). Genes that were significantly associated with response to 
citalopram include FKBP5 (Lekman et al. 2008a), glutamate receptor, ionotropic kainite 1 
(GRIK1), N-methyl d-aspartate 2A (GRIN2A), 5-hydrxytryptamine receptor 2A (HTR2A), 
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potassium channel, subfamily K, member 2 (KCNK2), phosphodiesterase (PDE), and solute 
carrier family 6 member 4 (SLC6A4) (Lin and Chen 2008). 
A link between genes and depression exists, however, putative genes identified to date do 
not significantly account for the phenotypic variance observed (Mann and Currier 2006).  
Although these initial results may seem disappointing, they indicate that the genetics of 
depression is far from simple. It is likely that multiple genes with minor effect sizes interact with 
environmental factors to affect mood, making identification of genetic biomarkers challenging.  
Efforts to investigate gene by environmental effects can further delineate the contribution of each 
gene on disease and treatment outcomes (Lesch 2004; Wermter et al. 2010). 
3. Biochemical Alterations 
 
Several mechanisms are altered in depression and these include neurotransmission, 
neuroendocrine signaling, and neuroimmune functions. It is unclear whether these biochemical 
alterations are products or causative factors of depression. This section will discuss common 
biological alterations that have been observed in depression, facilitating identification of 
candidate biochemical markers for depression and antidepressant response. 
3.1 Monoamines 
The monoamine theory of depression developed following the observation that 
iproniazid, a drug that inhibits the metabolism of monoamines by blocking MAO, improved the 
mood of patients who are taking the drug (Delay et al. 1952).   In addition, depletion of 
monoamines by agents like reserpine was found to induce depression (Goodwin and Bunney 
1971). This theory led to the development of antidepressant drugs that elevate monoamine levels 
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at the synapse by blocking uptake transporters, catabolic enzymes or inhibitory pre-synaptic 
auto- or hetero-receptors. The monoamines provided a biochemical basis for depression, 
whereby depression was thought to result from a „chemical imbalance‟ of monoamines in the 
brain (Schildkraut 1965).  However, several observations have cast doubt on the major role of 
monoamines in MDD. In addition to the untimely manner in which elevation of monoamines 
occur with respect to symptom resolution (Baldessarini 1989), treatments that do not elevate 
monoamine levels like electroconvulsive therapy (ECT) have been effectively shown to treat 
depression (Pagnin et al. 2004). The monoamine theory of depression was then modified to 
indicate that elevation of monoamines is the first step in a cascade of molecular events that 
ultimately leads to symptom improvement (Pineyro and Blier 1999). Research focus began to 
shift towards evaluating the long-term adaptive changes that result from increased monoamines 
in the synapse. It was hypothesized that elevation in monoamines leads to reduction in the 
sensitivity and/or number of monoamine receptors. Although desensitization and internalization 
of monoamine receptors have been observed in several animal and post-mortem studies, results 
were often inconsistent and conflicting (Elhwuegi 2004). Effective antidepressant agents that do 
not act by inhibiting monoamine reuptake proteins or metabolizing enzymes can still facilitate 
receptor internalization despite the absence of pre-synaptic input (Fishman and Finberg 1987; 
Kientsch et al. 2001). More recently, it has been shown that monoamine elevation may lead to 
cellular genesis. Various antidepressant agents, including specific serotonin reuptake inhibitor 
(fluoxetine), monoamine oxidase inhibitor (tranylcypromine), specific norepinephrine reuptake 
inhibitor (reboxetine), and serotonin/norepinephrine uptake inhibitor (tricyclic antidepressants) 
have been shown to induce cell proliferation and neurogenesis (Santarelli et al. 2003), which 
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suggests that monoamine elevation leads to other downstream molecular effects that can alter 
behavior.   
Despite decades of research aimed to evaluate the relationship between depression and 
monoamine alteration, direct evidence supporting the causative role of monoamines in MDD is 
lacking (Nestler 1998), thus prompting efforts to study other pathways that may underlie 
depressive behavior.  
3.2 Hypothalamic Pituitary Adrenal (HPA) axis 
Dysregulation in the HPA axis, which is characterized by elevated plasma cortisol and 
CRH is a common finding in depressed patients (Holsboer 2000; Raison and Miller 2003). In 
response to stress, the parvocellular neurons in the hypothalamus secrete CRH, stimulating the 
release of adenocorticotropin releasing hormone (ACTH) from the anterior pituitary. ACTH, in 
turn, activates the synthesis and release of glucocorticoids (cortisol from humans and 
corticosterone in rodents) from the adrenal cortex. Glucocorticoids negatively regulate the HPA 
axis by inhibiting the synthesis and release of CRH from the hypothalamus.  
Activation of the HPA axis mediates physiologic adaptation to stress, however, persistent 
stimulation can lead to glucocorticoid receptor (GR) desensitization (de Kloet et al. 2005).  
Patients with depression typically exhibit high levels of cortisol in plasma, saliva, and urine, as 
well as an increase in the size and activity of the pituitary and adrenal glands (Nemeroff and 
Vale 2005). Impairment of the HPA axis, which is primarily characterized by the inability to 
suppress cortisol levels following pharmacologic stimulation of GR by dexamethasone, has been 
observed in depressed patients (Ising et al. 2005; Kunzel et al. 2003; Sher 2006). HPA alterations 
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normalize with antidepressant therapy (Holsboer 2000) and this is associated with less relapse 
(Ising et al. 2007). Glucocorticoids not only exhibit immune and metabolic functions but they 
also regulate neurogenesis, neuronal survival, hippocampal size and structure, and acquisition of 
new memories (Herbert et al. 2006). Reduced maternal handling increases CRH signaling (Ladd 
et al. 1996) and sustains HPA hyperactivity, inducing depressive-like behavior in the pups 
(Francis et al. 1999; Meaney 2001). In humans, early stressful life event is associated with 
dysregulated HPA axis (Heim et al. 2002) and development of depressive symptoms (Chapman 
et al. 2004; McCauley et al. 1997). One of the mechanisms by which antidepressants induce 
hippocampal neurogenesis is by activating GR (Anacker et al. 2011), thus implicating a direct 
relationship between HPA axis and neural brain signaling.   
3.3 Other Neuroendocrine Markers 
It was discovered that hypothyroidism elicits depressive behavior and that these 
symptoms can be reversed by thyroxine therapy (Asher 1949). Similar symptoms are observed in 
depression and hypothyroidism, which include dysphoric mood, fatigue, anhedonia, and 
alteration in weight (Jackson 1998). Low levels of thyroid hormones (T3 and T4) stimulate the 
release of thyrotropin releasing hormone (TRH) from the hypothalamus to the anterior pituitary. 
The pituitary, in turn, releases thyrotropin-stimulating hormone (TSH), which leads to the release 
of triiodothyronine (T3) and thyroxine (T4) from the thyroid. Thyroid hormones primarily 
regulate metabolism but may also be involved in neurotransmission (Dratman and Gordon 1996). 
Although not all depressed patients display abnormalities in thyroid function, alterations have 
been observed, including elevation in T4 (Baumgartner et al. 1988; Kirkegaard and Faber 1991), 
lower TSH levels (Maes et al. 1989), as well as blunted response of TSH to TRH (Hein and 
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Jackson 1990; Maes et al. 1989). Type-II deiodinase (D-II) catalyzes deiodination of T4 to T3. 
Psychotropic medications like lithium (Baumgartner et al. 1994b), desipramine (Campos-Barros 
et al. 1994), carbamezapine (Baumgartner et al. 1994a), and fluoxetine (Baumgartner et al. 
1994c) stimulate the activity of D-II, indicating that mood regulatory agents indirectly regulate 
T3 levels. Another group, however, did not find any effects of antidepressant on thyroid function 
(Brambilla et al. 1982). Interestingly, one study found that morning and nocturnal changes in 
TSH may predict antidepressant response (Duval et al. 1996). 
There is increasing evidence implicating the involvement of stress-responsive 
neuropeptide systems in depression and anxiety. The involvement of various neuropeptides has 
been reviewed (Alldredge 2010; Holmes et al. 2003) and a number of them will be described 
here. Administration of neuropeptide antagonists/agonists results in altered responses in rodent 
models of anxiety and depression (Rotzinger et al. 2010). Stress stimulates the release of 
vasopressin, which in turn enhances the effects of CRH on ACTH (Aguilera et al. 2003; 
Engelmann et al. 2004; Zhou et al. 2001). Depressed patients display altered levels of 
vasopressin in the suprachiasmatic nucleus (SCN) (Zhou et al. 2001), paraventricular nucleus 
(Purba et al. 1996), and supraoptic nucleus (Meynen et al. 2006). A polymorphism in the 
vasopressin receptor (V1B) may be protective against MDD (Overstreet and Griebel 2005; 
Salome et al. 2006). Antagonism of the V1B receptor reduced depressive-like behavior (Griebel 
et al. 2002), which was comparable to treatment with antidepressant agents (Salome et al. 2006). 
This effect was mainly due to inhibition of the V1B receptors in the lateral septum and amygdala 
(Stremmelin 2005). Similar to vasopressin, the neuropeptide Y (NPY) is released under stress. 
NPY is abundantly expressed in the brain and is co-localized with noradrenaline, somatostatin, 
and GABA (γ-aminobutyric acid) (Kask et al. 2002). Reduction in NPY is associated with 
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increased sensitivity to depression and stress, indicating that NPY agonists may exhibit 
antidepressive effects (Redrobe et al. 2002). A variant in the promoter region of Npy alters the 
expression of NPY in vivo and is linked with anxiety behavior and neural responses to stress 
(Zhou et al. 2008). Substance P (SP), a known modulator of pain signaling, has been shown to 
interact with serotonergic signaling (Schwarz et al. 1999). Substance P binds to neurokinin-1 
(NK1) receptors found in the brain and in the periphery. Genetic ablation or pharmacologic 
antagonism of NK1 receptors promotes monoaminergic activity (Froger et al. 2001; Maubach et 
al. 2002; Santarelli et al. 2001) and reduces anxiety-like behavior (Santarelli et al. 2001).  
Depressed patients have higher SP levels in the serum (Bondy et al. 2003). Interestingly, NK1 
antagonists activate the serotonergic system similarly to a serotonin reuptake inhibitor 
(escitalopram) (Guiard et al. 2004), indicating that NK1 antagonists may have antidepressive 
effects. Galanin is a 29-30 amino acid peptide that regulates various physiological responses like 
metabolism and food intake. Galanin binds to several galanin receptors (GALR), which in turn 
interact with different G proteins, activating various signal transduction pathways (Smith et al. 
1998; Wang et al. 1998).  Galanin administration in rodents produces a variety of effects, 
including nerve regeneration, nociception, and alteration in sexual and feeding behavior (Wrenn 
and Crawley 2001; Yoshitake et al. 2003). Galanin mediates 5-HT and norepinephrine levels 
(Ogren et al. 2006) and antagonism of GALR can enhance or reduce depressive-like behavior 
depending on which GALR subtype is being inhibited (Barr et al. 2006; Lu et al. 2005).  
Many years of research implicate the role of the neuroendocrine system in depression. 
Most neuroendocrine regulatory mechanisms occur through the bidirectional communication 
between the hypothalamus and pituitary. These findings indicate that the neural circuitry, 
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neuronal signaling, and structural plasticity within this region are likely to be critical in 
behavioral responses.  
4. Metabolic Alterations 
Metabolic syndrome is comprised of several features, including central obesity and 
insulin resistance, which, in concert, increases risk for developing cardiovascular disease and 
diabetes. Compared to healthy controls, depressed individuals are more likely to develop obesity, 
diabetes, and hypertension (Lindley et al. 2009), indicating potential overlap between depressive 
symptoms and metabolic syndrome. Independent of the criteria used to define metabolic 
syndrome (Raikkonen et al. 2007), a strong bidirectional association between depression and 
metabolic syndrome exists in women (Gil et al. 2006; Kinder et al. 2004; Raikkonen et al. 2007). 
The correlation between depressive symptoms and metabolic syndrome is slightly higher in 
monozygotic twins than dizygotic twins, suggesting that genetics play a critical role in both 
disorders (McCaffery et al. 2003). Resistance to insulin, which is a risk factor for developing 
metabolic syndrome, is a common occurrence in depressed patients (Koslow et al. 1982; 
Okamura et al. 2000; Winokur et al. 1988), which suggests that insulin links depression with 
metabolic syndrome. Insulin exerts dose-dependent effects on food intake and energy regulation. 
Ablation of insulin receptors on neuronal cells leads to increased body fat disposition, suggesting 
that insulin negatively regulates adiposity (Bruning et al. 2000). Additionally, insulin regulates 
monoamine uptake and metabolism, phosphoinositol turnover, as well as norepinephrine and 
dopamine transporter mRNA levels (Craft and Watson 2004). It has been shown that insulin can 
recruit GABA receptors (Wan et al. 1997) and promote internalization of α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) receptors, which suggests that insulin plays a critical 
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role in neuronal signaling and synaptic plasticity (Huang et al. 1998). Interestingly, brain volume 
abnormalities and neurocognitive deficits commonly found in MDD patients have been observed 
in individuals with diabetes mellitus (DM), suggesting overlapping pathophysiology between 
MDD and DM (McIntyre et al. 2010). Insensitivity to insulin likely develops due to HPA axis 
hyperactivity (Rizza et al. 1982), impaired immune system (Fernandez-Real et al. 2001; Maes 
1995; Moller 2000), and altered central serotonergic signaling (Goodnick et al. 1995; Horacek et 
al. 1999), all of which are common findings in depressed patients (Belmaker 2008; Krishnan and 
Nestler 2008). 
Association between depression and obesity has been identified in several cross sectional 
studies (de Wit et al. 2010; Faith et al. 2002; Scott et al. 2008). A recent meta-analysis looked at 
the association between obesity and depression in a community-based setting and found that 
obese patients have an 18% increased risk of developing depressive symptoms (overall OR, 
1.18) (de Wit et al. 2010). Subsequent sub-group analyses showed that the association with 
obesity holds true for depressed women but not for men, which suggests that comorbidity is 
likely to be affected by sex (de Wit et al. 2010).  Similarly, a meta-analysis of longitudinal 
studies showed that baseline obesity increased the risk of depression (pooled OR, 1.57) and that 
depression increased the odds for developing obesity (pooled OR, 1.40). Prospective analysis of 
the cause-effect relationship between obesity and depression indicate reciprocal findings, 
whereby obesity was found to be a predictor of depression in eight out of the ten studies 
reviewed, while 53% of the studies found that depression predicts obesity (Faith et al. 2011). 
Interestingly, the positive association between depression and obesity is only detected in studies 
conducted in the United States but not in other European countries, indicating a strong 
contributory effect of environment (Atlantis and Baker 2008). It is increasingly recognized that 
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similar neural circuitry that regulate memory, reward, mood, and emotion also controls appetite, 
body weight, and energy homeostasis (Dallman 2009; Zheng et al. 2009).  
Food induces olfactory and visual sensory inputs, which stimulate the orbitofrontal 
cortex, where acquisition, storage, and processing of memory and experiences associated with 
food is thought to occur (Verhagen 2007). Stimulation of the mu-opioid receptor in the nucleus 
accumbens and ventral pallidum results in further intake of pleasurable foods (Will et al. 2003; 
Zhang and Kelley 2000). The ventral tegmental area and the nucleus accumbens are part of the 
mesolimbic dopaminergic system, which regulates behavioral response (motivation) towards 
favorable stimuli (Berridge 1996; 2007; Pecina et al. 2006), indicating that food intake and 
motivation are, at least partly, co-regulated by similar circuitry. The hypothalamus regulates 
homeostatic responses to altered nutrient levels and adiposity levels (Berthoud 2002; Xue and 
Kahn 2006) through various endocrine hormones, including leptin (Farooqi et al. 2002; Friedman 
1999; O'Rahilly 2002) and NPY (Luquet et al. 2005).  Although leptin is primarily known for its 
role in appetite suppression and energy expenditure, leptin also mediates reproduction and 
cognition (Chehab 2000; Farr et al. 2006). Independent of body mass, depressed patients show 
lower plasma levels of leptin (Jow et al. 2006; Kraus et al. 2001) although other studies did not 
find similar results (Antonijevic et al. 1998; Deuschle et al. 1996; Rubin et al. 2002). Rodents 
exposed to chronic unpredictable stress showed reduction in sucrose preference and higher 
depressive-like behavior, which was reversed by leptin administration, indicating that leptin 
exhibits antidepressive effects likely through innervations of the limbic brain circuitry (Lu et al. 
2006). In response to stressful events, leptin suppresses CRH, ACTH, and corticosterone 
secretion, suggesting a direct impact of leptin on the HPA axis (Ahima et al. 1996; Heiman et al. 
1997; Huang et al. 1998). In addition, leptin-deficient ob/ob mice display altered Slc6a4 
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expression (Collin et al. 2000), decreased neuronal and glial cells, and reduced brain weight and 
cortical volume (Ahima 1999, Stepan 1999), further supporting the role of leptin in MDD.  
A common thread between MDD, DM, and heart disease exists. The co-occurrence and 
pathophysiologic overlap between metabolic syndrome, obesity, and depression may explain the 
significant association between depression, diabetes, and cardiovascular disease (Frasure-Smith 
et al. 1993; Goldney et al. 2004; Paile-Hyvarinen et al. 2007).     
5. Neuroimmune 
An interaction between behavior and the immune system was first recognized in 200 AD, 
when Galen observed that melancholic women were more susceptible to cancer (Leonard 1988). 
Depressed patients exhibit reduced neutrophil phagocytosis, natural killer cell activity, and 
mitogen stimulated lymphocyte proliferation (Irwin et al. 1990). Furthermore, patients with 
MDD show increased cytokine secretion from activated macrophages and elevated acute phase 
proteins in the liver (Sluzewska et al. 1996), indicating dysregulation in immune response. 
Antidepressants inhibit the ability of lipopolysaccharide (LPS) to induce the synthesis and the 
release of pro-inflammatory cytokines, likely through elevation of cyclic adenosine 
monophosphate (cAMP) levels (Xia et al. 1996). It has been hypothesized that abnormal 
secretion of macrophage monokines leads to depressive behavior (Smith 1991). Macrophages 
secrete neuroendocrine and immune modulators, including interleukins (IL), tumor necrosis 
factors (TNF), ACTH, and endorphins (Nathan 1987), thus indicating a regulatory role for 
macrophages in mediating the neuro-endocrine-immune interface. 
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A bidirectional relationship between the brain, neuroendocrine, and immune systems 
exists, particularly in response to stress. Overactivity of the HPA axis, which is a common 
finding in depressed individuals (Holsboer 2000; Raison and Miller 2003), results in 
hypercortisolemia and suppression of the immune system. Conversely, persistent stress can result 
in fewer B cells, T cells, and lymphocytes (Olff 1999), which can confer susceptibility to 
infections and cancer (Garssen and Goodkin 1999; Kiecolt-Glaser et al. 1995; Reiche et al. 
2005). Stressful events like separation or divorce are correlated with increased cancer risk, low 
proportions of NK and T cells, impairment of DNA repair, and abnormal immune response 
(Kiecolt-Glaser et al. 1987). The presence of reactive oxygen species has been detected in 
depressed patients (Irie et al. 2005). Levels of 8-hydroxydeoxyguanosine (8-OH-dG), a 
biomarker of cancer-related oxidative DNA damage, is positively correlated with depressive 
symptoms (Irie et al. 2005), which suggests that depression may be associated with cancer.  
 
In 1987, Wagner-Jauregg demonstrated that activation of the immune system can affect 
various mental states (Raju 1998). Cytokines regulate growth, differentiation, and function of 
many cells (Turnbull and Rivier 1999). They can be broadly classified as pro-inflammatory or 
anti-inflammatory cytokines. Pro-inflammatory cytokines like interleukin-1 (IL-1), interleukin-6 
(IL-6), and TNF-α stimulate immune cell production, activation, and proliferation. On the other 
hand, anti-inflammatory cytokines, including interleukin-4 (IL-4), interleukin-10 (IL-10), and 
interleukin-13 (IL-13) dampen the immune response. The role of cytokines in depression was 
identified following observation that interferon treatment induces „sickness behavior,‟ which 
mimics depressive symptoms such as dysphoric mood, fatigue, anorexia, weight loss, and altered 
sleep patterns (Papanicolaou et al. 1998; Yirmiya 2000). Depression is characterized by elevation 
19 
 
of pro-inflammatory markers  IL-6, c-reactive protein (CRP) (Maes 1995), IL-1, and IL-2 (Dunn 
et al. 2005; Song et al. 1994). Treatment with LPS stimulated depressive-like behavior and 
cytokine secretion, which were reversed by antidepressants or cytokine antagonists (Yirmiya 
2000). Administration of IL-6 and IL-1 results in elevation of vasopressin, cortisol, CRH, and 
ACTH (Brebner et al. 2000; Harbuz et al. 1992; Xu et al. 1999), which suggests a pivotal role of 
cytokines in HPA axis activation (Dentino et al. 1999). In rodents, treatment with IL-1 resulted 
in increased DA, NE, and 5-HT activity in the brain (Dunn and Swiergiel 1999; Merali et al. 
1997; Song et al. 1999). Cytokines acutely stimulate 5-HT neurotransmission and reduce its 
production by stimulating indoleamine 2,3-dioxygenase (IDO), an enzyme that converts the 
precursor of 5-HT (tryptophan) into kynurenine (Wichers and Maes 2002). Pro-inflammatory 
cytokines have been shown to up-regulate serotonin transporter (Morikawa et al. 1998; Mossner 
and Lesch 1998; Wichers and Maes 2002), while anti-inflammatory cytokines like IL-4 reduces 
5-HT uptake (Mossner et al. 2001). Together, these findings suggest that cytokines affect 
depressive behavior likely through regulation of monoamines and the HPA axis.  
The symptom heterogeneity observed in depressed patients suggests that biological 
abnormalities are likely to be patient-dependent and disease-specific. Collectively, these results 
indicate that biochemical mechanisms likely interact to mediate a complex behavior like mood 
and anhedonia. It is therefore unlikely that a single biological marker will characterize a 
heterogeneous disorder like depression. Significant benefits can be rendered in evaluating the 
behavioral effects of a panel of biological markers or biochemical signatures, particularly since 
reciprocal communication between nervous, endocrine, and immune systems have been noted 
(Cserr and Knopf 1992; Felten 1991; Reichlin 1993). For most cases, when associations between 
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biochemical alterations and depression are detected, the causal relationship is often poorly 
understood. 
6. Brain and Molecular Correlates  
 
Direct and indirect evidence from neurostructural, neurofunctional, and molecular studies 
indicate impairments in neural circuitry, structural plasticity, and cellular resilience. These 
abnormalities reflect the molecular neurobiological underpinnings of depression as discussed 
below. 
6.1 Neurostructural and Neurofunctional Studies  
The cortical-limbic circuitry is implicated to mediate emotional processing in depressed 
patients (Davidson et al. 2002; Dougherty and Rauch 1997; Mayberg 1997). Results from 
positron emission tomography (PET) studies indicate that unmedicated patients with MDD 
exhibit increased activity and cerebral blood flow (CBF) to the amygdala, orbital cortex, and 
medial thalamus, as well as decreased CBF to the pre-frontal cortex (PFC) and anterior cingulate 
cortex (ACC) (Drevets 2000a; Drevets et al. 1999).  Meta-analyses of structural neuroimaging 
studies indicate that MDD is characterized by reduction of gray matter volumes in the ACC 
(Koolschijn et al. 2009), subgenual cingulate cortex (Hajek et al. 2008), and hippocampus 
(McKinnon et al. 2009).  Post-mortem neuropathological studies have shown that patients with 
MDD exhibit reduced cortex volume, decreased number of glial cells, and/or reduced neuron 
sizes (Ongur et al. 1998; Rajkowska 2000; Rajkowska et al. 1999). Given the functional roles of 
specific brain regions in emotional processing, neuropathological abnormalities observed in 
depression suggest that areas that mediate autonomic and neuroendocrine responses (amygdala) 
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are associated with increased activity and cerebral blood flow, while reduction in activity is 
observed in brain regions that control emotional processing (cortex) (Manji et al. 2001). 
Antidepressant treatment reduces CBF and metabolism in the amygadala (Drevets 2000b; 
Drevets et al. 1999), attenuating hyperresponsiveness to stress (Rosenkranz et al. 2010). 
Similarly, larger hippocampal volume (Frodl et al. 2008; Kronmuller et al. 2008; MacQueen et 
al. 2008) and gray matter density in the ACC (Costafreda et al. 2009) were positively correlated 
with antidepressant response.   
Inferences regarding the structural integrity of neural tracts can be made through 
diffusion tensor imaging (DTI), which measures the diffusion properties of water through brain 
tissues, in vivo. Patients that did not respond to 12 weeks of escitalopram (Alexopoulos et al. 
2008) or citalopram (Alexopoulos et al. 2002) treatment showed microstructural abnormalities in 
white matter pathways connecting the cortex with the limbic and paralimbic areas, which 
indicates that poor therapeutic outcome is related to impaired cortical-limbic connectivity 
(Mayberg 2003). Patients with prior exposure to parental verbal abuse (Choi et al. 2009) or have 
genetic polymorphisms (5-HTTLPR) (Alexopoulos et al. 2009) exhibit microstructural white 
matter abnormalities, suggesting that neural brain structure is subject to genetic and 
environmental control. Of note, impairment in brain morphology, neural circuitry, and brain 
function have been linked with monoaminergic and non-monoaminergic genetic variants 
(Scharinger et al. 2010).  In addition to evaluating the structural integrity of neural brain circuits, 
functional activity within the limbic-cortical circuitry has been investigated. Brain activity can be 
evaluated by measuring blood oxygen level-dependent (BOLD) signals while patients are resting 
(intrinsic activity) or when performing a task (task-related activity). BOLD signaling is 
associated with changes in blood flow and tissue oxygen concentration, which are markers of 
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brain activity. Depressed individuals have reduced activity in the limbic and cortical regions 
(Anand et al. 2005), which normalizes as symptoms resolve (Anand et al. 2005). Patients with 
MDD show hyperactivity in the amygdala (Surguladze et al. 2005) and reduced co-activation of 
the dorsal ACC (Matthews et al. 2008)  when viewing negative facial expressions. These 
changes in brain activity are ameliorated with chronic antidepressant treatment (Chen et al. 2008; 
Fu et al. 2004; Sheline et al. 2001).  
Similar to the electrocardiogram (ECG), unfiltered electrical activity generated by the 
brain can be measured by an electroencephalogram (EEG). EEG signals can be converted to 
show a topographical representation of the distribution of the EEG waveforms across the cortex 
known as the quantitative electroencephalograph (QEEG) brain map. The QEEG image is used 
to assess brain activity and metabolism in real-time, providing a global assessment of brain 
activity. Brain electrical activity can be measured using cordance, low-resolution brain 
electromagnetic tomography (LORETA), and antidepressant treatment (ATR) index. Cordance, 
which uses QEEG measurements conducted from a full scalp electrode array, assesses perfusion 
of cerebral cortex and brain activity on cortical convexities like PFC (Cook et al. 1998; Leuchter 
et al. 1999). Several groups have demonstrated the usefulness of cordance in characterizing 
antidepressant response (Bares et al. 2008; Cook et al. 2002). Responders and non-responders 
differ in QEEG measurements at rest and during task-oriented activities (Bruder et al. 2008).  
LORETA, which assesses activity of deeper cortical regions like ACC and orbitofrontal cortex 
(Pizzagalli et al. 2001), identifies cortical alterations in relation to depression and antidepressant 
response (Anderer et al. 2002; Saletu et al. 2010). Both cordance and LORETA require whole-
head electrode montages for data collection, which entails up to 75 minutes of QEEG recording, 
limiting its clinical utility. On the other hand, the ATR only uses a five-electrode montage on the 
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frontal brain regions, which limits QEEG recording to 10 minutes (Leuchter et al. 2009a; 
Leuchter et al. 2009b). The largest study that evaluated the use of ATR in predicting 
antidepressant response is the Biomarkers for Rapid Identification of Treatment Effectiveness 
trial in Major Depression (BRITE-MD) trial. In this study, positive ATR predicted response and 
remission to escitalopram. Patients with negative ATR values were either switched to bupropion 
or continued to be treated with escitalopram. In comparison to patients who stayed on 
escitalopram, patients who switched to bupropion were 1.9 times more likely to respond to 
treatment (Leuchter et al. 2009a; Leuchter et al. 2009b). These findings support the use of ATR 
as a biomarker for monitoring treatment response and clinical progression. 
6.2 Cellular and Molecular Markers 
Lower hippocampal volume (Videbech and Ravnkilde 2004), which is commonly found 
in post-mortem brain tissues of depressed individuals (MacQueen et al. 2003), results in reduced 
hippocampal plasticity. Reduction in neurogenesis, brain volume, and thickness is likely due to 
decreased neurotrophins and/or changes in neuroplasticity (Geuze et al. 2005). Neurotrophins, 
including brain-derived neurotrophic factor (BDNF), have been repeatedly implicated in the 
pathogenesis and treatment of MDD (Duman and Monteggia 2006). Administration of BDNF 
induces cell proliferation and neurogenesis (Pencea et al. 2001; Zigova et al. 1998) and leads to 
decreased depressive-like behavior (Shirayama et al. 2002; Siuciak et al. 1997). Neurogenesis, 
resulting from either antidepressant treatment or cell implantation, attenuates depressive 
behavior (Tfilin et al. 2009). Depressed patients show reduced BDNF levels (Sen et al. 2008), 
which can result in lower number of dendrites in the synapse (Manji et al. 2003; Nestler et al. 
2002). Antidepressants stimulate BDNF synthesis (Duman 2004) and normalizes  reduced BDNF 
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levels in depressed patients (Brunoni et al. 2008; Sen et al. 2008). A functional variant located at 
codon 66 in the BDNF promoter region, resulting in a valanine to methionine change 
(Val66Met), is reported to correspond with drug response. Carriers of the Met allele were 
reported to have better treatment outcomes (Gratacos et al. 2008; Kato and Serretti 2010), 
however, others did not find any correlation between the Val66Met variant and treatment 
response (Kato and Serretti 2010; Tsai et al. 2003; Wilkie et al. 2007). Furthermore, genetic 
susceptibility to depression was not associated with the BDNF Val166Met variant (Gratacos et 
al. 2007; Lopez-Leon et al. 2008). The met allele is associated with impaired intra-cellular 
packaging and activity dependent secretion of BDNF, which disrupts hippocampal function 
(Egan et al. 2003). Impaired suppression of the HPA axis following dexamethasone treatment 
was also observed in the BDNF Met carriers (Schule et al. 2006). Of note, mouse lines that did 
not express Bdnf during fetal development or post-natal development were hyperactive, 
hyperaggressive, and showed higher depressive-like behavior compared to transgenic mice that 
were conditioned to express Bdnf during post-natal development (Chan et al. 2006), which 
suggests that the behavioral effects of BDNF are region and time-dependent. Interestingly, an 
interaction between the BDNF G196A variant, the serotonin transporter gene, and stressful life 
events have been observed (Aguilera et al. 2009; Pezawas et al. 2008). 
BDNF is activated by cyclic-AMP response element-binding protein (CREB). The 
cAMP-CREB cascade has been extensively studied for its involvement in cell survival and 
neural plasticity (D'Sa and Duman 2002; Duman et al. 1997). The cAMP-CREB pathway is 
upregulated following chronic antidepressant treatment (Duman et al. 1999). Activation of the 
CREB pathway is thought to result in neurogenesis. Activated or phosphorylated CREB is found 
in actively dividing neural progenitor cells in the hippocampal subgranular zone (SGZ) 
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(Nakagawa et al. 2002a). Mice lacking Creb show markedly reduced cell proliferation 
(Nakagawa et al. 2002b) and administration of a phosphodiesterase inhibitor, which activates the 
cAMP cascade, increases neurogenesis and improves depressive behavior (Takahashi et al. 
1999).  Although CREB plays a critical role in neurogenesis, CREB is not necessary to elicit 
antidepressant effects. After antidepressant treatment, no difference in depressive-like responses 
was observed between Creb deficient mice and wild-type controls, indicating that the behavioral 
effects of antidepressant drugs may occur through other CREB-independent mechanisms.   
Given that depressed patients exhibit reduced numbers of neuronal and glial cells, 
molecular mechanisms that stimulate neurogenesis (activation of CREB and BDNF synthesis) 
are likely to be critical in MDD. Presently, the clinical significance of neuro/gliogenesis in 
depression is largely unknown. It is likely that cellular proliferative and survival processes 
interact to facilitate remodeling of synaptic connections that can lead to altered mood. It is 
noteworthy to consider, however, that in the absence of stress, the neural circuitry underlying 
depression may be different (Krishnan and Nestler 2008). There is a possibility that  reversal of 
stress-induced neural plasticity changes is not required for antidepressive effects (Nestler et al. 
2002).    
7. Depression Signatures 
 
 
7.1 Gene Expression Signatures 
 
Gene expression profiling studies provide an unbiased look at the relationship between 
gene expression and depressive disorder, which is useful in identifying novel targets for 
antidepressant therapy (Sequeira and Turecki 2006). Bernard and colleagues collected gene 
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expression data from the locus coeruleus of healthy, depressed, and bipolar patients. In this 
study, they found significant alterations in patients with MDD but not bipolar subjects. Gene 
expression alterations were detected in the glutamate signaling genes (SLC1A2, SLC1A3 and 
GLUL), growth factor genes (FGFR3 and TrkB), and several astroglial genes (Bernard et al. 
2010). Similarly, dysregulation of fibroblast growth factor genes (FGF1, FGF2, FGFR2, and, 
FGF3) were detected in cortical regions of depressed patients, irrespective of previous 
antidepressant treatment (Evans et al. 2004). Consistent with previous findings, expression of 
genes involved in signal transmission of glutamate and GABA were found to be dysregulated in 
depressed patients (Choudary et al. 2005) and in suicide victims with and without depression 
(Sequeira et al. 2009). Alteration in genes regulating oligodendrocyte function (Sequeira and 
Turecki 2006) and cell-cell communication (Sequeira et al. 2009) were altered in MDD, 
suggesting impairment in brain circuitry. Notably, reduced oligodendrocyte expression and 
neuronal changes in amygdala were detected in both depressed individuals and in rodents 
exposed to unpredictable chronic mild stress (Sibille et al. 2009), indicating a connection 
between stress response and neural circuitry.  
For biomarkers to be clinically useful, putative analytes must be detected in easily 
accessible samples like plasma or serum.  Using LPS-stimulated blood samples, Spijker et al. 
compared gene expression profiles between healthy and unmedicated patients with MDD. A 
significant difference in gene expression pattern was observed in a subset of genes, all of which 
have not been previously associated with depression (Spijker et al. 2010). Transcriptome changes 
in the leukocyte mRNA is correlated with response to antidepressant agents or lithium therapy 
(Iga et al. 2008). The authors found that normalization in gene expression pattern correlates with 
antidepressant response (Iga et al. 2008).  In addition to analyzing global changes in the brain or 
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plasma transcriptome, genetic regulatory elements of depression or antidepressant response can 
be identified using quantitative trait loci (QTL) mapping analysis. In this approach, DNA 
variants that regulate gene expression locally or distally (cis or trans-regulatory elements) are 
analyzed for correlation with depressive behavior, thereby facilitating analysis for regulatory 
genes underlying depressive behavior. This approach has been used to detect regulatory genetic 
elements for several behaviors (Bryant et al. 2009; Radcliffe et al. 2006).  
7.2 Protein Signatures 
Other efforts to identify depression signatures include protein expression profiling. 
Plasma samples from control, depressed, and schizophrenic patients were analyzed for 79 plasma 
biochemical analytes, including cytokines, neurotrophins, and chemokines (Domenici et al. 
2010). Interestingly, insulin and matrix metallopeptidase 9 (MMP-9) displayed the biggest 
difference between control and depressed patients (Domenici et al. 2010). Efforts to expand the 
panel of protein markers to include peripheral and neuropsychological markers are currently 
underway (Tadic et al. 2011). The global analysis of protein expression is still in its infancy 
although several groups have performed proteomic analysis in the  cerebrospinal fluid (CSF) 
(Raedler and Wiedemann 2006) and in discrete brain regions collected post-mortem (Beasley et 
al. 2006). In order to characterize the cause-effect relationship between biological alterations, 
treatment, and behavior, protein profiling studies in human samples should be complemented 
with proteomic studies in animals, which are more amenable for determination of disease and 
treatment effects.    
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8. Other Mechanisms 
 
8.1 Epigenetics 
 
 
Discordance of depression between monozygotic twins suggests other non-genetic factors 
are involved (Mill and Petronis 2007). Alteration in gene expression can occur without changes 
in the DNA sequence through epigenetic mechanisms like histone modification and methylation 
of DNA CpG islands. Deacytelation of histones results in DNA coiling, which prevents binding 
of transcription factors to the DNA, suppressing gene transcription. Alternatively, methylation 
alters DNA chemistry, which blocks gene transcription. Epigenetic mechanisms can explain how 
genetically weak signals of risk combined with environmental factors predispose patients to 
depression (Caspi and Moffitt 2006).  
 
Adverse childhood experiences confer risk to depressive behavior (Heim and Nemeroff 
2001) likely through epigenetic alteration.  In animal studies, offspring who received minimal 
maternal care had higher DNA methylation at the glucocorticoid receptor (GR) promoter region 
and were more responsive to stress compared to control animals (Liu et al. 1997; Weaver et al. 
2004). Methylation in the GR promoter region leads to reduced binding of the nerve growth 
factor induced protein-A (NGF-1A), affecting GR regulation (Weaver et al. 2004; Weaver et al. 
2007). Notably, low levels of maternal care led to epigenetic repression of the estrogen-alpha 
receptor that resulted in transmission of maternal behavior to offspring (Champagne et al. 2006; 
Champagne et al. 2003), thus indicating transgenerational phenotypic transfer through epigenetic 
alterations.   
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Mice that are deficient in Hdac5 display enhanced vulnerability to stress, suggesting that 
stress reduces histone deacytelase activity leading to down-regulation of gene expression 
(Renthal et al. 2007). The adverse effect of stress on Hdac5 activity is reversed by chronic 
antidepressant treatment (Renthal et al. 2007).  Antidepressant treatment increases histone 
acetylation at the Bdnf promoter region, activating Bdnf expression (Tsankova et al. 2006). 
BDNF mediates formation and differentiation of new neurons, facilitating long-term potentiation 
and memory development.  
RNA-mediated modifications through non-coding RNAs (ncRNA) and microRNAs 
(miRNA) can activate or silence gene transcription. The role of miRNA in regulating 
serotonergic transmission has been reviewed (Millan 2011). MicroRNAs are short RNAs (22-24 
nucleotides) that bind to complementary sequences on target mRNAs, typically leading to gene 
silencing (Bartel 2009; Carthew and Sontheimer 2009; Winter et al. 2009). A recent study by 
Baudry et al. shows that miR-16 negatively regulates the expression of serotonin transporter 
(SERT). Fluoxetine treatment stimulates the release of S100 beta protein (S100β) in the raphe, 
leading to elevation of miR-16 and reduction in SERT (Baudry et al. 2010). MiR-16 also 
represses the expression of anti-apoptotic protein (B-cell lymphoma 2) Bcl-2 (Cimmino et al. 
2005), indicating a critical role of miR-16 in neurotransmission as well as cell proliferation. In 
addition, genetic studies using seahare (Aplysia) identified miR-124 as a translational repressor 
of CREB, which suggests that microRNAs indirectly regulate secondary messenger pathways by 
modulating CREB expression (Rajasethupathy et al. 2009). Overexpression of ncRNA was 
found in Alzheimer‟s patients (Faghihi et al. 2010), however, an association between ncRNA and 
depression is yet to be established.   
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Consistent with the notion that genes are interconnected within a network, it is 
conceivable that an epigenetic regulatory network exists.  Efforts to identify epigenomic 
signatures are underway (Akbarian and Huang 2009) and this data should be integrated with 
other data sets like the brain transcriptome and behavior to identify causative pathways in 
depression. Of great interest is the assessment of epigenetic transgenerational transmission of a 
trait and genomic imprinting (epigenetic alteration on gene expression is based on whether the 
gene is inherited from the father or the mother). These epigenetic phenomena facilitate our 
understanding of how environment and genetics interact to mediate behavior, ultimately 
providing a comprehensive picture of the molecular mechanisms underlying depression.   
8.2 Sleep and Circadian Rhythm 
 
 
It was previously thought that insomnia is a risk factor for depression (Breslau et al. 
1996; Ford and Kamerow 1989; Hohagen et al. 1993) and years of research did not clarify the 
exact relationship between insomnia and depression (Riemann 2007; Riemann et al. 2001). In an 
EEG, normal sleep can be partitioned into several stages. The first is progression from light sleep 
(N1 stage), followed by an “intermediate” level of sleep (stage N2) that leads to the “deep” sleep, 
which is characterized by slow delta waves on the EEG (stage N3). Stages N1-N3 are part of 
non-rapid eye movement sleep, which alternates with rapid eye movement (REM) sleep 
throughout the night (Benca and Peterson 2008). Depression is characterized by abnormal sleep 
(difficulty falling asleep, nocturnal awakenings, early-morning awakenings), decreased slow-
wave sleep, shortened rapid eye movement (REM) latency, and increased REM density (Thase et 
al. 1997; Tsuno et al. 2005). Interestingly, total sleep deprivation improves symptoms in 40-60% 
of depressed patients (Giedke and Schwarzler 2002; Wirz-Justice and Van den Hoofdakker 
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1999), which is thought to be due to activation of the limbic dopaminergic pathways (Ebert et al. 
1994; Ebert et al. 1996). Additionally, the slow-wave sleep is marginally affected by 
antidepressant therapy (Sharpley and Cowen 1995; Tsuno et al. 2005), indicating partial 
involvement of monoamines in sleep regulation.   
 
In addition to disruption in sleep pattern, depressed patients also exhibit alteration in 
biological rhythms, including appetite and hormone levels. Patients with seasonal affective 
disorders (SAD) have depressive symptoms during the winter months when daylight is shorter. 
The bright light therapy has been effectively used to treat SAD (Lam 2006) and non-seasonal 
depression (Terman and Terman 2005) and is thought to work by shifting the circadian clock 
(Wirz-Justice et al. 2005). Similar to 5-HT, melatonin is derived from tryptophan and is a critical 
regulator of circadian rhythm. Depressed patients display altered melatonin release and abnormal 
melatonin levels (Rubin et al. 1992; Wetterberg 1999), particularly in the acute phase of 
depressive illness (Srinivasan et al. 2006). Antidepressant therapy increases melatonin 
(Srinivasan et al. 2006; Thompson et al. 1985). Of note, a pilot study that looked at the use of 
melatonin in addition to cortisol as prognostic marker for depression found promising results 
(Buckley and Schatzberg 2010).   
Genetic regulators of the molecular clock (Clock, Bmal1, Npas2, GSK3β, and Timeless) 
have been linked with mood disorders (McClung 2007). Mutant mouse models exhibiting point 
mutations on the Clock gene display anxiety-like and depressive-like behavior (Roybal et al. 
2007) and increased dopamine transmission in the ventral tegmental area (VTA) (McClung et al. 
2005; Nestler and Carlezon 2006), which suggests  that the Clock gene regulates dopamine 
signaling. Interestingly, there is circadian rhythm with regards to concentration, release, and 
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synthesis of 5-HT, norepinephrine, and dopamine (Barassin et al. 2002; Shieh et al. 1997; 
Weiner et al. 1992), as well as in the expression and activity of monoamine receptors (Kafka et 
al. 1983; WESEMANN and Weiner 1990; Witte and Lemmer 1991), indicating a link between 
monoamine signaling and circadian rhythm.  
9. Our Approach: Identification of genetic and neurobiochemical markers for depression 
and fluoxetine response using a panel of genetically diverse mouse inbred strains 
 
Based on these findings, it is unlikely that a single biomarker can describe a 
multifactorial disorder like depression. Data from the last decades indicate that alterations in 
MDD are inter-connected (Figure 1.1). This figure illustrates that there are neuroanatomical, 
neurobiochemical, neuroimmune, neuroendocrine, genetic, and metabolic mechanisms 
underlying MDD. Given the involvement of various biological systems, it is no surprise that 
depression is characterized by heterogeneous molecular and clinical manifestations, which 
complicate the search for biomarkers for depressive-like behavior.  Therefore, a systems biology 
approach that investigates connections on genetic, neurobiochemical, and behavioral levels is 
critical to the identification of prognostic and treatment response biomarkers for depression.     
Our laboratory has collected behavioral data for over 30 mouse inbred strains for the tail 
suspension test, in both naïve mice and mice chronically-treated with the antidepressant 
fluoxetine. We have also analyzed whole-genome gene expression in the same inbred strains in 
multiple brain regions believed to play a role in the regulation of mood. In this application, we 
propose to quantify 40 biochemical biomarkers in the same three brain regions among all 30 
inbred strains in both naïve mice and mice that have been chronically-treated with the 
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antidepressant fluoxetine. The biochemical markers, which were chosen based on literature 
searches and in consultation with experts in the field of psychiatry and psychiatric genetics, 
assess multiple mechanisms that have been implicated in human depression, including neuronal 
modulation, neurogenesis, gliogenesis, and hypothalamic-pituitary mediated immunomodulation. 
By comparing biochemical and behavioral profiles in both naïve and drug-treated mice, we will 
identify biomarkers that can predict predisposition to depressive-like behavior and treatment 
response. Furthermore, comparison of these data with inter-strain gene expression differences 
will provide information regarding the role of gene regulation on depression. Genetic and 
biochemical markers that are significantly correlated with differences in behavior in the 
treatment naïve group can predict predisposition to depressive-like behavior in mice that may 
influence response to treatment, while genetic and biochemical markers that are significantly 
different between response groups can provide a biological explanation for differences in 
treatment response.  
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10. Figures 
 
 
 
Figure 1.1 Biological alterations in depression 
Figure 1.1 Biological alterations in depression. Impairment in the HPA axis, neural circuitry, 
neuroendocrine, neuroimmune, neuronal signaling, neurogenesis, and metabolic functions have 
been observed in depressed patients, resulting in symptom heterogeneity. As shown, 
bidirectional communication among several pathways exists (i.e., crosstalk between sympathetic 
nervous system and inflammatory markers). Cellular (genetic) and molecular (proteomic) 
alterations in depression can be identified by performing global gene and protein expression 
analyses between healthy controls and depressed individuals (bottom left), leading to 
identification of depression molecular signatures.  
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CHAPTER 2 
IDENTIFICATION OF QUANTITATIVE TRAIT LOCI FOR DEPRESSION AND 
ANXIETY IN MULTIPLE MOUSE INBRED STRAINS 
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1. Introduction  
Anxiety and depression have a significant socioeconomic impact. In the United States, 
the lifetime prevalence rates for anxiety and mood disorder are 31% and 21.4%, respectively 
(Kessler et al. 2007). A strong comorbidity exists between anxiety and major depressive 
disorder. Patients with comorbid anxiety and depression are more likely to experience slower 
recovery, greater psychosocial disability, more chronicity, and increased rates of recurrence and 
medication use (Hirschfeld 2001). There are minimal studies that have examined treatment 
efficacy in anxious depressive patients (Hirschfeld 2001). As a result, evidence-based rationale 
for treatment selection, dose requirement, and duration of therapy in this patient population is 
lacking.  
Evidence from twin studies indicates a strong genetic correlation between anxiety and 
major depression with minimal to modest shared environmental effects on both disorders 
(Kendler 1996; Kendler et al. 2007; Roy et al. 1995). It appears that numerous small-effect genes 
affect both illnesses and that genetic influence on anxiety and depression is independent of age 
(Demirkan et al. 2011). To elucidate common genetic mechanisms shared between both 
disorders, we performed genome-wide mapping analysis across multiple mouse inbred strains. 
The use of mouse inbred strains to investigate genetic variants for behavior offers several 
advantages, including lower cost, availability of relevant population, ease in sample accessibility, 
and reduced genomic complexity.  
In this study, we have measured baseline anxiety-like and depressive-like responses and 
performed genome-wide association analysis to identify quantitative trait loci (QTL) or genomic 
regions associated with anxiety-like and depressive-like behaviors. By conducting a QTL 
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mapping analysis for both anxiety-like and depressive-like responses, we aim to: 1) identify 
genetic risk variants for both disorders and 2) propose a molecular pathway that is potentially 
shared between major depression and anxiety.  
2. Materials and Methods 
2.1 Animals 
 
Thirty-five mouse inbred strains (129S1/SvImJ, A/J, AKR/J, BALB/cByJ, BTBRT<t>tf/J, 
BUB/BnJ, C3H/HeJ, C57BL/6J, C57BR/cdJ, C58/J, CBA/J, CE/J, CZECHII/EiJ, DBA/2J, 
DDY/Jc1SidSeyFrkJ, FVB/NJ, I/LnJ, KK/HIJ, LG/J, LP/J, MA/MyJ, MRL/MpJ, NOD/LtJ, 
NON/LtJ, NOR/LtJ, NZB/BlNJ, NZO/HILtJ, PERA/EiJ, PL/J, PWD/PhJ, RIIIS/J, SJL/J, SM/J, 
SWR/J, and WSB/EiJ)  aged 8-9 weeks old were obtained from The Jackson Laboratory (Bar 
Harbor, ME). Male mice were housed four per cage in polycarbonate cages on a 12-hour 
light/dark cycle (lights on at 0700h) with access to food and water ad libitum. The number of 
animals in each treatment group ranged from 7 to 18 animals per strain.  Following one week of 
habituation, mice were subjected to a behavioral test battery in the order of the least to the most 
stressful test. Mice were tested every two days for a maximum of three behavioral tests to 
minimize carryover effects between tests. All procedures were approved by the Institutional 
Animal Care and Use Committee and followed the guidelines set forth by the National Institutes 
of Health (NIH) Guide for the Care and Use of Laboratory Animals. Mean behavioral scores are 
reported in Table 2.1.   
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2.2 Open Field Test (OF) 
The OF test was conducted using a 27.3 cm x 27.3 cm open field apparatus (MED-OFA-MS, 
Med Associates, St. Albans, VT), which was surrounded by infrared detection beams on the x-, 
y- and z-axes that automatically recorded the animals' position and activity over the course of the 
experiment. The OF is commonly used to measure exploratory and locomotor behavior in mice. 
This test exploits the rodent‟s innate aversion to well-lit open spaces. Based on previous 
observations that showed increased exploration towards illuminated open areas following 
administration of anxiolytics (Choleris et al. 2001; Crawley 1985), anxiety-like behavior was 
measured as percent time spent in the center of the open field. Activity in the open field was 
recorded for ten minutes. 
2.3 Tail Suspension Test (TST) 
Mice were tested in a tail-suspension apparatus (PHM-300 TST Cubicle, Med Associates, St. 
Albans, VT) between 1300h and 1600h. In this test, the mouse is subjected to short-term 
inescapable stress by being suspended by its tail. Following failed attempts to escape, the mouse 
becomes immobile, a response generally considered as behavioral despair, a depressive-like 
behavior that is proposed to model “hopelessness” (Steru et al. 1987; Steru et al. 1985). 
Immobility was recorded for 6 min in 60-sec blocks. Mice that climbed up their tail during 
testing were excluded from data analysis.  
2.4 Stress-Induced Hyperthermia (SIH) 
Mammals, including humans, show an elevation in core body temperature after exposure 
to stress (stress-induced hyperthermia). Previous studies have shown that mice removed last 
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from their cage develop hyperthermia compared to mice removed first (Borsini 1989), indicating 
that SIH response is an index for anticipatory anxiety in mice. Using a modified SIH protocol, 
rectal temperatures were obtained sequentially, with a 1-min interval between the first and the 
last mouse in the cage. After 10 min, a second rectal measurement was performed for all mice 
using the same procedure. For each mouse, the SIH was calculated as the difference in 
temperature (ΔT) between the first rectal measurement (basal) and the last rectal temperature 
(after 10 min).  
2.5 QTL Mapping  
Since mice within the same strain are genetically identical, genetic mechanisms 
underlying complex diseases like anxiety and depression can be identified by mapping genomic 
regions associated with inter-strain phenotypic variation. Behavioral measures collected from 
multiple inbred strains were analyzed on SNPster version 3.3.1 and EMMA R package 1.1.2 to 
infer genomic regions significantly correlated with inter-strain differences in anxiety-like and 
depressive-like behavior.  
Haplotype Associated Mapping (HAM) analysis and Efficient Mixed-Model Association 
(EMMA) have been well-described elsewhere (Kang et al. 2008; McClurg et al. 2007; Pletcher et 
al. 2004) and thus will be only briefly summarized here. Experimental SNP genotypes 
encompassing over seven million polymorphic loci across 49 commonly-used laboratory strains 
were obtained from the Center for Genome Dynamics at http://cgd.jax.org (Szatkiewicz et al. 
2008). Over 190,000 SNPs were informative for the 37 mouse inbred lines, which provided the 
basis for inferring genotype or haplotype structure at every 3-SNP window. Associations 
between genotype (1-SNP or 3-SNP window) and phenotype were calculated by an F-statistic 
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corrected for genome-wide significance and plotted using SpotFire software (TIBCO Palo Alto, 
CA). Genomic loci that were associated with behavioral phenotypes at an FDR ≤0.05 were 
considered significant. We also examined if QTLs have been previously linked with behavioral 
responses related to anxiety and depression. Candidate genes within anxiety-like and depressive-
like QTLs are listed in Tables 2.2 and 2.3. 
2.6 Criteria for depressive-like gene marker characterization 
Because our focus is to identify genetic markers for depression, we extensively examined 
all QTLs significant for depressive-like phenotype as measured by the TST. For candidate gene 
identification to be effective and efficient, we focused our attention on the top three loci 
associated with depressive behavior and eliminated any QTLs that were similar to background 
peaks. This decision was based on previous mapping simulations which showed that the locus 
most significantly associated with the phenotype is 95% likely to be found within the top peak 
given that the phenotype has an effect size of 30% (unpublished data).  
Genes were prioritized based on the following criteria: a) similar haplotype structure 
between SNPs within candidate genes and depressive QTLs, b) correlation of candidate gene 
expression with behavior, c) association between candidate gene expression with levels of 
neurobiochemical molecules, d) role of genes in behavior based on previous findings, and e) 
association of genes with major depressive disorder. In addition, we searched for mouse models 
and experimental assays that can be used for gene validation experiments.   
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3. Results 
3.1 Behavioral QTLs 
Baseline behavioral responses were measured in the open field test, stress-induced 
hyperthermia test, and tail suspension test. Analysis of anxiety-like and depressive-like responses 
revealed significant effects of strain (percent time spent in the center OF: F = 37.25, p< 0.0001; 
change in temperature following stress: F = 4.86, p< 0.0001; percent time immobile in the TST: 
F = 16.37, p< 0.0001).  Genetic analysis can be performed using inbred-strain phenotype data to 
identify genetic loci associated with behavioral phenotypes (Miller et al. 2010; Williams et al. 
2009). Loci on Chrs 2 (Chr 2: 161.1 - 162.8; -logP = 5.52, FDR≤ 0.059), 3 (Chr 3: 82.0 - 86.9; -
logP = 5.69, FDR≤ 0.059), 6 (Chr 6: 102.7 - 106.7, -logP = 5.52, FDR≤ 0.059), and 17 (Chr 17: 
18.7 - 23.7; -logP = 5.70, FDR≤ 0.069) correlated with percent time spent in the center of the 
OF. The anxiety-like QTL on Chr 17 (Figure 2.1) has been previously linked with circadian 
photosensitivity (Chr 17: 17.9 - 43.3, LOD = 3.7) (Yoshimura et al. 2002), which suggests that 
similar genetic mechanisms underlie anxiety behavior and circadian rhythm. Fpr1, a gene within 
anxiety-like QTL on Chr 17, has been previously associated with anxiety behavior in rodents 
(Gao et al. 2011). 
We discovered three loci with genome-wide significance for SIH (Chr 1: 64.8 - 65.2, -
logP = 5.68, FDR≤ 0.039; Chr 4: 134.8 - 135. 5 -logP = 5.69, FDR≤ 0.039; Chr 5: 108.2 - 110.9, 
-logP = 6.49, FDR≤ 0.013; Chr 10: 121.3 - 123.6, -logP = 5.88, FDR≤ 0.039). Results from F2 
mapping analyses between two phenotypically divergent strains (CBA/J and A/J) reveal two loci 
on Chr 5 (Chr 5: 107.6 - 123.9, LOD = 16.4 and Chr 5: 130.7 - 142.5, LOD = 30.9) that have 
been previously linked with preference for entering the open arms, a behavior that indicates less 
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anxious responses in the elevated plus maze (EPM). The EPM QTLs on Chr 5 account for 30% 
of the variance in arm preference (Cohen et al. 2001). Additionally, a QTL on Chr 5 has been 
detected for nurturing ability (Chr 5: 127.7 - 133.5, LOD = 4.5) (Suto et al. 2002). Two out of 
the thirty-seven genes within the SIH QTL on Chr 5 (Pde6b and Pxmp2) were previously linked 
with anxiety or depression (Aston et al. 2005; Cohen et al. 2001; Cook et al. 2001) (Figure 2.2). 
Independent QTL mapping analysis for depressive-like phenotype identified significant 
loci on Chrs 2, 4, 9, and 18. Genomic regions on Chrs 2 (Chr 2: 179.5 - 179.6, -logP = 8.52, 
FDR≤ 0.0006 and Chr 2: 60.1 - 63.3, -logP = 4.92, FDR≤ 0.10), 4 (Chr 4: 129.8 - 132.5, -logP = 
4.27, FDR≤ 0.10), 9 (Chr 9: 46.7- 47.6 Mb, -logP = 6.17, FDR≤ 0.059), and 18 (Chr 18: 16.6 - 
18.1, -logP = 5.39, FDR≤ 0.074) associated with baseline depressive-like behavior. Although a 
QTL for depressive-like behavior has not been reported previously at any of the loci we found, a 
region on Chr 4 has been linked with anxiety-like responses as measured by the EPM (Chr 4: 
78.3 - 125.3, LOD = 3.2) (Nakamura et al. 2003) and thermal pain responses in male mice (Chr 
4: 115.1 - 139.5, r = 0.34 - 0.42) (Mogil et al. 1997). Interestingly, association with anxiety 
and/or depression has been reported for two genes (Hcrtr1 and Oprd1) within the despair locus 
on Chr 4 (Filliol et al. 2000; Scott et al. 2011; van Rijn et al. 2010) (Figure 2.3). 
3.2 Identifying a candidate genetic marker for depression 
Although all candidate genes were found within behavioral loci, only thirty-six out of 
seventy candidate genes showed similar haplotype structure with the putative depressive QTLs. 
This information is critical in delineating which genes are likely to drive association between 
genomic and behavioral differences observed in mice. Convergence of gene expression with 
behavioral and biochemical data narrowed our list from 36 to 20 priority genes. Using 
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Spearman‟s rank correlation coefficient, 20 genes were significantly correlated with behavior 
and levels of neurobiochemical markers (p<0.05). From the list of 20 candidate genes, Dpp4 is 
the only gene that has been previously associated with major depression in humans (see Chapter 
3 for more details regarding Dpp4). A reduction in DPP4 enzymatic activity is common in 
patients with mood disorder and treatment resistant depression (Maes et al. 1996; Maes et al. 
1991; Maes et al. 1997). Animal studies have also found an association between DPP4 and 
behavioral despair.  Mice deficient in CD26/DPP4 exhibit lower immobility scores on both 
forced swim and tail-suspension tests, which suggests that absence of Dpp4 produced anti-
depressive effects (El Yacoubi et al. 2006). Contradictory results between studies are likely due 
to biological alterations that occur specifically from activation of DPP4 enzyme, such as change 
in structural conformations that would otherwise be absent and thus undetected in Dpp4
 
knockout studies. Alternative explanations include secondary mechanisms that may arise from 
genetic ablation of Dpp4. Despite ambiguous findings, evidence from human and animal studies 
suggests that Dpp4 plays a significant role in depression. This information, in addition to the 
availability of powerful research tools, led us to investigate the link between DPP4 and 
depression. To further clarify the connection between Dpp4 and depressive behavior, we 
compared DPP4 protein levels as well as enzymatic activity in behaviorally dissimilar strains 
(Details of the study are found in Chapter 3).   
4. Discussion 
 
Given the significant pathophysiologic overlap between anxiety and depression, it is 
thought that there are common neurogenetic mechanisms underlying these disorders. Findings 
from genetic twin studies conducted in patients with comorbid anxiety and depression (Kendler 
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1996; Kendler et al. 2007; Roy et al. 1995) indicate a strong genetic correlation between both 
disease states. To identify genomic regions shared between these illnesses, we conducted QTL 
mapping analysis for anxiety-like and depressive-like responses in 35 mouse inbred strains.  
Two of the anxiety-like QTLs we identified, Chr 5: 108.2 - 110.9 and Chr 17: 18.7 - 23.7, 
have been previously associated with anxiety-related responses and circadian photosensitivity, 
respectively (Cohen et al. 2001; Yoshimura et al. 2002). Three genes within these regions have 
been previously associated with anxiety or depression. The Fpr1 gene encodes for N-
formylpeptide receptor, a G-protein coupled receptor that stimulates the release of pro-
inflammatory cytokines by phagocytic cells and negatively mediates the action of 
glucocorticoids. Mice lacking Fpr1 exhibit reduced anxiety-like responses, increased exploratory 
behavior, and impaired fear memory (Gao et al. 2011). Transcription profiling analysis of cortex 
samples from depressed individuals and healthy control subjects revealed significant differences 
in the expression of 17 genes involved in oligodendrocyte function; included in that list is 
Pxmp2. The Pxmp2 gene encodes for a peroxisomal membrane channel, which is critical for 
myelination. Compared to control subjects, patients with depression show reduced mRNA levels 
for genes associated with cell communication and neurodevelopment (Aston et al. 2005). This 
finding indicates that depression may be affected by impairment in synaptic function and cell 
communication. It is thought that light affects alertness, mood, and anxiety behavior. In 
mammals, retinal photoreceptors, including rods, cones, and intrinsically photosensitive retinal 
ganglion cells (ipRGCs), mediate both image-forming and non-image-forming responses to light. 
The Pde6b gene encodes for an enzyme that mediates phototransduction in rods and cones 
known as the rod phosphodiesterase subunit beta protein. Mutation in Pde6b
 
results in visual 
impairment and age-related degeneration of rods and cones. The SIH locus on Chr 5 where 
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Pde6b
 
resides has been correlated with anxiety-like behavior (Cohen et al. 2001; Cook et al. 
2001), which suggests that similar genetic mechanisms may underlie responses to light and 
anxiety behavior. Notably, the anxiety-like locus on Chr 17 for time spent in the center OF has 
been previously linked with circadian photosensitivity. Collectively, our anxiety-like QTL 
findings indicate that genes affecting circadian rhythm may also influence anxiety responses. 
Further characterization of candidate anxiety-like genes can help to elucidate molecular 
pathways linking light responses with anxiety, thus facilitating new avenues for anxiolytic drug 
research. 
We identified five regions that were significantly linked with depressive-like behavior. 
Of particular interest is the region on Chr 4. This locus has been previously reported to be 
associated with anxiety behavior and responses to thermal pain (Mogil et al. 1997; Nakamura et 
al. 2003). Two genes within the despair locus on Chr 4, Hcrtr1 and Oprd1, were previously 
correlated with depressive and/or anxiety behavior (Filliol et al. 2000; Scott et al. 2011; van Rijn 
et al. 2010). Orexins are excitatory neuropeptide neurons primarily located in the hypothalamus. 
Orexin neurons bind to orexin receptors 1 and 2, which are encoded by Hcrtr1 and Hcrtr2, 
respectively. Reduction in Hcrtr1 through either pharmacologic intervention or genetic ablation 
results in decreased depressive-like behavior (Scott et al. 2011). The Oprd1 gene encodes for the 
delta1 opioid receptor, which when activated elicits analgesic effects. The Oprd1 null mice 
display increased behavioral despair and anxious-like behavior, indicating that delta1 opioid 
receptor activity is critical for mediating both anxiety and mood disorders (Filliol et al. 2000). 
Similarly, activation of the OPRD1 receptor reduces depressive-like behavior (Torregrossa et al. 
2006) and anxiety-like behavior in ethanol-withdrawn mice (Kraft et al. 2009). Additional 
studies are needed to identify the molecular pathway underlying opioid effects on anxiety and 
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depressive behavior. Whether administration of a delta opioid receptor agonist attenuates anxiety 
and depressive symptoms remain to be seen.   
All genes within putative QTLs associated with variable depressive-like behavior were 
analyzed for its potential role in major depression. Comprehensive analysis of gene expression, 
neurobiochemical, and behavioral data that were obtained from two independent studies 
narrowed the list of putative depressive-like genes to 20 promising candidates. Only Dpp4 has 
been previously linked with clinical depression and other disorders, including anxiety (Emanuele 
et al. 2006), depression (Maes et al. 1996; Maes et al. 1991), anorexia (van West et al. 2000), and 
bulimia (van West et al. 2000). Additionally, availability of research tools, which included 
commercially-available drugs that target the protein product, ELISA kits, and qPCR primers and 
probes, made Dpp4 a good candidate gene to validate. The details of the candidate gene 
validation study are described in Chapter 3.   
Taken together, results from our QTL mapping analyses generated several good 
candidate genes for anxiety and depression. Importantly, these results indicate that similar 
genetic mechanisms underlie anxiety and major depression. This study also demonstrates the use 
of QTL mapping analysis for detection of genetic loci that influence complex phenotypes. 
Although causative genes for anxiety and MDD are yet to be identified, the road to gene 
identification is promising. New approaches, such as next-generation sequencing and epigenetic 
tools (DNA methylation, chromatin, and non-coding RNA analysis) can advance gene mapping 
analyses, facilitating the identification of genes underlying anxiety and major depression.    
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5. Tables 
Table 2.1 Inter-strain behavioral responses in  the open field test, stress-induced hyperthermia, 
and tail suspension test 
Table 2.1. Inter-strain Behavioral Responses in  the Open Field Test, Stress-Induced Hyperthermia, 
and Tail Suspension Test 
Strain 
Number 
of 
Animals 
(n) 
Mean 
Percent 
Time 
Spent in 
the 
Center 
OF SEM 
Mean 
Change in 
Temperature 
(ºC) SEM 
Mean 
Percent 
Time Spent 
Immobile SEM 
129S1/SvImJ 14 2.98 1 1.68 0.18 41.85 2.52 
A/J 14 0.91 0.26 1.24 0.11 28.95 2.92 
AKR/J 14 10.51 1.22 2.14 0.2 36.41 3.61 
BALB/cByJ 14 5.99 1.12 1.79 0.15 33.92 3.08 
BTBRT<t>tf/J 16 14.68 1.33 1.49 0.11 35.73 2.85 
BUB/BnJ 7 11.91 1.16 2.76 0.16 34.64 5.76 
C3H/HeJ 15 12.59 1.18 2.26 0.14 22.58 2.17 
C57BL/6J 16 19.72 1.35 1.83 0.14 36.03 7.1 
C57BR/cdJ 14 23.88 1.77 2.04 0.1 20.06 2.23 
C58/J 16 15.4 1.48 1.63 0.17 22.54 1.58 
CBA/J 15 9.95 0.93 2.34 0.14 40.89 2.97 
CE/J 8 9.54 1.23 1.84 0.11 27.1 3.32 
CZECHII/Ei 9 2.02 0.35 0.99 0.42 59.25 7.17 
DBA/2J 14 6.86 1.08 2.56 0.19 21.75 1.74 
DDY/Jc1SidSeyFrkJ 8 14.54 2.15 1.8 0.26 73.93 2.25 
FVB/NJ 14 14.92 1.12 2.14 0.17 34.94 2.8 
I/LnJ 8 10.39 1.33 1.39 0.23 39.11 7.78 
KK/HlJ 18 5.43 0.84 1.25 0.12 46.66 4.4 
LG/J 12 7.44 1.24 1.93 0.15 25.63 2.53 
LP/J 10 4.09 1.25 1.57 0.22 34.45 4.81 
MA/MyJ 9 13.24 1.08 1.8 0.26 39.25 5.83 
MRL/MpJ 14 9.34 1.38 1.84 0.28 26.98 2.12 
NOD/LtJ 17 25.38 2.1 1.88 0.18 41.19 2.54 
NON/LtJ 16 13.75 0.95 2.2 0.15 18.87 2.19 
NOR/LtJ 10 22.14 1.26 1.78 0.11 35.59 4.1 
NZB/BlNJ 14 9.88 0.97 2.14 0.18 48.64 4.15 
NZO/HILtJ 11 4.82 0.95 1.61 0.17 33.86 4.49 
PERA/Ei 8 15.35 2.21 1.81 0.23 57.99 11.65 
PL/J 18 11.72 0.76 2.58 0.18 37.59 2.64 
PWD/Ph 10 7.01 1.07 0.79 0.18 Not tested   
RIIIS/J 15 7.54 0.66 2.31 0.21 30.03 1.6 
SJL/J 16 10.81 1 2.23 0.25 59.35 2.8 
SM/J 14 8.67 0.71 2.1 0.13 41.73 4.79 
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SWR/J 17 12.71 0.7 2.29 0.17 25.58 1.67 
WSB/EiJ 10 14.32 0.74 1.1 0.45 29.61 3.44 
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Table 2.2 List of candidate genes within anxiety-like QTLs 
Table 2.2. List of candidate genes within anxiety-like QTLs   
Gene symbol Gene Name 
1010001B22Rik RIKEN cDNA 1010001B22 gene 
1700007G11Rik RIKEN cDNA 1700007G11 gene 
1700013N18Rik ubiquitin-conjugating enzyme E2D 2 pseudogene 
1700029M20Rik RIKEN cDNA 1700029M20 gene 
2610011I18Rik RIKEN cDNA 2610011I18 gene 
2810408I11Rik RIKEN cDNA 2810408I11 gene 
3110052M02Rik RIKEN cDNA 3110052M02 gene 
4930432H08Rik RIKEN cDNA 4930432H08 gene 
4930432O21Rik RIKEN cDNA 4930428O21 gene 
4930515G13Rik RIKEN cDNA 4930515G13 gene 
4930555I21Rik RIKEN cDNA 4930555I21 gene 
4930564K09Rik RIKEN cDNA 4930564K09 gene 
4930565D16Rik RIKEN cDNA 4930565D16 gene 
4933425M03Rik RIKEN cDNA 4933425M03 gene 
5830490A12Rik RIKEN cDNA 5830490A12 gene 
6330415G19Rik RIKEN cDNA 6330415G19 gene 
6820402A03Rik RIKEN cDNA 6820402A03 gene 
9030218A15Rik RIKEN cDNA 9030218A15 gene 
9130219A07Rik RIKEN cDNA 9130219A07 gene 
9330198I05Rik RIKEN cDNA 9330198I05 gene 
9430021M05Rik RIKEN cDNA 9430021M05 gene 
9430099H24Rik 9430099H24Rik Description: RIKEN cDNA 9430099H24 gene 
A330049M08Rik RIKEN cDNA A330049M08 gene 
A430028G04Rik RIKEN cDNA A430028G04 gene 
A830010M20Rik RIKEN cDNA A830010M20 gene 
Acadl acyl-CoA dehydrogenase, long chain 
Akr1cl aldo-keto reductase family 1, member C-like 
Ankle2 ankyrin repeat and LEM domain containing 2 
Arfip1 ADP-ribosylation factor interacting protein 1 
Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 
AU019157 expressed sequence AU019157 
AU021001 expressed sequence AU021001 
Avpr1a arginine vasopressin receptor 1A 
Barhl2 BarH-like 2 
Brdt bromodomain, testis-specific 
C1qtnf6 C1q and tumor necrosis factor related protein 6 
C630001G18Rik RIKEN cDNA C630001G18 gene 
C77068 expressed sequence C77068 
Card10 caspase recruitment domain family, member 10 
Ccdc18 coiled-coil domain containing 18 
Ccnyl1 cyclin Y-like 1 
Cd1d2 CD1d2 antigen 
Cdc7 cell division cycle 7 homolog 
Chfr checkpoint with forkhead and ring finger domains 
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Chl1 cell adhesion molecule with homology to L1CAM 
Clic4 chloride intracellular channel 4 (mitochondrial) 
Cnr2 cannabinoid receptor 2 (macrophage) 
Cntn4 contactin 4 
Cntn6 contactin 6 
Creb1 cAMP responsive element binding protein 1 
Cryga crystallin, gamma A 
Crygb crystallin, gamma B 
Crygd crystallin, gamma D 
Crygf crystallin, gamma F 
Cyth4 cytohesin 4 
D4Ertd264e DNA segment, Chr 4, ERATO Doi 264, expressed 
D530037H12Rik RIKEN cDNA D530037H12 gene 
D630023F18Rik RIKEN cDNA D630023F18 gene 
D630033A02Rik RIKEN cDNA D630033A02 gene 
D930015E06Rik RIKEN cDNA D930015E06 gene 
Dclk2 doublecortin-like kinase 2 
Dr1 down-regulator of transcription 1 
Elfn2 leucine rich repeat and fibronectin type III, extracellular 2 
Ephx4  epoxide hydrolase 4 
Evi5 ecotropic viral integration site 5 
Fam160a1 family with sequence similarity 160, member A1 
Fam19a2 family with sequence similarity 19, member A2 
Fam69a family with sequence similarity 69, member A 
Fbrsl1 fibrosin-like 1 
Fbxw7 F-box and WD-40 domain protein 7 
Fga fibrinogen alpha chain 
Fgb fibrinogen beta chain 
Fgg fibrinogen gamma chain 
Fhdc1 FH2 domain containing 1 
Fpr1 formyl peptide receptor 1 
Fpr2 formyl peptide receptor 2 
Fpr3 formyl peptide receptor 3 
Fpr-rs3 formyl peptide receptor, related sequence 3 
Fpr-rs4 formyl peptide receptor, related sequence 4 
Fuca1 fucosidase, alpha-L- 1, tissue 
Fzd5 frizzled homolog 5 
Gfi1 growth factor independent 1 
Glmn glomulin, FKBP associated protein 
Glt28d2 glycosyltransferase 28 domain containing 2 
Golga3 golgi autoantigen, golgin subfamily a, 3 
Grhl3 grainyhead-like 3 
Gtpbp6 GTP binding protein 6 (putative) 
Has1 hyaluronan synthase1 
Hmgcl 3-hydroxy-3-methylglutaryl-Coenzyme A lyase 
Idh1 isocitrate dehydrogenase 1 (NADP+), soluble 
Il28ra interleukin 28 receptor alpha 
Il2rb interleukin 2 receptor, beta chain 
Il5ra interleukin 5 receptor, alpha 
Kirrel kin of IRRE like 
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Klf7 Kruppel-like factor 7 (ubiquitous) 
Lpcat2b lysophosphatidylcholine acyltransferase 2B 
Lrat lecithin-retinol acyltransferase (phosphatidylcholine-retinol-O-acyltransferase) 
Lrba LPS-responsive beige-like anchor 
Mab21l2 mab-21-like 2 
Mettl21a methyltransferase like 21A 
Mllt4  
myeloid/lymphoid or mixed lineage-leukemia translocation to 4 homolog 
pseudogene 
Mnd1 meiotic nuclear divisions 1 homolog 
Mon2 MON2 homolog 
Mtap2 microtubule-associated protein 2 
Mtap9 microtubule-associated protein 9 
Mtf2 metal response element binding transcription factor 2 
Myom3 myomesin family, member 3 
Ncaph2 non-SMC condensin II complex, subunit H2 
Ncrna00085 non-protein coding RNA 85 
Nipal3 NIPA-like domain containing 3 
Npy2r neuropeptide Y receptor Y2 
P2rx2 purinergic receptor P2X, ligand-gated ion channel, 2 
Pde6b phosphodiesterase 6B, cGMP, rod receptor, beta polypeptide 
Pet112l PET112-like 
Pgam5 phosphoglycerate mutase family member 5 
Pigg phosphatidylinositol glycan anchor biosynthesis, class G 
Pikfyve phosphoinositide kinase, FYVE finger containing 
Pknox2 Pbx/knotted 1 homeobox 2 
Plcxd1 phosphatidylinositol-specific phospholipase C, X domain containing 1 
Plekhm3 pleckstrin homology domain containing, family M, member 3 
Plrg1 pleiotropic regulator 1, PRL1 homolog 
Pnrc2 proline-rich nuclear receptor coactivator 2 
Pole polymerase (DNA directed), epsilon 
Ppm1h protein phosphatase 1H (PP2C domain containing) 
Ppp2r1a protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform 
Pth2r parathyroid hormone 2 receptor 
Ptpla protein tyrosine phosphatase-like (proline instead of catalytic arginine), member a 
Ptprt protein tyrosine phosphatase, receptor type, T 
Pxmp2 peroxisomal membrane protein 2 
Rac2 RAS-related C3 botulinum substrate 2 
Rad23b RAD23b homolog 
Rcan3 regulator of calcineurin 3 
Rpap2 RNA polymerase II associated protein 2 
Rpe ribulose-5-phosphate-3-epimerase 
Rpl5 ribosomal protein L5 pseudogene 
Rps3a ribosomal protein S3A 
Sfrp2 secreted frizzled-related protein 2 
Sfrs6 serine/arginine-rich splicing factor 6 
Sh3d19 SH3 domain protein D19 
Srrm1 serine/arginine repetitive matrix 1 
Srsf10 serine/arginine-rich splicing factor 10 
Sstr3 somatostatin receptor 3 
Tgfbr3 transforming growth factor, beta receptor III 
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Tlr2 toll-like receptor 2 
Tmed5 transmembrane emp24 protein transport domain containing 5 
Tmem154 transmembrane protein 154 
Tmem5 transmembrane protein 5 
Trim2 tripartite motif-containing 2 
Unc80 unc-80 homolog 
Usp15 ubiquitin specific peptidase 15 
Vmn2r-ps129 vomeronasal 2, receptor, pseudogene 129 
Zfp160 zinc finger protein 160 
Zfp213 zinc finger protein 213 
Zfp229 zinc finger protein 229 
Zfp40 zinc finger protein 40 
Zfp51 zinc finger protein 51 
Zfp52 zinc finger protein 52 
Zfp53 zinc finger protein 53 
Zfp54 zinc finger protein 54 
Zfp605 zinc finger protein 605 
Zfp644 zinc finger protein 644 
Zfp677 zinc finger protein 677 
Zfp758 zinc finger protein 758 
Zfp820 zinc finger protein 820 
Zfp944 zinc finger protein 944 
Zfp945 zinc finger protein 945 
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Table 2.3 List of candidate genes within depressive QTLs 
Table 2.3. List of candidate genes within depressive QTLs   
Gene symbol Gene Name 
2300010F08Rik RIKEN cDNA 2300010F08 gene 
2900052N01Rik RIKEN cDNA 2900052N01 gene 
3100003M19Rik RIKEN cDNA 3100003M19 gene 
4733401A01Rik RIKEN cDNA 4733401A01 gene 
4930451E06Rik RIKEN cDNA 4930451E06 gene 
5830409B07Rik RIKEN cDNA 5830409B07 gene 
9430011C21Rik RIKEN cDNA 9430011C21 gene 
A930004J17Rik RIKEN cDNA A930004J17 gene 
Atpif1 ATPase inhibitory factor 1 
C530007A02Rik RIKEN cDNA C530007A02 gene 
Cdh2 neural cadherin 
Cdh4 retinal cadherin 
Col16a1 collagen, type XVI, alpha 1 
Dnajc8 DnaJ (Hsp40) homolog, subfamily C, member 8 
Dpp4 dipeptidyl-peptidase 4 
Epb4.1 erythrocyte protein band 4.1 
Epha7 Ephrin receptor A7 
Eya3 eyes absent homolog 3 
Fabp3 fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) 
Fam76a family with sequence similarity 76, member A 
Fap fibroblast activation protein, alpha 
Gca grancalcin, EF-hand calcium binding protein 
Gcg Glucagon 
Gmeb1 glucocorticoid modulatory element binding protein 1 
Hcrtr1 hypocretin (orexin) receptor 1 
Ifih1 interferon induced with helicase C domain 1 
Itgb6 integrin, alpha 11 
Kcnh7 potassium voltage-gated channel, subfamiliy H (eag-related), member 7 
Laptm5 lysosomal protein transmembrane 5 
Ly75 lymphocyte antigen 75 
Matn1 matrilin 1, cartilage matrix protein 
Mecr mitochondrial trans-2-enoyl-CoA reductase 
Med18 mediator complex subunit 18 
Nkain1 Na+/K+ transporting ATPase interacting 1 
Oprd1 opioid receptor, delta 1 
Pef1 penta-EF-hand domain containing 1 
Phactr4 phosphatase and actin regulator 4 
Pla2r1 phospholipase A2 receptor 1, 180kDa 
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Ppp1r8 protein phosphatase 1, regulatory (inhibitor) subunit 8 
Psmd14 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 
Ptafr platelet-activating factor receptor 
Ptpru protein tyrosine phosphatase, receptor type, U 
Pum1 pumilio homolog 1 
Rab42 RAB42, member RAS oncogene family 
Rbms1 RNA binding motif, single stranded interacting protein 1 
Rcc1 regulator of chromosome condensation 1 
Rpa2 replication protein A2, 32kDa 
Sdc3 syndecan 3 
Serinc2 serine incorporator 2 
Sesn2 sestrin 2 
Sfrs4 serine/arginine-rich splicing factor 4 
Slc4a10 solute carrier family 4 sodium bicarbonate transporter, member 10 
Smpdl3b sphingomyelin phosphodiesterase, acid-like 3B 
Snhg12 small nucleolar RNA host gene 12 
Snhg3 small nucleolar RNA host gene (non-protein coding) 3 
Snrnp40 small nuclear ribonucleoprotein 40kDa (U5) 
Stx12 syntaxin 12 
Taf12 
TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
20kDa 
Tank TRAF family member-associated NF-kappa-B activator 
Tbr1 T-box, brain, 1 
Tinagl1 tubulointerstitial nephritis antigen-like 1 
Trnau1ap tRNA selenocysteine 1 associated protein 1 
Xkr8 XK, Kell blood group complex subunit-related family, member 8 
Ythdf2 YTH domain family, member 2 
Zcchc17 zinc finger, CCHC domain containing 17 
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6. Figures 
 
 
 
Figure 2.1 Genome-wide association plot for anxiety-like behavior as measured by percent 
time spent in the center of the open field 
Figure 2.1. Genome-wide association plot for anxiety-like behavior as measured by percent 
time spent in the center of the open field. A genomic region on Chr 17 significantly correlates 
with amount of time spent in the center of the open field (-logP = 6.17). The figure shows QTL 
for anxiety-like behavior. To the right, is the putative gene formyl peptide receptor 1 (Fpr1) 
underneath the Chr 17 locus. The y-axis denotes the strength of association between genotype 
and phenotype (-logP), and the x-axis illustrates the cumulative SNP position in the genome 
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Figure 2.2 Genome-wide association plot for stress-induced hyperthermia 
 
Figure 2.2. Genome-wide association plot for stress-induced hyperthermia. A locus on Chr. 
5 significantly associates with changes in temperature following exposure to acute stress (-logP = 
6.17). This assay is a measure of anticipatory anxiety. To the right are the putative genes, Pde6b 
(phosphodiesterase 6B) and Pxmp2 (peroxisomal membrane protein 2) underneath the Chr 5 
locus for anxiety-like behavior. The y-axis denotes the strength of association between genotype 
and phenotype (-logP), and the x-axis illustrates the cumulative SNP position in the genome. 
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Figure 2.3 Genome-wide association plot for depressive-like behavior 
 
Figure 2.3. Genome-wide association plot for depressive-like behavior. We observed a 
significant association between a locus on Chr 4 and time spent immobile in the tail suspension 
test (-logP = 6.17). To the right are the putative genes, hypocretin (orexin) receptor 1 (Hcrtr1) 
and opioid receptor delta 1 (Oprd1) underneath the Chr 4 locus for depressive-like behavior. The 
y-axis denotes the strength of association between genotype and phenotype (-logP), and the x-
axis illustrates the cumulative SNP position in the genome. 
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CHAPTER 3 
CHARACTERIZING THE ROLE OF DIPEPTIDYL PEPTIDASE 4 IN DEPRESSION 
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1. Introduction 
 
Results from family, twin, and adoption studies indicate that there is a link between 
genetics and development of major depression. Family and twin studies have estimated the 
heritability of depression at 35-50% (Kendler et al. 2001; Sullivan et al. 2000), suggesting the 
potential utility of genetic variants as diagnostic and prognostic markers. An unbiased analysis 
for genetic regions linked to depression can be performed by investigating genome-wide 
associations between genetic variants and behavior. Depression is a clinically and genetically 
heterogeneous disorder, which complicates the identification of causative genes in human 
populations. Besides ease in accessibility, mice within the same strain are homogeneous at each 
locus, facilitating gene mapping studies by reducing genetic complexity. Furthermore, the effects 
of environment and diet can be controlled in mouse populations, thus genetic effects on behavior 
are more readily discernible compared to human populations.   
Using QTL mapping analysis, we identified an association between dipeptidyl peptidase 
4 (Dpp4) and depressive-like responses (-logP >5.0) (Figure 3.1). DPP4 is an ectoenzyme that 
cleaves polypeptides with proline and alanine, to a lesser extent, at the penultimate position. 
DPP4 is highly conserved across species and displays considerable sequence homology between 
the mouse and human DPP4 protein. The crystal structure of this protein contains a catalytic 
domain found in the internal cavity and a protein binding region located on the external surface 
(Abbott et al. 1999; Bjelke et al. 2004; Rasmussen et al. 2003). The catalytic domain is involved 
primarily in cleaving dipeptides with proline residues at the penultimate position, which typically 
renders molecules less active (Table 3.1).  
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Enzymatic cleavage of peptides that regulate the immune and endocrine processes 
indicate that DPP4 may mediate the neuroendocrine-immune interface. Although DPP4 is not the 
only enzyme that can cleave neuropeptide Y, it is the primary peptidase that breaks down plasma 
NPY levels making DPP4 a major contributory factor in mediating movement of NPY across the 
blood-brain barrier. Neuropeptide Y (NPY) modulates circadian rhythm (Otori et al. 1993; 
Weber and Rea 1997), food intake (Levine and Morley 1984; Morley 1987; Morley et al. 1987; 
Stanley et al. 1985; Stanley and Leibowitz 1985), and learning and memory (Flood et al. 1989; 
Morley and Flood 1990). N-terminal truncation of NPY by dipeptidyl peptidase IV leads to 
structural alterations that may influence function and receptor binding (Frerker et al. 2007). 
Reduction in NPY is associated with depressive behavior and altered response to stress (Redrobe 
et al. 2002). Additionally, Dpp4
-/- 
mice exhibit higher levels of substance P, which corresponds 
to a decreased in latency in response on the tail pinch and hot plate tests (Guieu et al. 2006). 
Treatment with DPP4 inhibitor reduced nociceptive response but only on wild type mice 
suggesting that elevation of substance P is due to lower enzymatic cleavage by DPP4 (Guieu et 
al. 2006). Substance P (SP) is a potent neuromodulator of pain that can alter behavioral response 
to stress and serotonergic signaling (Jessop et al. 2000; Malendowicz et al. 1996a; Malendowicz 
et al. 1996b, Schwarz et al. 1999). Both endocrine mediators, NPY and SP, have been shown to 
be involved in major depression (see Chapter 1 for details).  
 
DPP4 is a glycoprotein molecule that associates with other immune cell surface markers, 
including CD3 and CD45 (Ishii et al. 2001; Tanaka et al. 1992). DPP4 functions as a co-
stimulatory mediator of T-cell activation, which initiates downstream processes such as 
interleukin-2 production (Ishii et al. 2001), T-cell proliferation (Ishii et al. 2001), and T-cell 
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migration (Ikushima et al. 2002). Although its involvement in T-cell activation and proliferation 
is mainly attributed on its protein binding domain, cleavage of several cytokines by DPP4 may 
have an indirect effect on immune regulation (Table 3.1). Its enzymatic activity may influence 
its co-stimulatory effects on T-cell activation (Tanaka et al. 1993).    
  
The neuro-endocrine-immune integrated system is critical for many psychiatric disorders 
including depression, anxiety, and pain as reviewed in (Kopp 2001; Leonard and Song 1996; 
Miller 1998). The involvement of dipeptidyl peptidase IV in regulating both neuroendocrine and 
immune processes is suggestive of a DPP4-mediated bidirectional modulation along the 
neuroendocrine-immune circuitry. Interestingly, DPP4 has been implicated in various mental 
disorders, including anxiety (Emanuele et al. 2006), depression (Maes et al. 1996; Maes et al. 
1991), anorexia (van West et al. 2000), and bulimia (van West et al. 2000). DPP4 enzymatic 
activity has been associated with depressive symptoms in both clinical and pre-clinical studies 
(El Yacoubi et al. 2006; Krupina et al. 2009; Maes et al. 2001; Maes et al. 1996; Maes et al. 
1991). We hypothesize that Dpp4 is important for depression due to its role in inflammation and 
neuropeptide catabolism (Table 3.1). The goal of this study is two-fold: first, is to validate our 
QTL result that showed an association between Dpp4 haplotype and depressive-like responses 
and second, we will examine whether behavioral responses to chronic DPP4 inhibition differ 
between haplotype groups, which will assess functional DPP4 activity between strains.  
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2. Materials and Methods 
2.1 Animals 
 
Twenty-four male mice of the C57BL/6J (B6) and DBA/2J (D2) strains aged 8-9 weeks 
old were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were housed four per 
cage in polycarbonate cages on a 12-hour light/dark cycle (lights on at 0700h) with access to 
food and water ad libitum. Following one week of habituation, mice were randomized to either 
control or treatment group.  All procedures were approved by the Institutional Animal Care and 
Use Committee and followed the guidelines set forth by the National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals. 
2.2 Drug Treatment 
Sitagliptin is a selective reversible inhibitor of DPP4 that, in addition to diet and exercise, 
is the currently approved treatment for type 2 diabetes. Sitagliptin was purchased from BioVision 
(Mountain View, CA) and was administered via oral gavage. Mice were randomized to receive 
either water or 100 mg/kg of sitagliptin for 14 days (n = 12 mice per strain per treatment group). 
This dosing regimen was selected based on previous enzymatic and toxicity studies. Treatment 
with 10 mg/kg of sitagliptin resulted in 90% inhibition after 1 hr and more than 70% inhibition 
after 8 hr (Davis et al. 2010). Administration of 125 mg/kg of sitagliptin in mice (dose is 12 
times higher than the recommended daily dose of 100 mg in humans) did not result in 
hepatotoxicity and carcinogenicity (Sitagliptin [package insert], 2010). Mice were treated daily 
with water or sitagliptin throughout the end of the study and were sacrificed by cervical 
dislocation1 hr after the last dose, which was two days after the last behavioral test.  
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2.3 Open Field Test (OF) 
To minimize potential carryover effects between tests, behavioral tests were conducted 
every other day, in order from the least to the most stressful test. All behavioral tests were 
performed between 1300 h and 1600 h. After chronic administration of 0 or 100 mg/kg of 
sitagliptin for 14 days, mice were tested in the OF. This assay was conducted using a 27.3 cm x 
27.3 cm OF apparatus (MED-OFA-MS, Med Associates, St. Albans, VT), which has infrared 
detection beams that automatically recorded the animals' position and activity on the x-, y- and z-
axes over the course of the experiment. The OF is commonly used to measure exploratory and 
locomotor behavior in rodents. This test exploits the rodent‟s innate aversion to well-lit, open 
spaces. Based on previous observations that showed increased exploration in illuminated, open 
areas following administration of anxiolytics (Choleris et al. 2001; Crawley 1985), we measured 
anxiety-like behavior as percent time (sec) spent in the center of the OF. Activity in the OF was 
recorded for 10 min. 
2.4 Light-Dark Exploration Test (LD) 
The LD test was performed following the OF test. The LD assay is commonly used to 
detect anxiogenic effects of compounds. Similar to the OF, the LD test is based on the inherent 
aversion of mice to well-lit open areas and on their spontaneous responses to novel stimuli like 
light. Half of the LD apparatus was open and brightly illuminated, while the remaining half of 
the arena was occupied by a small black plexiglass compartment that was dark. Entry between 
the two compartments was through a small open doorway. Mice were permitted to freely explore 
the light and dark areas for 10 min. The number of transitions between compartments and the 
time spent in the light compartment are measures of anti-anxiety-like response.  
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2.5 Tail Suspension Test (TST) 
Following the LD test, mice were tested in a TST apparatus (PHM-300 TST Cubicle, 
Med Associates, St. Albans, VT). In this test, the mouse is subjected to the short-term, 
inescapable stress of being suspended by its tail. Following repeated escape attempts, the mouse 
becomes immobile. This response is generally considered behavioral despair, a depressive-like 
behavior that is proposed to model “hopelessness” (Steru et al. 1987; Steru et al. 1985). 
Immobility was recorded for 6 min in 60 sec blocks using the Actimetrics FreezeFrame software 
version 2.0 (Wilmetter, IL). Since all strains were uniformly active for the first 2 min, percent 
time spent immobile was calculated for the last 4 min of the test. Mice that climbed up their tail 
during testing were excluded from analysis.  
2.6 Measurement of DPP4 levels 
Brain and plasma CD26/DPP4 levels were quantified using Mouse DPP4 ELISA kit 
(Wuhan EIAab Sciences Co., Wuhan, China) according to the manufacturer‟s recommendation. 
In brief, standards ranging from 15.6 ng/mL to 1000 ng/mL were prepared by performing serial 
two-fold dilutions with sample diluent, which was provided in the kit. Brain and plasma samples 
were diluted 1:10 and 1:100, respectively. A total of 100 µL of standard, sample or blank were 
added onto wells that were pre-coated with a specific antibody to DPP4. Optical density of each 
well was determined using a microplate reader (BioTek Instruments, Winooski, VT) set to 450 
nm. Unknown DPP4 sample concentrations were determined from the standard curve, which was 
generated by plotting the optical densities of the standards against known DPP4 concentrations.   
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2.7 Assessment of DPP4 activity 
DPP4 activity was quantified by measuring the amount of fluorescence generated 
following enzymatic hydrolysis of the flourogenic substrate H-Gly-Pro-AMC. Recombinant 
human DPP4 (0.26 mU per well) was added to the appropriate wells, followed by the addition of 
samples and blanks. DPP4 inhibitor (P32/98; 10 µM per well) was added to the appropriate wells 
as a negative control. Following a 30-min incubation at 25ºC, 10 µL of H-Gly-Pro-AMC was 
added to each well. The plate was read at excitation and emission wavelengths of 380 nm and 
460 nm, respectively.  DPP4 activity was normalized for total protein concentration, as measured 
by Pierce Coomasie (Bradford) Protein Assay (Thermo Fisher Scientific, Rockford, IL). 
2.8 Statistical Analysis 
Given the uneven number of strains between haplotypes 1 and 2, behavioral difference 
between haplotype groups was calculated using a Mann-Whitney U-test. Mean behavioral and 
biological measurements for C57BL/6J and DBA/2J were calculated and analyzed using 
Student‟s t-tests. Statistical analysis was performed using SAS 9.2 (Cary, NC) and Graphpad 
Prism 5.0 (La Jolla, CA).  
3. Results 
 
3.1 Strain distribution pattern within Dpp4 locus 
Our study shows that inter-strain difference in baseline depressive-like responses associate 
with polymorphic variants within Dpp4. As seen in figure 3.2, the haplotype structure within 
Dpp4 perfectly aligns with the strain distribution pattern across the behavioral locus on 
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Chromosome 2 (-logP >5.0).  Difference in depressive-like behavior was found to be significant 
between haplotype groups 1 and 2 (U = 6.0, p<0.007) (Figure 3.3). It is important to note that 
the region where Dpp4 resides has been previously associated with high density lipoprotein 
(HDL) levels, hepatic lipase activity, and insulin levels (Mehrabian et al. 1998), which indicates 
a potential role of Dpp4 in diabetes and metabolic syndrome. Both disorders co-occur and 
exhibit pathophysiologic overlap with major depression (Chapter 1). 
3.2 Higher baseline immobility score is linked with higher DPP4 protein levels 
A significant difference in plasma (t = 2.96, p<0.01) and brain DPP4 (t = 2.44, p<0.04) levels 
was observed between B6 and D2 mice at baseline. Compared to B6, D2 mice have lower DPP4 
levels in plasma and brain (Figures 3.4 and 3.5).  Results from our microarray studies did not 
show significant difference in Dpp4 mRNA expression between strains. The expression of one 
probe set for Dpp4 (1441342_at) was higher in D2 than B6 mice, while the remaining three 
probe sets did not show a difference in Dpp4 mRNA expression between both strains. To 
determine whether difference in DPP4 protein levels can be attributed to DNA variants that 
affect amino acid sequence, imputed and experimental SNP genotypes were obtained from the 
Center for Genome Dynamics (http://cgd.jax.org) for comparison of Dpp4 sequence across 
mouse inbred strains (Szatkiewicz et al. 2008). Polymorphic SNPs across 30 strains were all 
synonymous and were found in the intron, exons, and untranslated regions (UTR). Interestingly, 
data from Ensembl indicate that six different Dpp4 transcript variants have been reported for B6. 
One isoforms leads to an alternative protein product, which may explain the difference in DPP4 
protein levels between B6 and D2. Additionally, two Dpp4 mRNA transcripts with different 
3‟UTR sequences have been reported in C57BL/10 ScNJ mice, which are closely related to B6 
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(Bernard et al. 1994). Due to low expression of Dpp4 in the brain, expression QTL analyses were 
not performed on Dpp4, which limits our ability to predict if Dpp4 expression is regulated by 
local or distal QTLs. 
No difference in enzymatic activity was observed between strains under control and 
sitagliptin conditions (Figures 3.9 and 3.10), which suggests that inter-strain behavioral 
differences are likely due to differences in DPP4 protein levels. B6 mice had higher baseline 
immobility scores (t = 11.04, p<0.0001) (Figure 3.8) and lower DPP4 protein levels than D2 
mice (Figures 3.4 and 3.5), which suggests that reduced DPP4 protein levels correspond with 
higher depressive-like behavior. Interestingly, B6 mice displayed lower anxiety-like behavior 
compared to D2. B6 mice spent more time in the center of the open field (t = 6.58, p<0.0001) 
and more time in the light compartment of the LD apparatus (t = 2.77, p<0.008) (Figures 3.6 
and 3.7). 
3.3 Inter-strain sensitivity to DPP4 inhibition   
 
Plasma DPP4 activity was significantly inhibited for both B6 (t = 9.03, p<0.0008) and D2 (t 
= 15.77, p<0.0001) mice. After chronic treatment with sitagliptin, there was an 88.5% and 84.9% 
reduction in DPP4 activity for B6 and D2 mice, respectively (Figure 3.9). However, treatment 
with sitagliptin did not alter DPP4 activity in the brain in either strain (Figure 3.10). Although 
no significant strain-specific differences were observed between vehicle and sitagliptin-treated 
mice in our behavioral tests, B6 mice show a trend of increased sensitivity to DPP4 inhibition 
(Figures 3.11 - 3.13). 
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4. Discussion 
 
 
To facilitate the application of pharmacogenetics in drug development and therapeutic 
selection, research efforts towards gene validation are warranted.  Identification of genes 
underlying depression is challenging to perform in human populations due to limitations of cost, 
disease heterogeneity, and sample size requirements. However, these limitations can be mitigated 
through the use of mouse models. The genetic diversity among inbred mouse strains, the 
availability of murine genetic sequence information, and the development of numerous genetic 
resources are additional benefits to using mouse models to study the genetic basis of depressive 
behavior. 
This study confirms our initial findings that showed an association between Dpp4 
haplotype and inter-strain baseline depressive-like behavior (Chapter 2). We found that DPP4 
protein levels correlate with basal behavioral despair and anxiety-like responses. Higher levels of 
DPP4 were associated with higher TST immobility scores and lower anxiety-like behavior, as 
measured by the OF and LD tests. This result is consistent with previous findings that have 
shown lower depressive-like responses in Dpp4 null mice. Rodents deficient in Dpp4 exhibited 
lower immobility scores for both animal models of behavioral despair (TST and forced swim 
test), indicating that the absence of Dpp4 yielded anti-depressive effects (El Yacoubi et al. 2006). 
No differences in anxiety-like behavior were observed between wild-type and Dpp4
-/-
 mice in the 
light/dark test (El Yacoubi et al. 2006).  
We did not observe a significant difference in behavior between vehicle- and sitagliptin-
treated B6 and D2 mice. Contradictory to clinical findings that show reduction in plasma DPP4 
enzymatic activity is common in patients with mood disorder and treatment-resistant depression 
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(Maes et al. 1996; Maes et al. 1991; Maes et al. 1997), inhibition of plasma DPP4 activity by 
sitagliptin did not significantly alter behavior in B6 and D2 mice. This conflicting result may be 
due to inadequate duration of DPP4-inhibition. It has been shown that 12-week treatment with 20 
mg/kg of sitagliptin in mice susceptible to the development of Alzheimer‟s disease resulted in 
reduced memory impairment and decreased brain inflammatory markers and amyloid-β protein 
(D'Amico et al. 2010), suggesting that long-term inhibition may be required to elicit behavioral 
changes. Additional studies are required to examine whether prolonged DPP4 inhibition alters 
depressive-like behavior. The results of this study are important, given that sitagliptin is used for 
long-term management of type 2 diabetes.  
The direction of the association between Dpp4 and depressive behavior remains unclear. 
Clinical studies indicate that lower DPP4 activity correlates with depressive symptoms, while 
results from our study and previous Dpp4 knockout study suggest that increased behavioral 
despair is linked with higher levels of DPP4 protein and absence of Dpp4, respectively. 
However, because DPP4 protein levels were not quantified in human serum samples, it is unclear 
whether reduction in DPP4 activity is due to lower DPP4 protein concentration, low or/and 
altered DPP4 enzymatic activity, or both. Thus, pre-clinical and clinical assessment of DPP4 
transcript levels, protein expression, and enzyme activity along with behavior is required to 
assess the direction of the correlation between Dpp4 and depression. Furthermore, the 
relationship between major depression and DPP4 activity in the brain remains unknown. No 
previous studies have examined DPP4 activity in post-mortem brain tissues of depressed 
individuals. Additionally, we could not inhibit DPP4 activity in the brain because the ratio of 
brain to plasma concentration for sitagliptin is fairly low (< 0.06 - 0.1) (Chu et al. 2007). 
Conseqently, further studies are required to examine if reduction in brain DPP4 activity 
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influences depressive behavior. It is important to note that the TST is primarily used to evaluate 
antidepressant activity of novel compounds and does not itself elicit depressive behavior. 
Behavioral paradigms like chronic social defeat stress and reduced sucrose preference, which 
assess other aspects of depressive behavior (e.g. anhedonia) (Nestler and Hyman 2010), can be 
used to further evaluate the role of Dpp4
 
in depression.  
Given the likelihood of false positive results from genome-wide association studies, it is 
critical to conduct independent studies for gene validation. Our initial findings indicate that 
DPP4 mediates baseline depressive-like behavior, which suggests that Dpp4 may be used as a 
genetic prognostic or diagnostic marker for depression.  
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5. Tables  
Table 3.1 Potential biological alterations of known DPP4 substrates 
Table 3.1. Potential biological alterations of known DPP4 substrates  
Substrate Significance Reference 
Neuropeptides 
 
  
β-Casomorphin Inactivation 
(Heymann and Mentlein 1986; Nausch 
et al. 1990) 
Endomorphins Inactivation (Shane et al. 1999) 
Gastric inhibitory peptide Inactivation 
(Ahren and Hughes 2005; Mentlein et 
al. 1993b; Nausch et al. 1990)  
Gastrin-releasing peptide Inactivation 
(Ahren and Hughes 2005; Nausch et al. 
1990) 
Glucagon-like-peptides 
(GLP1, GLP2) Inactivation 
(Baggio and Drucker 2007; Drucker et 
al. 1997) 
Growth hormone releasing 
factor Inactivation (Martin et al. 1993) 
Neuropeptide Y 
Inactivation/ altered 
receptor specificity 
(Frerker et al. 2007; Mentlein et al. 
1993a) 
Peptide YY 
Inactivation/ altered 
receptor specificity 
(Mentlein et al. 1993a; Unniappan et 
al. 2006) 
Pituitary adenylate-cyclase-
activating polypeptide Inactivation (Lambeir et al. 2001a) 
Prolactin Inactivation (Nausch et al. 1990) 
Tyr-melanostatin Inactivation (Shane et al. 1999) 
Substance P Inactivation (Guieu et al. 2006) 
Vasoactive intestinal peptide Inactivation (Lambeir et al. 2001a) 
Inflammatory mediators 
 
  
Eotaxin (CCL11) Altered receptor specificity (Forssmann et al. 2008) 
IP10 (CXCL10) Altered receptor specificity 
(Ajami et al. 2008; Oravecz et al. 
1997) 
ITAC(CXCL11) Altered receptor specificity (Ajami et al. 2008) 
Macrophage derived 
chemokines (CCL2) Altered receptor specificity 
(Lambeir et al. 2001b; Proost et al. 
1999) 
Mig (CXCL9) Reduced activity 
(Lambeir et al. 2001b; Proost et al. 
2001) 
Monocyte chemotactic 
proteins Inactivation (Van Coillie et al. 1998) 
RANTES Altered receptor specificity (Oravecz et al. 1997) 
Stromal-cell-derived-factor 
(CXCL12) Altered receptor specificity (Ajami et al. 2008) 
TNF-α Inactivation (Bauvois et al. 1992) 
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6. Figures 
 
 
Figure 3.1 Genome-wide association plot for depressive-like behavior 
Figure 3.1 Genome-wide association plot for depressive-like behavior. Genomic region on Chr 2 
significantly correlates with immobility scores in the tail suspension test (-logP = 5.0). The 
figure shows the baseline behavioral despair QTL. To the right is the putative gene, dipeptidyl 
peptidase 4 (Dpp4), underneath behavioral locus on Chr 2. The y-axis denotes the strength of 
association between genotype and phenotype (-logP scores), and the x-axis illustrates the 
cumulative SNP position in the genome. 
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Figure 3.2 Haplotype structure within Dpp4 aligns with the top peak 
 
Figure 3.3 Dpp4 haplotype is associated with a difference in baseline immobility score 
Figure 3.2. Haplotype structure within Dpp4 aligns with the top peak. The figure illustrates 
the strain distribution pattern for Dpp4 (bottom) and for the despair locus on Chr 2 (-logP >5.0, 
top 3-SNP window). SNP positions are on the y-axis. The x-axis denotes strain. 3.3. Dpp4 
haplotype is associated with a difference in baseline immobility score. Strains in haplotype 
group 2 (GGG) exhibit lower depressive-like behavior. Percent time spent immobile in the TST 
is a measure of depressive-like behavior (p<0.005). 
3.2 
3.3 
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Figure 3.4 Difference in plasma Dpp4 protein levels 
 
Figure 3.5 Difference in brain Dpp4 protein levels 
 
Figure 3.4. Difference in plasma Dpp4 protein levels. C57BL/6J have higher plasma Dpp4 
protein levels in at baseline (p<0.05). 3.5. Difference in brain Dpp4 protein levels. 
Comparison to DBA/2J, C57BL/6J exhibit higher Dpp4 protein levels in the brain (p<0.05).   
3.5 
3.6 
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Figure 3.6 Anxiety-like responses in the open field 
 
Figure 3.7 Anxiety-like responses in the light-dark exploration test 
 
Figure 3.8 Immobility responses in the tail suspension test. 
3.6 
3.7 
3.8 
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Figure 3.6. Anxiety-like responses in the open field. In comparison to DBA/2J, C57BL/6J 
mice spent more time in the center of the open field (p<0.0005).  3.7. Anxiety-like responses in 
the light-dark exploration test. During the 10 min light-dark test, C57BL/6J mice spent more 
time in the light compared to DBA/2J (p<0.005). 3.8. Immobility responses in the tail 
suspension test. C57BL/6J mice exhibited greater immobilility, indicative of “depressive-like” 
behavior, compared to DBA/2J mice (p<0.0005).   
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Figure 3.9 Measurement of plasma Dpp4 activity 
 
 
Figure 3.10 Measurement of Dpp4 activity in the brain 
Figure 3.9. Measurement of plasma Dpp4 activity. Baseline plasma DPP4 activity did not 
differ between C57BL/6J and DBA/2J (white bars). Treatment with DPP4 inhibitor (sitagliptin), 
resulted in greater than 80% reduction of plasma DPP4 activity in both strains (black and white 
bars) 3.10. Measurement of Dpp4 activity in the brain. No difference in plasma DPP4 activity 
was observed between C57BL/6J and DBA/2J (white bars). For both strains, 14-day treatment 
with sitagliptin did not alter brain DPP4 activity.  
 3.9 
3.10 
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Figure 3.11 Anxiety-like responses in the open field after chronic sitagliptin treatment 
 
 
Figure 3.12 Anxiety-like responses in the light-dark assay after chronic sitagliptin 
treatment 
 
3.11 
3.12 
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Figure 3.13 Depressive-like responses in the open after chronic sitagliptin treatment 
 
Figure 3.11. Anxiety-like responses in the open field after chronic sitagliptin treatment. For 
both C57BL/6J and DBA/2J strains, we found no significant difference between treatment 
groups in the amount of time spent in the center of the open field. 3.12. Anxiety-like responses 
in the light-dark assay after chronic sitagliptin treatment. Fourteen-day treatment with 
sitagliptin did not alter anxiety-like responses in the light dark test for C57BL/6J and DBA/2J 
strains. 3.13. Depressive-like responses in the open after chronic sitagliptin treatment. No 
difference in immobility was observed between water and sitagliptin-treated mice. White bars 
denote behavioral scores for control group. Black and white bars indicate mean behavioral 
responses for the sitagliptin group.  
3.13 
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1. Introduction 
 
The social and economic burden of major depressive disorder (MDD) is substantial. Despite the 
significant cost associated with depression, less than 30% of patients achieve adequate response to a 
selective serotonin reuptake inhibitor (SSRI) (Trivedi et al. 2006). There are several factors that 
contribute to poor treatment outcome including gender, disease onset, and presence of comorbid 
psychiatric disorders (Kornstein and Schneider 2001). Presently, the therapeutic management of 
patients who relapse or fail to respond is poorly defined. Partial responders or non-remitters typically 
undergo a series of antidepressant treatment modifications that are largely based on trial and error, 
leading to delay in symptom resolution and treatment discontinuation (Olfson et al. 2006; Warden et al. 
2007). A set of biomarkers that can prospectively identify patients who will respond to a specific 
medication can provide an evidence-based rationale for selecting an appropriate course of 
antidepressant therapy.    
Several large studies have been undertaken to identify genetic biomarkers of antidepressant 
response (Garriock et al. 2010; Ising et al. 2009; Uher et al. 2010). Pharmacogenetic studies of 
antidepressants in the Sequenced Treatment Alternatives for Depression (STAR*D) trial have led to the 
identification of genes associated with treatment response (Hu et al. 2007; Kraft et al. 2007; Lekman et 
al. 2008a; McMahon et al. 2006; Paddock 2008), treatment resistance (Perlis et al. 2008), and 
treatment-emergent suicidal ideation (Laje et al. 2009; Laje et al. 2007; Perlis et al. 2007). In addition, 
polymorphisms in genes that encode drug-metabolizing enzymes and transporters have been tested for 
correlation with treatment response (Peters et al. 2008). Although several studies have yielded notable 
findings, none meet currently accepted standards in human genetics for replication (Chanock et al. 
2007).  
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The search for antidepressant biochemical markers is complicated by multiple neurobiological 
abnormalities that have been observed in depression, indicating that it is unlikely for a single biological 
marker to characterize a multifactorial disease like MDD. Many analytes, including brain-derived 
neurotrophic factor (BDNF), serotonin transporter, and monoamines, have been linked with depressive 
symptoms and response to antidepressant therapy (Manji et al. 2001; Nestler et al. 2002; Thase 2007). 
A few studies have looked at biochemical markers that can be used as diagnostic (Domenici et al. 
2010; Jehn et al. 2006) or treatment markers (Ising et al. 2007; Schule et al. 2009) for depression. Other 
physiologic markers including neurostructural and neurofunctional measures have shown promise as 
potential markers of antidepressant response (Leuchter et al. 2010; Leuchter et al. 2009b). It is yet to be 
determined if these biomarkers can prospectively predict response prior to treatment. 
A major limitation in evaluating the relationship between antidepressant response and 
biochemical alterations in human subjects is sample accessibility, whereby analysis is typically 
restricted to human serum and post-mortem brain samples. The assessment of post-mortem brain 
tissues is limited by the inability to distinguish if neurobiochemical abnormalities are causal or a 
consequence of disease or treatment, while serum samples are more accessible but provide a relatively 
myopic view of the neurobehavioral mechanisms that occur in the brain. Importantly, these limitations 
can be mitigated through the use of inbred mouse strains, which are easily maintained and manipulated 
for research purposes. Besides ease in accessibility, mice within the same strain are homogeneous at 
each genomic locus, which makes identification of genetic variants of drug response more feasible due 
to reduced genomic complexity.    
In order to understand how biochemical and genetic differences correlate with treatment 
response, we measured depressive-like behavior, anxiety-like behavior, gene expression, and the levels 
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of thirty-six neurobiochemical analytes across a panel of genetically-diverse mouse inbred lines after 
chronic treatment with vehicle or fluoxetine. Neurobiochemical markers were chosen based on their 
putative molecular function within pathways proposed to underlie depression and anxiety, which 
include neuronal transmission, HPA-axis regulation, and neuroimmune processes. To our knowledge, 
this is the first study that simultaneously measured and examined the role of thirty-six putative 
neurobiochemical markers across thirty mouse inbred strains. In this study, we examined how baseline 
and treatment-induced biochemical differences affect depressive-like and anxiety-like responses. Our 
goal was to establish genetic and biochemical biomarkers that can predict fluoxetine response and to 
propose a molecular pathway that is critical in mediating response to SSRIs. In addition, we examined 
baseline neurobiological differences that affect depressive-like and anxiety-like behaviors in an effort 
to identify biomarkers that contribute to risk for poor treatment outcomes.  
2. Materials and Methods 
 
2.1 Animals 
 
 
Thirty mouse inbred strains (129S1/SvImJ, A/J, AKR/J, BALB/cJ, BTBRT<t>tf/J, BUB/BnJ, 
C3H/HeJ, C57BL/6J, C57BLKS/J, C57BR/cdJ, C58/J, CBA/J, CE/J, DBA/2J, FVB/NJ, I/LnJ, LG/J, 
LP/J, MA/MyJ, MRL/MpJ, NOD/LtJ, NOR/LtJ, NZB/BlNJ, NZW/LacJ, P/J, PL/J, RIIIS/J, SJL/J, 
SM/J, and SWR/J)  aged 5-6 weeks old were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Male mice were housed four per cage in polycarbonate cages on a 12-hour light/dark cycle (lights on at 
0700h) with access to food and water ad libitum. Following one week of habituation, mice were 
randomized to either control or treatment group. Depending on cost, availability, and estimated intra-
strain response variability, the number of animals treated per treatment group ranged from 9 to 21 
animals per strain.  All procedures were approved by the Institutional Animal Care and Use Committee 
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and followed the guidelines set forth by the National Institutes of Health (NIH) Guide for the Care and 
Use of Laboratory Animals. 
 
2.2 Drug Treatment 
Fluoxetine is an SSRI that has been extensively studied for its effect on depressive behavior 
(Cipriani et al. 2005; Rossi et al. 2004). Fluoxetine HCl was purchased from Spectrum Chemicals 
(Gardena, CA). Mean water intake for each strain was determined previously by measuring daily water 
consumption for three weeks. This information, along with average weight measurements for each 
strain, was used to determine the amount of fluoxetine required to provide a daily oral dose of 0 or 18 
mg/kg per mouse.  A chronic fluoxetine regimen of 18 mg/kg for 21 days was selected based on results 
of a previous dose-response study which investigated the behavioral effects of fluoxetine 
administration at 0, 5, 10, 14, or 18 mg/kg for 1, 6, or 21 days (Miller et al. 2008). In each strain, 
comparison of mean daily water intake between vehicle and fluoxetine-treated animals indicates 
minimal effect of fluoxetine on water consumption (Supplementary Table 4.1). Mice were treated 
daily with fluoxetine or water throughout the end of the study and were sacrificed one week after the 
open field test between 1300 and 1600H.  
2.3 Tail Suspension Test (TST) 
Strains were randomly tested across day, time of testing, and equipment. At any given time, 
only four to eight animals per strain were tested. Each animal was tested only once in each procedure. 
After chronic administration of 0 or 18 mg/kg of fluoxetine for 21 days, mice aged 9-10 weeks were 
tested in a tail-suspension apparatus (PHM-300 TST Cubicle, Med Associates, St. Albans, VT) 
between 1300h and 1600h. In this test, the mouse is subjected to short-term inescapable stress by 
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having its tail suspended. Following failed attempts to escape, the mouse becomes immobile, a 
response generally considered as behavioral despair, a depressive-like behavior that is proposed to 
model “hopelessness” (Steru et al. 1987; Steru et al. 1985). Immobility was recorded for 7 min in 60 
sec blocks using the following parameters: threshold = 3, gain = 8 and resolution = 200ms. Since all 
strains were uniformly active for the first min, percent time spent immobile was calculated for the last 
6 min of the test. This procedure has been used previously to determine TST responses to 
antidepressants (Fujishiro et al. 2002; Ukai et al. 1998). Mice that climbed up their tail during testing 
were excluded from analysis (number of animals excluded = 104 out of 721 mice). Mean depressive-
like behavior is reported in Supplementary Table 4.2.   
2.4 Open Field Test (OF) 
To minimize potential carryover effects between tests, behavior in the open field was recorded a 
week following TST. The OF test was conducted between 1300h and 1600h using a 27.3 cm x 27.3 
open field apparatus (MED-OFA-MS, Med Associates, St. Albans, VT), which was surrounded by 
infrared detection beams on the x-, y- and z-axes that automatically recorded the animals' position and 
activity over the course of the experiment. Activity in the open field was recorded for ten minutes 
within an environmental chamber that provided white noise (60-64 dB) and low, indirect lighting 
(Supplementary Table 4.2). The OF is commonly used to measure exploratory and locomotive 
behavior in mice. This test exploits the rodent‟s innate aversion to well-lit open spaces. Based on 
previous observations that showed increased exploration towards illuminated open areas following 
administration of anxiolytics (Choleris et al. 2001; Crawley 1985), anxiety-like behavior was measured 
as percent time spent in the center 25% of the open field. In addition, locomotor activity was recorded 
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by calculating the total distance traveled in the open field. This behavior was measured to assess if 
general locomotor activity confounded response in the TST.  
2.5 Tissue Collection 
Upon completion of the study, mice were sacrificed by cervical dislocation and decapitation 
between 0900h and 1300h. Trunk blood was quickly collected and allowed to clot on ice. Following 
centrifugation, serum samples were collected and stored at -20ºC for determination of fluoxetine and 
norfluoxetine levels using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). 
Micro-dissections of individual regions were performed on serial coronal brain sections that were 
placed on a cold metal block. Cortex was taken from the same section for each animal and immediately 
snap frozen on dry ice and stored at -80ºC for gene expression and neurobiochemical analysis. Other 
brain regions were used for RNA isolation and subsequent gene expression analysis. Given that the 
neurobiochemical markers we examined were primarily expressed in the brain (Table 4.1), we 
measured the levels of these analytes in brain tissue. 
2.6 Fluoxetine/norfluoxetine quantification  
  A solution with 10 µL of serum and 150 µL of acetonitrile was spiked with 5 µg/mL of each 
internal standard (fluoxetine- D6 and norfluoxetine-D6). Following sample filtration with 0.45 µm filter 
plate, 50 µL of the filtrate were diluted with 0.1% formic acid and injected into a Sciex 4000 LC 
MS/MS (Sciex Inc., Concord ON) equipped with a Waters YMC Cyano HPLC column (2.0 x 23 mm) 
(Milford, MA). The mobile phase consisted of water/acetonitrile/formic acid (75:25:0.1). A standard 
curve with concentrations from 20 to 10, 000 ng/mL was used to extrapolate amounts of fluoxetine and 
norfluoxetine in each sample (n = 8-19 mice per strain per treatment group). Peak areas were detected 
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for ions with the following mass to charge (m/z) ratios: m/z 31044 (fluoxetine), m/z 296 134 
(norfluoxetine), m/z 316  44 (fluoxetine- D6), and m/z 302 140 (norfluoxetine-D6). This information 
was used to quantify serum fluoxetine and norfluoxetine levels (Supplementary Table 4.3).  
2.7 Neurobiochemical analyte quantification 
Prior to ELISA experiments, all antibodies were tested for specificity by performing western 
blot experiments in pooled brain samples acquired from three mouse inbred strains. Abundance of 
neurobiochemical markers was measured using a parallelized reverse ELISA methodology (Zeptosens 
– a division of Bayer (Schweiz) AG, Witterswil, Switzerland). From each strain, cortex tissues were 
taken from three animals in each treatment group and homogenized in CLB1 buffer (Zeptosens) with 
zirconium oxide beads for 30 sec using QIAgen TissueLyser II (QIAgen, Valencia, CA). Semi-solid 
brain tissues were mixed gently on a tumbling shaker for 30 min at room temperature. Following 
centrifugation (2 min at 10,000 x g), supernatants were transferred and stored at -80ºC until further 
analysis. Total protein concentrations for each sample were determined using a modified Bradford 
assay (Coomassie Protein Plus Assay, Pierce Biotechnology, Rockford, IL). All samples were adjusted 
with CLB1 buffer to obtain a uniform concentration of 2 mg/mL. Immediately after dilution, each 
sample was spotted twice at concentrations of 0.05, 0.10, 0.15, and 0.2 mg/mL of total protein. 
Reference signals were obtained from simultaneous spotting of assay buffer and labeled antibodies on 
the array chip. Following overnight incubation with primary antibodies, arrays were washed and 
incubated with fluorescence-labeled anti-species secondary antibody for 2.5 h in the dark. Arrays were 
imaged simultaneously using ZeptoREADER (Zeptosens) at excitation/emission wavelengths of 
635/670 nm with exposure times of 0.3, 1, 5, and 10 sec.  
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All images were analyzed using ZeptoVIEW 3.0 (version 3.0.1.17). Background intensities for 
each individual spot were determined by taking the mean signals of four additional spots equidistant 
from the sample spot. Net fluorescence intensities (NFI) were calculated by subtracting background 
signal from each sample spot signaling. Following NFI determination, each NFI value was normalized 
to the mean intensity of the reference spots. Using least-squares method, eight normalized NFI values 
obtained from each sample were fitted linearly against tissue lysate protein concentrations. The 
extrapolated signal intensity that corresponds in the mid-point of the concentration range (0.125 
mg/mL) is defined as the reference fluorescence intensity (RFI). Relative abundance for each 
neurobiochemical marker was obtained by comparing inter-strain RFI values. All neurobiochemical 
markers measured in this study are listed in Table 1. Mean RFI scores for each analyte are listed in 
Supplementary Table 4.4.  
Behavioral, neurobiochemical, and drug (fluoxetine and norfluoxetine) concentration data for 
each animal were deposited at The Jackson Laboratory Phenome Database (http://phenome.jax.org/) 
under the name Wiltshire 2 and Wiltshire 3. 
2.8 Statistical analysis 
Response to treatment was calculated by taking the ratio of fluoxetine behavioral scores to 
vehicle behavioral scores. Percent change in immobility was calculated by multiplying the ratio of 
fluoxetine immobility scores to vehicle immobility scores by 100 and then subtracting the product from 
100. We defined positive and negative responders as having at least 20% decreased or increased in 
immobility scores, respectively. Given that the criterion was defined subjectively, we also investigated 
difference in response using more stringent criteria, which were 30% and 40% change in immobility 
scores. Strain and treatment effects on immobility scores and percent time spent in the center of the OF 
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were obtained using a two-way analysis of variance (ANOVA). Post-hoc pairwise comparisons of 
behavioral scores between control and fluoxetine groups were performed using a Mann-Whitney U 
test. False discovery rate is controlled at the 0.10 level using the Benjamini-Hochberg method.  
Because both baseline neurobiochemical levels and fluoxetine-induced biochemical alterations 
can affect SSRI response, we wanted to identify the relationship between behavior and 
neurobiochemical alterations at baseline and after fluoxetine treatment. Partial least squares (PLS) 
regression analysis was used to extract latent vectors that account for most of the covariance between 
biochemical analytes and behavior in each treatment group. Once the vector was extracted, we 
determined the biochemical analytes that covary most with behavioral response by assessing the PLS 
loading score for each analyte onto the vector.  
To identify biochemical markers that discriminate positive or negative responders, we used a 
Distance Weighted Discrimination (DWD) analysis. Unlike traditional multivariate analysis, this 
approach was intended for analysis of high dimension, low sample size data sets (Marron et al. 2007; 
Qiao et al. 2010). The DWD method was used to identify a hyperplane that best distinguishes the 
positive or the negative response groups. Following identification of a DWD hyperplane, the DWD 
loading vector (orthonormal to the hyperplane) was calculated, indicating the contribution of each 
neurobiochemical marker in discriminating negative or positive responders. The Direction Projection 
Permutation based hypothesis test (DiProPerm) with DWD was used to test for an overall 
neurobiochemical mean difference in each response group. In this procedure, the neurobiochemical 
scores were projected onto the DWD vector and the two sample t-statistic was computed. The t-statistic 
obtained from the real data set was compared to the t-statistics obtained from 1,000 relabeled group 
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pairs with recomputed DWD vector to determine if the overall difference in neurobiochemical levels 
was significant (p<0.05).  
We performed Pearson‟s correlation analysis to determine if neurobiochemical levels 
correspond with fluoxetine, norfluoxetine, or mRNA expression levels. Molecular connections between 
candidate treatment biomarkers were evaluated using Ingenuity Pathway Analysis (IPA) software 
(Ingenuity Systems, Inc. Redwood, CA). Statistical analyses were performed using SAS 9.2 (SAS 
Institute, Cary, NC), R Package version 2.13 (http://www.r-project.org/), and MATLAB 7 (The 
MathWorks, Natwick, MA). 
2.9 Transcriptome gene expression analysis  
Brain regions were homogenized in 500 µL of Trizol using a QIAgen TissueLyser at 30 Hz 
(QIAgen, Valencia, CA). RNA for each animal was isolated by guanidinium thiocyanate-phenol-
chloroform extraction and was further purified using the RNAeasy miniprep kit (QIAgen, Valencia, 
CA) according to the manufacturer‟s directions. For each strain, RNA samples for three animals from 
each treatment group were pooled and converted to cDNA and biotinylated cRNA (Enzo kit, 
Affymetrix, Santa Clara, CA). The resulting cRNA was hybridized to Affymetrix GeneChip Mouse 
Genome 430 2.0 arrays.  
Following normalization with the gcRMA algorithm, expression data were analyzed using 
ArrayAssist software (Stratagene, La Jolla, CA). To identify genetic alterations associated with 
fluoxetine administration and treatment response, we analyzed gene expression profiles between 
control and fluoxetine treated mice as well as profiles between negative and positive responders as 
defined by the tail-suspension phenotype. Microarray data were preprocessed to identify genes with 
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expression levels greater than background levels (intensity >50). Gene expression profiles for each 
treatment group (control vs. fluoxetine) were filtered by calculating fold change difference between 
probes with minimum and maximum intensity values. In each treatment group, genes that were 
significantly variable between strains (fold change ≥3 between minimum and maximum values) were 
analyzed. Alternatively, expression data between response groups (negative vs. positive) were filtered 
by taking the ratio of fluorescence intensities between fluoxetine and control mice within each strain. 
Probe sets that were significantly affected by fluoxetine treatment (intensity ratios of fluoxetine to 
vehicle ≥2 for at least one strain) were selected. Following filtration, genes were prioritized based on 
their signal-to-noise ratio (SNR), which is the difference in median gene expression values divided by 
the standard deviation. The p-value for each observed SNR was determined from the empirical null 
distribution of SNRs, which was obtained by permuting the sample labels and recalculating the SNRs 
1,000 times (Gould et al. 2006). Genes with a false discovery rate (FDR) of ≤ 0.05 were considered 
significant.  
SNR rank scores were used to identify genes that were differentially expressed in either 
treatment (control vs. fluoxetine) or response (negative vs. positive responders) groups. These genes 
were then tested for their ability to assign samples in each response or treatment category using a k-
nearest-neighbors (k-NN) classification with leave-one-out cross-validation test previously described in 
(Cover T.M. and Hart 1967; Golub et al. 1999). Briefly, the k-NN algorithm assigned a treatment or 
response label on the unknown sample based on the class assignment most frequently represented 
among its closest neighbors. Class assignments were determined based on the expression profiles of 
genes deemed to be informative. The validity of the model was tested using a leave-one-out cross-
validation test, in which the algorithm withheld a sample, built a class predictor model using the 
remaining samples, and then predicted the class label of the withheld test sample. Using a distance 
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function, the model determined which members of the training set were closest to the test sample and 
then weighted each “vote” according to the distance of the unknown test sample from its neighbors, 
giving the closest neighbor the biggest “vote.” This process was iteratively performed for each sample, 
and the cumulative error rate was calculated (Cover T.M. and Hart, 1967; Golub et al., 1999) (Golub et 
al. 1999). An unsupervised hierarchical clustering analysis was used to evaluate the expression pattern 
of the informative genes for each treatment and response group. Moreover, we performed eQTL 
analysis on genes with significant SNR values (FDR≤ 0.05) as described in (Wu et al. 2008) to 
determine if changes in gene expression following fluoxetine treatment were under cis-regulation. 
Gene expression analyses were performed using GenePattern 2.0 (Reich et al. 2006) and R Package 
version 2.13. Gene expression data were deposited into NCBI Gene Expression Omnibus (GEO) 
database (GSE28644). 
A logistic regression analysis was used to identify baseline genetic markers that can account for 
variable fluoxetine response. Probe sets that were variable in the control group (fold change ≥3 
between minimum and maximum values) were selected and evaluated for their influence on fluoxetine 
response. By using these analyses, we can identify baseline genetic markers that may be predictive of 
SSRI response. Statistical analyses were performed using R Package version 2.13.  
2.10 QTL Mapping  
Efficient Mixed-Model Association (EMMA) has been well-described elsewhere (Kang et al. 
2008) and will be summarized here. Experimental SNP genotypes encompassing over 500,000 
polymorphic loci across 72 commonly-used laboratory strains were obtained from the Center for 
Genome Dynamics at http://cgd.jax.org (Szatkiewicz et al. 2008; Yang et al. 2009). Over 190,000 
SNPs were informative for the 30 mouse inbred lines, which provided the basis for inferring genotype. 
133 
 
SNPs used in these analyses were fully genotyped, not imputed, and had been specifically selected to 
discriminate Mus musculus sub-species. This set of SNPs avoids some of the previous biases in 
genome-wide analyses and enables an accurate ascertainment of population substructure. Associations 
between genotype (1-SNP) and phenotype were calculated by an F-statistic corrected for population 
structure and genetic relatedness. Results were plotted using SpotFire software (TIBCO Palo Alto, 
CA). Genomic loci that were associated with behavioral or biochemical phenotypes at an FDR ≤0.05 
were considered significant.  
3. Results 
 
3.1 Behavioral measurements 
 
Behavioral responses were measured in the open field test and tail suspension test following 
chronic treatment with vehicle (water) or fluoxetine. Analysis of immobility scores across the 30 
mouse inbred strains revealed significant strain (F = 29.83, p< 0.0001) and treatment (F = 39.14, p< 
0.0001), as well as significant strain by treatment effects (F = 3.83, p< 0.0001). Similarly, significant 
strain (F = 23.16, p< 0.0001), treatment (F = 20.41, p< 0.0001), and strain by treatment effects (F = 
1.63, p< 0.02) were observed for percent time spent in the center of the OF. Compared to the control 
group, an overall reduction in mean immobility was observed in mice treated with fluoxetine (t = 
3.253, p<0.003). However, change in immobility scores (fluoxetine response) was variable between 
strains. Thirteen strains exhibited 20% reduction in immobility (positive responders) while five inbred 
strains exhibited 20% increased in immobility (negative responders) (Figure 4.1). Post-hoc pairwise 
comparisons of behavioral scores between treatment groups revealed significant difference in 
immobility scores for BALB/cByJ, BUB/BnJ, C57BL/6J, C57BR/cdJ, CBA/J, MA/MyJ, P/J, PL/J, and 
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SM/J. Significant difference in anxiety-like responses between vehicle and fluoxetine treated mice 
were observed for DBA/2J, MA/MyJ, SJL/J, and SM/J (Supplementary Table 5). 
Mean fluoxetine and norfluoxetine levels were variable across the strains, concentration ranges 
are (470.3 ng/mL - 1274.8 ng/mL) for fluoxetine and (578.6 ng/mL - 1612.2 ng/mL) for norfluoxetine. 
No significant correlation was observed between mean depressive-like behavior and mean serum levels 
of fluoxetine (r
2 
= 0.036) or its metabolite norfluoxetine (r
2 
= 0.047). This finding is similar to human 
studies, which do not find significant association with antidepressant response and serum levels of 
fluoxetine or norfluoxetine (Amsterdam et al. 1997; Beasley et al. 1990; Norman et al. 1993). With the 
exception of a few markers, no significant correlation was detected between neurobiochemical levels 
and drug concentration. Fluoxetine level was minimally correlated with GSK3β (r2 = 0.213), HDAC5 
(r
2 
= 0.131), and VEGF (r
2 
= 0.155). Minimal correlation between MCH protein levels and 
norfluoxetine levels (r
2 
=0.135) was also detected. There was no correlation between mean percent 
immobility in the TST and total distance traveled in the OF for control (r
2 
= 0.013) and treated animals 
(r
2 
= 0.083), indicating that depressive-like behavior was not affected by locomotor activity. We 
observed a modest correlation between baseline and fluoxetine-induced immobility scores (r
2 
= 0.628), 
which suggests that baseline TST behavior is linked with drug response.   Genetic analysis can be 
performed using inbred-strain phenotype data to identify genetic loci associated with behavioral 
phenotypes (Miller et al. 2010; Williams et al. 2009).  Independent QTL mapping analysis for 
behavioral phenotypes identified significant loci for anxiety, treatment response (data not shown), and 
baseline behavioral despair. A locus on Chromosome 9 (9: 46.7- 47.6 Mb) associated with baseline 
depressive-like behavior (-logP = 6.17, FDR≤ 0.059) and this was of particular interest because of its 
co-localization with genome-wide association analysis for neurobiochemical markers.  
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3.2 Levels of S100β, GSK3β, HDAC5, and GFAP contribute most to treatment response 
Levels of thirty-six neurobiochemical markers proposed to be involved in depression and 
anxiety were measured in cortex (Table 4.1). Dopamine transporter (DAT), interleukin-6 (IL-6), 
FK506-binding protein 51 (FKBP51), glucocorticoid receptor (NR3C1), and neuron specific family 
gene member 2 (NSG2) were excluded from the analysis due to weak intensities, irregular staining, or 
non-linear dose-response signals. In the control group, correlation between protein levels and mRNA 
expression levels was detected for c-Fos (r
2 
= 0.269, 1423100_at), GFAP (r
2 
= 0.222, 1426508_at; r
2 
= 
0.184, 1426509_at; r
2 
= 0.187, 1440142_s_at), GLO1 (r
2 
= 0.244, 1424108_at; r
2 
= 0.274, 
1424109_a_at), and PAQR8 (r
2 
= 0.1796, 1431042_at). In the fluoxetine group, correlation between 
protein levels and mRNA expression levels were detected for GFAP (r
2 
= 0.183, 1440142_s_at; r
2 
= 
0.623, 1426508_at; r
2 
= 0.692, 1426509_s_at;), GNB1 (r
2 
= 0.144, 1454696_at; r
2 
= 0.161, 
1417432_at), and NPY (r
2 
=0.154, 1419127_at). The lack of strong correlation between 
neurobiochemical levels and corresponding transcript levels indicates an indirect relationship between 
mRNA and protein expression. Partial least squares analysis of the data indicated that the first vector 
accounted for 56% and 59% of the covariance in neurobiochemical and behavioral differences in the 
fluoxetine and control groups, respectively (Supplementary Table 4.6). Behaviors in the OF and TST 
accounted for baseline behavior (PLS loading score onto vector 1, percent time spent in the center OF: 
75.1% and immobility TST: 56.4%). However, behavioral differences observed after chronic fluoxetine 
treatment were mainly due to inter-strain responses in the TST (PLS loading score onto vector 1, 
percent time spent in the center OF: 17.2% and immobility TST: 72.6%).  Levels of glyoxylase 1 
(GLO1) and guanine nucleotide binding protein 1 (GNB1) account for most of the covariance in 
anxiety-like and depressive-like behavior in the control group. Higher levels of GLO1 and GNB1 
associated with higher baseline anxiety-like and depressive-like behavior. Alternatively, fluoxetine-
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induced immobility behavior was mostly affected by glial fibrillary acidic protein (GFAP), S100 beta 
protein (S100β), GLO1, and histone deacytelase 5 (HDAC5) (Figure 4.2). Lower immobility scores 
following fluoxetine treatment were linked with higher levels of GFAP, S100β, GLO1, and HDAC5.  
In order to identify biomarkers of fluoxetine response, we examined which biochemical 
analytes were most effective in discriminating positive or negative responders. An overall 
neurobiochemical difference was observed in positive and negative responders. Neurobiochemical 
alterations following fluoxetine treatment discriminate positive responders, while baseline biological 
differences distinguish negative responders. This finding was observed irrespective of the stringency in 
defining positive or negative response, defined as 20-40% reduction or increased in immobility, 
respectively (Figure 4.3). DWD analysis show levels of S100β, GSK3β, HDAC5, GFAP, and GNB1 
account for most of the variance in treatment response (Figure 4.2). Baseline levels of S100β, GSK3β, 
HDAC5, GFAP, and GNB1 can discriminate negative responders.  Chronic fluoxetine treatment affects 
these analytes and the levels of S100β, GSK3β, HDAC5, GFAP, and GNB1 post-treatment indicate 
positive response to fluoxetine.  The direction of the vectors was the same for GSK3β and HDAC5 but 
opposite for S100β and GNB1 when discriminating positive or negative responders. Negative 
responders had lower levels of S100β and higher levels of GNB1, HDAC5, and GSK3β at baseline, 
while positive responders had lower levels of GNB1 and higher levels of S100β, GSK3β, and HDAC5 
after fluoxetine treatment (Figure 4.2). GSK3β and HDAC5 can discriminate negative or positive 
response but have poor specificity in identifying negative and positive response groups from each 
other, while the opposing direction of the S100β and GNB1 vectors indicates that both analytes can 
discriminate negative and positive response groups from each other. Interestingly, we observed 
minimal influence of GFAP on positive response relative to its affect on negative response, which 
suggests that elevation in GFAP is mainly indicative of negative fluoxetine response.  
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In both analyses, response to fluoxetine was associated with alteration in candidate 
neurobiochemical levels (Figure 4.2). Results from different methods of analysis (PLS and DWD) 
show that levels of GFAP, S100β, HDAC5, and GSK3β contribute to differential TST responses after 
fluoxetine treatment. In order to address whether fluoxetine mediates levels of candidate treatment 
markers S100β, GFAP, HDAC5, and GSK3β through a common pathway, we looked for molecular 
connections between them. Using IPA software, we discovered that all candidate treatment markers are 
linked either directly or indirectly. S100β, GFAP, HDAC5, and GSK3β connect within a common 
cellular growth and proliferation network, indicating the importance of cellular genesis in mediating 
response to chronic fluoxetine treatment (Supplementary Figure 4.1).  
3.3 Gene expression profiles for treatment and response groups 
Gene expression data collected from cortex were preprocessed to eliminate invariable probe 
sets, reducing the number of probes from 45,101 to 4,818. From genome-wide gene expression 
analysis, we first identified genes that were strongly correlated with control or fluoxetine treatment by 
computing the SNR ratio for 4,818 probe sets. We found 203 probe sets that were differentially 
expressed in either treatment group (FDR ≤ 0.10). Based on the SNR rank scores, twelve genes were 
significantly up-regulated in control or fluoxetine group, indicating that these genes are likely to be 
informative for assigning treatment category (Supplementary Table 4.7). To evaluate whether the 
expression profiles of the informative genes can be used to predict treatment classifications, we 
performed the k-NN leave-one-out cross-validation test. The twelve informative genes correctly 
predicted treatment class for 38 out of the 60 samples (absolute error of 36.6%), indicating that the 
overall expression patterns of the informative genes do not effectively predict treatment class. Because 
it is likely that gene expression differences between vehicle and fluoxetine-treated mice may be 
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confounded by inter-strain difference in response, we then analyzed gene expression profiles in 
negative and positive response groups. There were over 171 genes with variable expression patterns in 
each response group (FDR≤ 0.05). Based on SNR rank scores, eight genes were significantly up-
regulated in either positive or negative responders, which make them likely to be genetic predictors of 
fluoxetine response (Supplementary Table 4.9). Using the k-NN leave-one-out cross-validation 
algorithm, we tested to see if responders can be correctly assigned (negative or positive) based on the 
expression patterns of the eight informative genes. Sixteen out of the eighteen samples were correctly 
assigned to the appropriate response groups, providing an absolute error rate of 11.1%. Results from 
the regression analysis indicate that several baseline genetic markers affect inter-strain variability in 
fluoxetine response (Supplementary Table 4.10). Using previously described eQTL analysis (Wu et 
al. 2008), we found that changes in gene expression for the 171 genes were not likely due to cis-
regulation. Gene expression changes as measured by the log ratios of fluorescence intensities 
(fluoxetine/vehicle) did not significantly associate with polymorphic variants found within 25-500 kb 
of the putative genes. A heat map was generated following hierarchical clustering analysis, wherein the 
expression patterns of the informative genes were used to cluster each treatment and response group 
(Figure 4.4). Apart from a few specific strain divergences the gene sets indicate clusters of treatment 
and response groups. Our results show that gene expression differences were more apparent between 
response groups (positive vs. negative) compared to treatment groups (control vs. fluoxetine) with the 
gene set for response groups being able to reasonably predict SSRI response (Figure 4.5).  
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3.4 Quantitative trait loci associated with baseline depressive-like behavior and variable 
neurobiochemical levels 
We also investigated whether differences in neurobiochemical analytes, which have been 
previously linked to anxiety and/or depression, are subject to a common genetic regulatory mechanism.  
Of particular interest, convergence of neurobiochemical and behavioral data revealed significant loci 
co-localization on Chr 9 (9: 46.7 - 47.6 Mb) (Figure 4.6). The Chr 9 QTL associated with baseline 
depressive-like behavior as well as baseline levels of cyclic AMP response element binding protein 
(CREB) (-logP = 4.46, FDR≤ 0.05) and vascular endothelial growth factor (VEGF) (-logP = 5.56, 
FDR≤ 0.05). Genes at this locus include Cadm1 and 2900052N01Rik. Cadm1 is involved in neural cell 
adhesion processes, facilitating cellular and molecular communication between cells and has been 
linked with social impairments and anxiety-like behavior in mice (Takayanagi et al. 2010; Zhiling et al. 
2008). 
 4. Discussion 
Identification of biomarkers that can establish diagnosis, prognosis, and response to treatment is 
critical to the advancement of research and management of patients with mood disorder. Biomarkers 
can be used to objectively assess clinical progression and response to antidepressant therapy. Relative 
to human studies, the use of mouse inbred strains can be an effective method for investigating 
biomarkers of drug response due to lower cost, greater tissue accessibility, reduced genomic 
complexity, and subject availability. However, the use of animal models to parallel subsets of 
behaviors that typify human disorders is challenging, and many of the symptoms used to establish 
psychiatric diagnoses in humans cannot be replicated in animals (Nestler and Hyman 2010). Here, we 
assess limited sets of specific behaviors that are relatively robust and have been previously validated as 
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responsive to antidepressive drug treatment (Cryan et al. 2005; Kulkarni and Dhir 2007) in a panel of 
genetically-diverse inbred mouse strains (Liu and Gershenfeld 2003; Ripoll et al. 2003; Trullas et al. 
1989). The TST is primarily used to evaluate antidepressant activity of novel compounds and does not 
itself elicit depressive behavior, hence evaluation of treatment responses following exposure to chronic 
stress, an animal model of clinical depression that has both face and predictive validity (Nestler and 
Hyman 2010; Willner 1997; 2005), is needed for independent validation of treatment biomarkers.  
 
Early studies from the STAR*D trial found a high co-occurrence of anxiety and depression. 
Over 49% and 42% of patients in the primary care and secondary care setting, respectively exhibited 
“anxious depressive” symptoms (Fava et al. 2006). Compared to patients with depression alone, 
patients with comorbid anxiety and depressive disorders are more likely to have prolonged, severe, and 
recurrent symptoms (Andreescu et al. 2007; Fava et al. 2004) and are less responsive to treatment 
(Emmanuel et al. 1998; Fava et al. 2008). In this study, we examined how baseline and treatment-
induced biochemical differences affect depressive-like and anxiety-like responses. While anxiety-like 
and depressive-like behavior both contribute to baseline behavioral differences, anxiety-like behavior 
as measured by percent time spent in the center of the OF was only minimally affected by fluoxetine 
treatment. This result supports previous findings, which have demonstrated that responses in the TST is 
more sensitive to antidepressant drugs as opposed to other psychotropic agents like anxiolytics, 
antipsychotics, and stimulants (Cryan et al. 2005). Levels of GLO1 and GNB1 mostly account for 
anxiety-like and depressive-like behavior in the control group, suggesting that alterations in GLO1 and 
GNB1 may be common in both depression and anxiety disorders. GLO1 is an antioxidant enzyme that 
catalyzes the detoxification of methylglyoxal and has been linked with various psychiatric disorders 
including depression (Fujimoto et al. 2008), panic disorder without agoraphobia (Politi et al. 2006), 
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schizophrenia (Arai et al. 2010), and anxiety-like behavior (Hovatta et al. 2005; Williams et al. 2009). 
Variable mRNA expression of Glo1 is likely due to difference in copy number variants. Duplication of 
a region where Glo1 resides (Chr 17: 30.12 - 30.65 Mb) was found to be associated with difference in 
anxiety-like behavior across a panel of mouse inbred strains (Williams et al. 2009). In agreement with a 
previous study that has found higher Glo1 mRNA transcripts in more anxious mice (Hovatta et al. 
2005), we found that elevation in GLO1 protein corresponds with higher anxiety-like behavior. 
Elevation in GLO1 protein is also correlated with increased baseline immobility in the TST. This result 
is discordant with other studies that have found higher expression of GLO1 in less anxious and 
depressed mice (Ditzen et al. 2006; Kromer et al. 2005). Inconsistent findings may be due to a number 
of factors including strain, age, and protein quantification methodologies. Therefore, functional and 
metabolic assessment of GLO1 through measurement of methylglyoxal-mediated glycation is required 
for clarification (Thornalley 2006).  GNB1 belongs to a family of heterotrimeric GTP-binding proteins 
that integrate signals among receptors and effector proteins. In a study that looked at dominant-
subordinate behavior as a rodent model of depression, lower mRNA expression of Gnb1 was 
associated with dominant behavior (Kroes et al. 2006).  In agreement with this finding, we found that 
increased behavioral despair is associated with higher GNB1 protein. It is interesting to note that mice 
lacking Gnb1 exhibit reduced cortical thickness, neural tube closure defects, and impaired neural 
progenitor cell proliferation, suggesting the importance of Gnb1 in neurogenesis (Okae and Iwakura 
2010). Treatment with psycho-stimulants like cocaine and amphetamines up-regulates Gnb1 
expression, which indicates that Gnb1 is involved in drug sensitization (Kitanaka et al. 2002). 
Interestingly, pre-treatment with fluoxetine attenuates methamphetamine-induced locomotor 
sensitization (Takamatsu et al. 2006), suggesting potential involvement of Gnb1 in fluoxetine response. 
Our results show that more anxious mice exhibit elevated levels of GNB1 protein. A recent study by 
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Benekareddy et al. found that early stress induced by maternal separation up-regulates Gnb1 
expression, implicating the involvement of Gnb1 in mediating risk to anxiety and mood disorder 
(Benekareddy et al. 2010). Taken together, the association of GLO1 and GNB1 with baseline 
behavioral despair and anxiety-like behavior offers a novel possibility in which these proteins can be 
targeted to modulate both disorders and improve treatment outcomes in patients who suffer with 
comorbid anxious depressive symptoms.       
To date, analysis of biochemical alterations has only been performed for a handful of markers 
in a few inbred strains despite inter-strain differences in response to antidepressants (Crowley et al. 
2006; Miller et al. 2008; Ripoll et al. 2003; Vaugeois et al. 1997). In this study, we show that response 
to fluoxetine treatment mirrors responses seen in human fluoxetine treatment with a subset of strains 
exhibiting an “expected response” of reduced immobility as a phenotype of depressive-like behavior. 
Additionally, a few inbred strains exhibited no significant response while the remaining strains 
responded with increased immobility. Similar to previous reports, we observed a strong effect of strain 
and SSRI treatment on TST responses (Crowley et al. 2006; Ripoll et al. 2003; Trullas et al. 1989). 
Although the TST immobility scores we measured after chronic fluoxetine treatment were slightly 
different from what others have reported, our findings are in agreement with a previous study that 
examined TST responses in multiple inbred strains after fluoxetine treatment (Lucki et al. 2001). 
Following acute administration of fluoxetine, Lucki and colleagues observed reduced immobility 
responses for BALB/cJ and DBA/2J but not for C57BL/6J, A/J, and C3H/HeJ (Lucki et al. 2001). With 
the exception of the data for C57BL/6J, these results are consistent with our findings.  
Little correlation was observed between change in immobility scores (treatment response) and 
serum fluoxetine and norfluoxetine levels, indicating that, at least in the mouse, pharmacokinetics does 
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not significantly modulate behavior and other factors like pharmacodynamics and pharmacogenetics 
may contribute to differential responses to fluoxetine treatment. Of note, negative and positive 
responses to fluoxetine can be distinguished based on neurobiochemical variability. Baseline biological 
differences discriminate negative responders, while biochemical alterations following fluoxetine 
treatment delineate positive responders. This result suggests that positive response to fluoxetine is 
mostly due to treatment-induced biochemical alterations, and negative response to fluoxetine is mainly 
attributed to baseline differences between mouse strains. Therefore, we propose that patients who fail 
to respond or remit from antidepressant therapy may have baseline biological abnormalities 
predisposing them to poor therapeutic outcomes.  
Results from both DWD and PLS analyses suggest that levels of S100β, GSK3β, HDAC5, and 
GFAP influence differential TST responses following SSRI treatment (Figure 2). Chronic fluoxetine 
treatment results in higher levels of S100β, which triggers expression of serotonin transporters (SERT) 
and activates de novo serotonin synthesis (Baudry et al. 2010). Similarly, increased levels of GSK3β 
have been observed following chronic fluoxetine administration in vivo (Fatemi et al. 2009; Li et al. 
2004). Inhibition of GSK3β blocked fluoxetine-mediated down-regulation of SERT through over-
expression of miR 16 (Baudry et al. 2010), thus linking serotonin regulation with GSK3β 
phosphorylation (Li et al. 2004). Tsankanova et al found that treatment with tricyclic antidepressants 
results in lower mRNA levels of Hdac5 and that overexpression of Hdac5 in the hippocampus blocks 
the antidepressant effects of imipramine in the chronic social defeat stress paradigm (Tsankova et al. 
2006). Consistent with previous studies (Baudry et al. 2010), higher levels of S100β following 
fluoxetine treatment were observed in positive responders. Interestingly, both negative and positive 
responders displayed higher levels of GSK3β and HDAC5. GSK3β phosphorylates various molecules 
typically leading to substrate inhibition, while chromatin remodeling by HDAC5 can prevent 
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transcription of many downstream genes. Thus, elevation of GSK3β and HDAC5 can affect several 
different downstream molecular processes, leading to variable treatment outcomes. Additional studies 
are required to examine the relationship between fluoxetine response and levels of GSK3β and 
HDAC5.  Little information is known about the relationship of GFAP with fluoxetine response.  In 
rodents, chronic treatment with fluoxetine results in elevation of amplifying neural progenitor cells 
(Encinas et al. 2006), while antidepressant treatment in humans results in increased numbers of 
quiescent neural progenitor cells, including nestin and GFAP (Boldrini et al. 2009). Rat astrocytic cells 
enriched with GFAP exhibit Na+ dependent and fluoxetine-sensitive serotonin uptake, suggesting 
involvement of GFAP in mediating serotonin levels (Dave and Kimelberg 1994). The underlying 
mechanism mediating the influence of GFAP on negative fluoxetine response warrants closer 
examination, given the low clinical response rates to SSRI treatment (Trivedi et al. 2006).  
Although our findings indicate that fluoxetine administration alters levels of S100β, HDAC5, 
GSK3β, and GFAP, it is likely that these biochemical changes are not specific to SSRIs. Other 
psychotropic medications, including clozapine, lithium, valproic acid, and haloperidol, have been 
shown to alter GFAP (Fatemi et al. 2008) and GSK3β levels (Fatemi et al. 2009) in vivo. Altered levels 
of S100β are observed in patients with schizophrenia (Gattaz et al. 2000; Wiesmann et al. 1999), which 
can be normalized by treatment with antipsychotic agents (Ling et al. 2007; Steiner et al. 2010). 
Treatment with HDAC inhibitors is associated with neuroprotective effects and may be beneficial in 
the treatment of various psychiatric disorders, including bipolar and schizophrenia (Kazantsev and 
Thompson 2008; Tsankova et al. 2007). Collectively, these findings suggest that S100β, GSK3β, 
HDAC5, and GFAP are likely to be involved in a behavioral pathway common to multiple psychiatric 
disorders, although the downstream mechanisms mediated by each analyte may be specific for each 
psychiatric disorder. An important avenue for future study is the assessment of these biomarkers in 
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easily accessible samples like plasma or serum, thus facilitating translation of pre-clinical findings to 
human studies. Current work in the lab aims to evaluate the relationship between behavioral responses 
and serum levels of neurobiochemical markers across multiple inbred strains. Additionally, sex 
differences in the metabolism of fluoxetine (Hodes et al. 2010) necessitate further investigation of these 
biomarkers in females.  
Overall, we observed minimal difference (203 probe sets with variable expression patterns) in 
gene expression profiles between vehicle and fluoxetine-treated mice. This result is consistent with 
what others have found when performing global transcriptome analyses between control and 
antidepressant treatment groups (Bohm et al. 2006; Lee et al. 2010; Miller et al. 2008; Takahashi et al. 
2006). Although other groups have found more genes that were up- or down-regulated following 
fluoxetine treatment, the filtering criteria we used to preprocess our microarray data are generally more 
stringent in comparison. We only analyzed genes with a minimum 3-fold difference between strains 
and had statistically significant SNR values. In addition, other factors including fluoxetine dosing 
regimen, microarray methodology, and time of tissue collection can influence gene expression results. 
When we compared gene expression profiles between negative and positive responders, we found that 
we can accurately assign samples as either negative or positive responders (absolute error rate 11.1%) 
based on the expression patterns of Copg2S2, Prcp, Gpr115, Gxylt2, Plb1, Txndc9, Mum1/1, and 
Gm1642, making these genes potential predictors of SSRI response. Although none of these genes have 
been directly linked to antidepressant response or major depressive disorder, several are involved in 
molecular processes that may be critical in mediating behavior or neuronal function, such as 
neuropeptide signaling and lysosomal serine carboxypeptidase activity. For six of the genetic markers 
of fluoxetine response, there are commercially available ELISA kits and antibodies that can be used to 
evaluate the relationship between protein levels and SSRI response. Additionally, we identified 
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baseline genetic markers that affect inter-strain despair responses to fluoxetine treatment, suggesting its 
use as a potential prognostic treatment biomarker. Interestingly, one candidate gene is poly (A) binding 
protein, cytoplasmic 1 (Pabpc1), a gene that was significantly associated with SSRI response in a 
genome-wide association study, which evaluated over 1,800 patients from the STAR*D trial (Shyn et 
al. 2011). Pabpc1 encodes for a poly (A) binding protein that binds to the poly (A) tail of mRNA, 
facilitating ribosome recruitment and translation initiation. Given that the association between Pabpc1 
and antidepressant response was observed in both pre-clinical and human studies, the mechanism 
underlying this association warrants further investigation.  
To identify genetic markers for depressive disorder, we focused on genomic regions that are 
associated with both behavioral and neurobiochemical phenotypes.  We identified a behavioral despair 
QTL on Chr 9 that correlated with inter-strain neurobiochemical variability. A QTL for depressive-like 
behavior has not been reported previously at this locus, which contains only two genes - Cadm1 and 
2900052N01Rik. Cadm1 encodes for neural cell adhesion molecules that mediate cell-to-cell 
communication. Further, Cadm1 is involved in synaptic function and neuronal differentiation (Watabe 
et al. 2003) and has been linked with anxiety-like and social behavior in mice (Takayanagi et al. 2010; 
Zhiling et al. 2008). A recent study by Takayanagi et al showed that mice lacking Cadm1 displayed 
higher anxiety-like phenotype and impairment in motor coordination and social behavior compared to 
wild-type mice (Takayanagi et al. 2010). However, no significant difference in depressive-like 
behavior as measured by the TST was observed between groups (Takayanagi et al. 2010). Other 
behavioral paradigms like chronic social defeat stress and reduced sucrose preference, which assess 
other features of depressive behavior (e.g. anhedonia) (Nestler and Hyman 2010) can be used to further 
evaluate the role of Cadm1
 
in depression. Since CADM1 act as synaptic adhesive molecule, functional 
disruption of Cadm1 may lead to impaired neural plasticity and neurogenesis, both of which have been 
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linked with major depressive disorder (Campbell and Macqueen 2004; Schmidt and Duman 2007).   
Links defining interactions between Cadm1 and the two biochemical markers (CREB and VEGF) that 
co-localize to the same genetic locus on Chr 9 provide a promising avenue for future study. 
Altogether, our results highlight the role of cellular proliferation in mediating SSRI response. 
Similar to Cadm1, Gpr115, Plb1, Gxylt2, and Prcp are involved in cellular proliferation and/or cellular 
adhesion (Bjarnadottir et al. 2004; Ganendren et al. 2006; Mallela et al. 2008; Mallela et al. 2009; 
Okajima et al. 2008; Sethi et al.). Furthermore, candidate fluoxetine markers S100β, GSK3β, HDAC5, 
and GFAP are linked through a common cellular growth and proliferation pathway, suggesting that 
treatment with fluoxetine stimulates cell growth. Our results indicate that response to fluoxetine is 
affected by cellular genesis, which is consistent with previous studies that have shown a critical role of 
neurogenesis in mediating SSRI response (Deltheil et al. 2009; Manev et al. 2001). Regulation of 
neurogenesis, cellular resilience, neuroplasticity, and cellular death/atrophy is important in the 
pathogenesis and treatment of depression (Duman 2002; Krishnan and Nestler 2008; Lucassen et al. 
2010; Manji et al. 2001; Manji et al. 2003). Neuroimaging and post-mortem brain studies show that 
patients with MDD have impaired neural circuitry and structural abnormalities. Compared to healthy 
controls, patients with mood disorder display lower number of glial cells, reduced cortical volume and 
thickness, and decreased neuronal size and density, all of which implicate cellular atrophy/loss (Manji 
et al. 2001; Manji et al. 2003). Antidepressant therapy increases levels of neurotrophic factors (Duman 
et al. 2001; Malberg et al. 2000; Sairanen et al. 2005) that promote neurogenesis and inhibit cell death 
signaling pathways (Riccio et al. 1999). Hippocampal neurogenesis is critical in facilitating adaptive 
response to stress (Duman et al. 2001; Malberg et al. 2000), memory development (Mirescu et al. 2004; 
Schloesser et al. 2009), and learning new experiences (Kempermann 2008) thus, impairment of 
neurogenesis may confer risk to depressive behavior. Elucidating the roles of neurogenesis, cellular 
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resilience, neural plasticity, and cell death in the development of depressive behavior requires a 
systems level exploration of these processes. Whether interplay between cellular proliferative and 
survival processes facilitates synaptic remodeling and leads to altered mood remains to be seen.   
In the absence of biological markers, therapeutic outcomes are defined based on reduction of 
baseline symptoms, which can lead to inconsistencies and irreproducibility. Genetic and 
neurobiochemical markers can provide an objective means to measure prognosis and treatment 
response. We identified genetic and biochemical markers of fluoxetine response that are involved in 
cellular genesis, highlighting the role of neurogenesis and neuroplasticity in major depressive disorder. 
Since neurogenesis is not specific to antidepressant treatment, it is critical for future studies to identify 
how psychotropic medications differentially affect neurogenesis and which downstream 
neurobiological pathways are affected. Such studies may illuminate differences between closely related 
psychiatric disorders including depression and anxiety.  
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5. Tables 
Table 4.1 List of neurobiochemical analytes simultaneously measured across multiple mouse 
inbred strains and their known functions 
Biomarker Name Function GO category 
ACTH 
Adrenocorticotropin releasing 
hormone Neuroimmune 
(GO:0005179), 
(GO:0007218)  
APOD 
Apolipoprotein D Neuroimmune 
(GO:0006629), 
(GO:0005215)  
BAG1 
BCL2-associated athanogene 1 Apoptosis 
(GO:0006916), 
(GO:0006950)  
BDNF 
Brain-derived neurotrophic factor Neurogenesis 
(GO:0006916) 
(GO:0048167)  
c-fos 
FBJ osteosarcoma oncogene Transcription 
(GO:0007399), 
(GO:0045941)  
CREB 
cAMP response element-binding Signal Transduction 
(GO:0007165), 
(GO:0007202)  
PPP1R1B 
Protein phosphatase 1 subunit 1B Modulation of phosphatase1 
(GO:0007165) , 
(GO:0004864)  
DAT Dopamine Transporter Regulation of dopamine levels 
(GO:0005329), 
(GO:0007268)  
FKBP51 FK506-Binding Protein 51 Signal Transduction 
(GO:0005528), 
(GO:0031072) 
GAD67 
Glutamic Acid Decarboxylase-67  
Decarboxylation of glutamate to 
GABA 
(GO:0004351), 
(GO:0006915) 
Galanin 
Galanin Neuronal modulation 
GO:0005184), 
(GO:0006950)  
GFAP 
Glial fibrillary acidic protein Maintenance of astrocytes 
(GO:0005200), 
(GO:0005882)  
Ghrelin 
Ghrelin 
Neurotrophy and appetite 
regulation 
(GO:0006916), 
(GO:0008343) 
GLO1 Glyoxylase1 
Neuroprotection 
(GO:0006916), 
(GO:0006749)  
GNB1 
Guanine nucleotide-binding protein 
subunit beta-1 Signal Transduction 
(GO:0006112), 
(GO:0007200)  
GSK3β 
Glycogen synthase kinase 3 beta   Phosphorylation 
(GO:0035255) , 
(GO:0006916)  
GSR Glutathione Reductase 
Neuroprotection 
(GO:0006749), 
(GO:0016491)  
HDAC5 
Histone deacetylase 5 Transcription 
(GO:0004407), 
(GO:0000122)  
IL-6 Interleukin6 Neuroimmune 
(GO:0001781), 
(GO:0006954) 
KCNJ9 
Potassium inwardly-rectifying 
channel, subfamily J, member 9  Regulation of K
+
 levels 
(GO:0015467), 
(GO:0006813)  
MCH 
Melanin Concentrating Hormone Sleep and circadian rhythm 
(GO:0007218), 
(GO:0046005)  
NET Norepinephrine Transporter Regulation of norepinephrine (GO:0006836), 
150 
 
levels (GO:0008504)  
NGF 
Nerve Growth Factor Neuronal growth and signaling 
(GO:0008504), 
(GO:0006954)  
NMDA1  
Glutamate Receptor, Subunit 1 Neurotransmission 
(GO:0004972), 
(GO:0005234)  
NPY 
Neuropeptide Y Neuropeptide signaling 
(GO:0005184), 
(GO:0001664)  
NR3C1 
Glucocorticoid Receptor Neuroendocrine 
(GO:0004883), 
(GO:0006351)  
NSG2 
Neuron specific family gene member 
2  
Dopamine receptor signaling 
pathway 
(GO:0007212), 
(GO:0050780)  
P2X7 
Purinergic Receptor Ligand-Gated 
Ion Channel7 Regulation of Ca
2+
 
(GO:0010524), 
(GO:0000187) 
PAQR8 
Progestin and AdipoQ Receptor 8 Steroid binding 
(GO:0004872), 
(GO:0005496)  
PTH 
Parathyroid Hormone Regulation of Ca
2+
 
(GO:0031856), 
(GO:0007186)  
S100β 
S100 beta protein Glial cell proliferation 
(GO:0007417), 
(GO:0008283)  
SERT 
Serotonin Transporter 
Regulation of norepinephrine 
levels 
(GO:0008504), 
(GO:0015222)  
SGNE 
Secretogranin V Neuroendocrine 
(GO:0016486), 
(GO:0007218)  
TNF-α 
Tumor Necrosis Factor-alpha Neuroimmune 
(GO:0006955), 
(GO:0005125)  
VEGF 
Vascular Endothelial Growth Factor Growth and angiogenesis 
 (GO:0001525), 
(GO:0005125)  
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6. Figures 
 
 
 
 
Figure 4.1 Inter-strain difference in fluoxetine response 
 
Figure 4.1. Inter-strain difference in fluoxetine response.  Response to treatment was calculated by 
taking the log ratio of fluoxetine behavioral scores to vehicle behavioral scores. Percent change in 
immobility was calculated by multiplying the ratio of fluoxetine immobility scores to vehicle 
immobility scores by 100 and then subtracting the product from 100. We defined positive and negative 
responders as having at least 20% decreased or increased in immobility scores, respectively. 
Immobility is a measure of “hopelessness” or depressive-like behavior in mice. Strains with positive 
response to fluoxetine exhibited significant reduction in depressive-like behavior, while negative 
responders had an increased in immobility 
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Figure 4.2 Neurobiochemical markers that covary with fluoxetine response 
 
4.2
2 
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Figure 4.3 Neurobiochemical analytes that contribute most to discriminating positive and 
negative responders 
 
Figure 4.2. Neurobiochemical markers that covary with fluoxetine response. PLS analysis show 
levels of GNB1, GLO1, S100β, GAD67, GFAP, and galanin covary most with response to open field 
and tail suspension tests (white bars). Levels of GFAP, S100β, GLO1, HDAC5, GAD67, P2X7, and 
GSK3β covary most with depressive-like response following chronic fluoxetine treatment (black bars). 
4.3. Neurobiochemical analytes that contribute most to discriminating positive and negative 
responders. DWD analysis shows that S100β, GSK3β, HDAC5, and GNB1 discriminate positive 
responses (black bars) or negative response (white bars). The opposing direction of the S100β and 
GNB1 vectors indicates that both markers can discriminate negative and positive response groups from 
each other.  Neurobiochemical differences induced by chronic fluoxetine treatment discriminate 
positive responders while baseline neurobiological differences discriminate negative responders. 
Overall neurobiochemical difference is observed when we defined positive response as 20% (p<0.006), 
30% (p<0.014) or 40% (p<0.026) reduction in immobility or when we defined negative response as 
20% (p<0.006), 30% (p<0.036) or 40% (p<0.016) increased in immobility. Data are shown when 
response is defined as 20% decreased or increased in immobility scores 
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Figure 4.4 Hierarchical clustering of genes discriminating treatment from control 
  
 
Figure 4.5 Hierarchical clustering of genes discriminating positive and negative response to 
treatment 
 
 
Figure 4.4. Hierarchical clustering of genes discriminating treatment from control. Gene 
expression patterns of the twelve most informative genes on each treatment group. 4.5. Hierarchical 
4.4 
4.5 
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clustering of genes discriminating positive and negative response to treatment.  Gene expression 
profile of the eight most informative genes on each response group. Only strains deemed to have a 
response to treatment are shown. In both figures, color denotes direction of gene expression changes 
(red = up-regulated, blue = down-regulated). Intensity illustrates the magnitude of change in gene 
expression 
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Figure 4.6 Genome-wide association plot for depressive-like behavior 
 
Figure 4.6. Genome-wide association plot for depressive-like behavior. Genomic region on Chr. 9 
significantly correlates with depressive-like behavior (-logP = 6.17) and baseline levels of VEGF (-log 
= 5.56) and CREB (-logP = 4.46). The figure shows baseline behavioral despair QTL. To the right, are 
the putative genes underneath behavioral locus on Chr 9. The y-axis denotes the strength of association 
between genotype and phenotype (-logP) and the x-axis illustrates the cumulative SNP position on the 
genome 
 
 
 
  
157 
 
7. Supplementary Tables  
 
Supplementary Table 4.1  Mean water intake between water and fluoxetine-treated mice  
 
Supplementary Table 4.1. Mean water intake for vehicle and fluoxetine treated mice.  
Strain 
Mean Water 
Intake Per Cage 
(mL), Control SEM 
Mean Water 
Intake Per Cage 
(mL), Fluoxetine SEM 
Difference in Mean Water 
Intake between Treatment 
Groups (mL) 
129S1/SvImJ 5.2 0.2 3.7 0.3 1.43 
A/J 5.3 0.2 4.7 0.2 0.63 
AKR/J 7.4 0.2 5.4 0.2 1.98 
BALB/cJ 5.7 0.3 5.1 0.3 0.61 
BTBRT<t>tf/J 7.1 0.2 6.4 0.2 0.71 
BUB/BnJ 7.3 0.4 5.8 0.2 1.53 
C3H/HeJ 5 0.2 4.7 0.2 0.27 
C57BL/6J 6 0.2 4.5 0.2 1.51 
C57BLKS/J 6.1 0.2 4.7 0.2 1.39 
C57BR/cdJ 8.9 0.3 8 0.3 0.92 
C58/J 5.7 0.2 4.6 0.2 1.08 
CBA/J 6.1 0.2 4.9 0.2 1.14 
DBA/2J 6.4 0.2 6 0.2 0.37 
FVB/NJ 5.4 0.3 5.2 0.2 0.25 
I/LnJ 6.4 0.2 4.8 0.2 1.57 
LG/J 8.9 0.4 5.8 0.2 3.1 
LP/J 3.7 0.2 3.6 0.2 0.14 
MA/MyJ 6.7 0.2 5 0.2 1.69 
MRL/MpJ 13.2 0.4 8.2 0.2 4.98 
NOD/LtJ 7.1 0.2 5.1 0.2 2.04 
NOR/LtJ 5.8 0.1 6.6 0.2 0.84 
NZB/BlNJ 6 0.2 4.9 0.2 1.16 
NZW/LacJ 9.7 0.2 11.2 0.5 1.53 
P/J 5.2 0.2 4.9 0.2 0.25 
PL/J 5.7 0.2 3.9 0.2 1.82 
RIIIS/J 4.2 0.2 4.1 0.2 0.12 
SJL/J 7.2 0.3 5.4 0.3 1.76 
SM/J 5.4 0.2 5.9 0.3 0.53 
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SWR/J 6.9 0.3 5 0.1 1.92 
SEM = standard error of the mean 
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Supplementary Table 4.2 Behavioral responses in the open field and tail suspension tests 
Supplementary Table 4.2. Behavioral responses in the open field and tail suspension tests between control and 
fluoxetine treatment groups 
Strain 
Total number 
of animals 
tested per 
strain 
Number of 
animals excluded 
from the TST 
analysis 
 Mean TST 
Immobility 
Scores (secs), 
Control SEM 
Mean TST 
Immobility 
Scores (secs), 
Fluoxetine SEM 
129S1/SvImJ 28 2 122.5 11.87 115.32 10.78 
A/J 30 3 106.87 11.66 115.44 5.35 
AKR/J 18 2 192.57 10.27 171.21 15.63 
BALB/cJ 39 4 107.22 10.64 56.57 7.87 
BTBRT<t>tf/J 21 4 15.71 8.83 7.34 4.27 
BUB/BnJ 18 1 142.32 10.15 97.28 10.46 
C3H/HeJ 30 2 97.34 8.79 112.25 12.32 
C57BL/6J 21 5 175.7 18.64 103.5 11.7 
C57BLKS/J 24 3 101.31 13.59 72.65 14.84 
C57BR/cdJ 27 5 97.51 19.6 33.28 10.39 
C58/J 18 0 80.92 13.1 83.22 7.18 
CBA/J 30 2 134.98 8.78 44.93 8.53 
CE/J 24 3 108.83 16.46 76.9 9.93 
DBA/2J 36 9 44.35 9.99 19.06 4.75 
FVB/NJ 18 2 53.29 13.63 70.42 11.52 
I/LnJ 24 8 79.2 28.57 77.19 18.43 
LG/J 21 3 27.25 13.39 4.5 1.42 
LP/J 28 9 196.7 13.47 177.73 19.51 
MA/MyJ 18 0 79.07 18.01 33.92 10.53 
MRL/MpJ 21 4 16.02 5.15 14.65 5.39 
NOD/LtJ 24 3 165.4 8.65 141.18 7.44 
NOR/LtJ 24 7 104.95 9.85 84.58 18.89 
NZB/BlNJ 24 6 161.27 31.01 201.34 8.47 
NZW/LacJ 21 4 124.69 19.72 161.92 17.14 
P/J 23 3 130.34 17.48 40.71 10.13 
PL/J 24 2 169.98 11.91 137.62 11.04 
RIIIS/J 21 0 18.58 4.63 32.78 10.98 
SJL/J 24 4 143.67 13.13 145.7 15.44 
SM/J 18 4 229.53 6.38 137.22 13.29 
SWR/J 24 0 50.3 9.91 69.65 12.38 
TST = tail suspension test; OF = open field; SEM = standard error of the mean 
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Supplementary Table 4.2. Behavioral responses in the open field and tail suspension tests between control and 
fluoxetine treatment groups 
Strain 
Mean 
OF 
Center 
Time 
(secs), 
Control SEM 
Mean OF 
Center Tme 
(secs), 
Fluoxetine SEM 
Mean Total 
Distance 
Traveled in 
the OF, 
Control 
(cm) SEM 
Mean Total 
Distance 
Traveled in 
the OF, 
Fluoxetine 
(cm) SEM 
129S1/SvImJ 23 17.68 2.33 1.57 450.21 98.51 360.18 87.55 
A/J 1.2 1.08 6.6 5.9 257.54 59.18 293.36 76.43 
AKR/J 70.89 10.84 71 15.52 1905.12 173.29 1824.08 119.5 
BALB/cJ 46.89 23.32 30.82 10.52 968.82 268.46 1018.54 211.55 
BTBRT<t>tf/J 56.22 11.15 48.25 9.33 1909.67 192.62 2131.04 237.36 
BUB/BnJ 111.88 13.99 147.78 14.61 1606.96 145.31 2392.91 272.73 
C3H/HeJ 65 6.84 63.73 5.89 1104.1 60.65 1079.79 42.79 
C57BL/6J 77.17 10.82 65.78 9 1128.44 74.57 1174.74 105.63 
C57BLKS/J 38.8 6.06 37.25 6.74 775.09 77.77 1004.9 190.83 
C57BR/cdJ 193 15.77 156 15.22 2134.34 109.86 2712.47 206.62 
C58/J 124.33 15.88 105.56 15.98 1998.07 240 2972.77 583.85 
CBA/J 70.47 11.5 56.38 12.35 1051.15 106.42 1506.63 103.85 
CE/J 79.22 11.95 89.5 7.62 1546.18 118.34 1518.35 140.48 
DBA/2J 33.83 5.84 15.59 3.36 1085.46 84.39 1824.32 255.39 
FVB/NJ 136 6.8 112.78 7.29 2209.28 148.26 1869.78 107.35 
I/LnJ 60.82 8.54 40.5 12.17 2065.28 124.35 2040.47 284.61 
LG/J 85.91 15.99 44.44 21.99 1677.07 97.9 1271.03 63.31 
LP/J 56.11 27.35 28.71 8.21 1011 195.36 611.74 90.84 
MA/MyJ 131.56 12.53 76.78 14.96 2349.18 182.85 3511.82 395.18 
MRL/MpJ 107.91 11.43 85.75 18.27 1471.85 67.62 1395.69 137.08 
NOD/LtJ 164.55 18.7 146.64 12.53 2669.31 229.64 2555.08 172.98 
NOR/LtJ 145.13 12.13 157.21 14.98 2410.6 180.58 2282.15 94.59 
NZB/BlNJ 33.55 6.97 13.55 4.06 1070.27 63.04 942.25 123.13 
NZW/LacJ 76.33 7.65 80.56 16.65 1078.48 54.64 1350.67 162.1 
P/J 114.67 20.32 59.8 13.12 1807.26 56.44 2445.75 300.53 
PL/J 71.33 4.71 57.17 4.46 1840.41 106.79 1770.16 113.83 
RIIIS/J 69.22 4.09 79.92 6.57 2050.63 100.38 1824.96 84.83 
SJL/J 109.18 37.19 27 17.67 945.1 106.2 853.45 78.73 
SM/J 70.63 5.86 38.44 7.68 1999.52 71.84 3180.84 641 
SWR/J 91.25 5.4 105.17 11.02 1393.46 83.01 1499.29 67.56 
TST = tail suspension test; OF = open field; SEM = standard error of the mean 
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Supplementary Table 4.3 Serum levels of fluoxetine and its metabolite norfluoxetine following 
chronic fluoxetine treatment. 
Supplementary Table 4.3. Serum Levels of Fluoxetine and its Metabolite Norfluoxetine Following 
Chronic Fluoxetine Treatment 
Strain Number of Animals (N) Fluoxetine (ng/ml) SEM Norfluoxetine (ng/ml) SEM 
129S1/SvImJ 13 1152.92 58.03 1079.77 45.23 
A/J 15 937.87 47.72 1222.60 47.96 
AKR/J 9 988.11 53.38 1119.22 49.29 
BALB/cJ 12 800.17 40.53 930.75 49.93 
BTBR T+ 
tf/J 12 912.08 51.43 1238.50 79.22 
BUB/BnJ 9 1396.89 143.39 1391.67 148.09 
C3H/HeJ 15 763.07 66.41 949.53 65.12 
C57BL/6J 7 1327.57 220.88 1509.00 186.31 
C57BLKS/J 12 1243.50 96.14 1195.00 47.55 
C57BR/J 10 988.90 151.01 1260.40 153.66 
C58/J 9 987.22 116.45 1335.56 105.95 
CBA/J 11 1103.91 108.33 1093.27 108.89 
CE/J 12 1084.42 73.17 1401.17 74.04 
DBA/2J 16 956.50 95.73 1026.69 56.39 
FVB/NJ 9 595.19 81.39 798.28 120.00 
I/LnJ 8 1606.50 318.33 1438.25 130.94 
LG/J 9 1540.00 116.96 1612.22 134.95 
LP/J 19 719.63 67.32 783.37 73.67 
MA/MyJ 9 1905.56 223.93 1314.33 120.01 
MRL/MpJ 9 1066.67 183.54 1047.44 143.05 
NOD/LtJ 12 775.50 81.93 912.00 80.58 
NOR/LtJ 15 483.33 48.37 746.93 65.22 
NZB/B1NJ 12 1311.08 142.63 1156.33 81.24 
NZW/LacJ 9 591.44 66.62 762.89 48.00 
P/J 11 1885.55 407.27 1267.55 246.70 
PL/J 12 757.35 97.23 825.86 111.87 
RIIIS/J 12 470.25 36.51 578.58 25.83 
SJL/J 11 1274.82 107.88 1124.45 64.77 
SM/J 8 1186.95 320.21 1160.23 256.45 
SWR/J 12 749.31 110.69 643.79 108.63 
SEM = standard error of the mean 
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Supplementary Table 4.4 Mean relative fluorescence intensity (RFI) values for thirty-one 
neurobiochemical analytes measured in the cortex of thirty mouse inbred strains 
Supplementary Table 4. 4 Mean relative flourescence intensity (RFI) values for thirty-one 
neurobiochemical analytes measured in the cortex of thirty mouse inbred strains   
Strains ACTH
#
 STD ACTH* STD FUT9
#
 STD FUT9* STD APOD
#
 STD APOD* STD 
129S1/SvImJ 1.80 0.07 1.62 0.11 0.65 0.02 0.50 0.02 0.60 0.01 0.56 0.01 
A/J 1.86 0.07 2.04 0.07 0.59 0.02 0.60 0.02 0.52 0.01 0.59 0.04 
AKR/J 1.95 0.11 2.05 0.10 0.68 0.01 0.52 0.02 0.56 0.02 0.52 0.04 
C57BL/6J 2.49 0.04 2.17 0.08 0.63 0.03 0.61 0.01 0.56 0.05 0.62 0.01 
BALB/cByJ 2.05 0.11 2.18 0.07 0.69 0.02 0.61 0.02 0.54 0.03 0.57 0.02 
C57BLKS/J 2.10 0.05 2.22 0.07 0.66 0.02 0.66 0.01 0.54 0.02 0.54 0.02 
C57BR/cdJ 2.17 0.07 2.47 0.09 0.66 0.02 0.60 0.02 0.57 0.02 0.61 0.03 
BTBRT+tf/J 2.25 0.05 2.12 0.05 0.74 0.02 0.60 0.02 0.52 0.01 0.57 0.01 
BUB/BnJ 2.28 0.07 2.21 0.10 0.76 0.03 0.71 0.02 0.59 0.01 0.58 0.02 
C3H/HeJ 2.26 0.06 2.40 0.05 0.77 0.03 0.55 0.01 0.60 0.02 0.61 0.03 
C58/J 2.05 0.05 2.18 0.07 0.73 0.02 0.69 0.02 0.52 0.01 0.53 0.02 
CBA/J 2.41 0.07 2.41 0.09 0.78 0.03 0.57 0.02 0.60 0.02 0.66 0.02 
CE/J 2.07 0.04 2.08 0.14 0.70 0.01 0.58 0.02 0.56 0.01 0.63 0.01 
DBA/2J 1.73 0.04 2.08 0.08 0.57 0.01 0.54 0.01 0.50 0.01 0.56 0.03 
FVB/NJ 2.21 0.10 2.34 0.09 0.71 0.03 0.72 0.04 0.63 0.02 0.71 0.03 
I/LnJ 2.01 0.07 2.03 0.12 0.75 0.03 0.61 0.02 0.53 0.03 0.57 0.01 
LG/J 2.22 0.04 2.50 0.08 0.77 0.02 0.65 0.02 0.57 0.02 0.65 0.02 
LP/J 2.45 0.09 1.39 0.07 0.86 0.02 0.45 0.01 0.60 0.01 0.39 0.01 
MA/MyJ 1.76 0.06 2.22 0.06 0.72 0.02 0.67 0.02 0.50 0.02 0.64 0.01 
MRL/MpJ 2.12 0.06 2.25 0.07 0.70 0.02 0.56 0.02 0.56 0.01 0.67 0.03 
NOD/ShiLtJ 2.30 0.05 2.35 0.08 0.83 0.03 0.70 0.01 0.61 0.02 0.71 0.03 
NOR/LtJ 1.70 0.06 1.97 0.07 0.65 0.02 0.66 0.02 0.48 0.02 0.62 0.02 
NZB/BINJ 2.49 0.06 2.23 0.12 0.84 0.02 0.59 0.01 0.58 0.02 0.65 0.02 
NZW/LacJ 2.87 0.11 1.67 0.08 0.87 0.02 0.53 0.01 0.70 0.02 0.47 0.04 
P/J 2.22 0.06 2.37 0.07 0.76 0.02 0.80 0.02 0.57 0.02 0.66 0.01 
PL/J 2.09 0.06 2.33 0.09 0.71 0.01 0.58 0.02 0.62 0.02 0.70 0.03 
RIIIS/J 2.47 0.08 2.30 0.07 0.71 0.01 0.70 0.02 0.65 0.01 0.64 0.02 
SJL/J 2.12 0.06 2.08 0.07 0.72 0.02 0.70 0.02 0.62 0.02 0.68 0.02 
SM/J 2.11 0.05 2.11 0.06 0.67 0.01 0.69 0.01 0.62 0.01 0.72 0.04 
SWR/J 2.26 0.07 2.59 0.08 0.69 0.01 0.75 0.02 0.62 0.03 0.69 0.03 
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# Denotes RFI values for control mice (water); * Denotes RFI values for fluoxetine-treated mice. STD stands for 
standard deviation. ACTH = Adrenocorticotropin releasing hormone; APOD= Apolipoprotein D; BAG1= BCL2-
associated athanogene 1; BDNF= Brain-derived neurotrophic factor; CREB=cAMP response element-binding; 
PPP1R1B= Protein phosphatase 1 subunit 1B; DAT= Dopamine transporter; GAD67 = Glutamic acid decarboxylase-67 
; GAL=Galanin; GFAP=Glial fibrillary acidic protein; GLO1=Glyoxylase1; GNB1=Guanine nucleotide-binding protein 
subunit beta-1;  GSK3β=Glycogen synthase kinase 3 beta; GSR=Glutathione reductase; HDAC5= Histone deacetylase 
5;  KCNJ9=Potassium inwardly-rectifying channel, subfamily J, member 9; MCH=Melanin concentrating hormone; 
NET=Norepinephrine transporter; NGF=Nerve growth factor; NMDA1=Glutamate receptor; NPY=Neuropeptide Y;  
P2X7= Purinergic receptor ligand-gated ion channel7; PAQR8=Progestin and adipoQ receptor 8; PTH=Parathyroid 
hormone; S100β=S100 beta protein; SERT=Serotonin transporter; SGNE=Secretogranin V; TNF-αTumor necrosis 
factor-alpha; VEGF=Vascular endothelial growth factor 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains BAG1
#
 STD BAG1* STD BDNF
#
 STD BDNF* STD c-fos
#
 STD c-fos* STD 
129S1/SvImJ 0.15 0.01 0.12 0.01 2.08 0.02 1.74 0.06 0.25 0.01 0.28 0.01 
A/J 0.17 0.01 0.16 0.01 1.75 0.04 1.65 0.04 0.25 0.01 0.30 0.01 
AKR/J 0.17 0.01 0.15 0.01 2.09 0.05 1.73 0.05 0.27 0.01 0.30 0.01 
C57BL/6J 0.15 0.01 0.17 0.01 1.74 0.06 2.13 0.06 0.29 0.02 0.31 0.01 
BALB/cByJ 0.17 0.01 0.15 0.01 1.80 0.09 1.71 0.08 0.29 0.01 0.35 0.01 
C57BLKS/J 0.18 0.01 0.16 0.01 2.08 0.04 2.14 0.06 0.26 0.01 0.28 0.02 
C57BR/cdJ 0.16 0.01 0.19 0.01 2.03 0.08 2.07 0.04 0.27 0.01 0.32 0.02 
BTBRT+tf/J 0.19 0.01 0.18 0.01 1.94 0.04 2.05 0.08 0.31 0.01 0.33 0.01 
BUB/BnJ 0.19 0.01 0.19 0.01 2.15 0.06 1.86 0.05 0.30 0.01 0.31 0.02 
C3H/HeJ 0.17 0.01 0.16 0.01 2.02 0.03 1.62 0.06 0.29 0.01 0.32 0.01 
C58/J 0.18 0.01 0.17 0.01 1.92 0.04 1.80 0.04 0.29 0.01 0.32 0.02 
CBA/J 0.20 0.01 0.18 0.01 2.09 0.03 2.01 0.06 0.32 0.01 0.31 0.01 
CE/J 0.15 0.01 0.16 0.01 1.54 0.05 1.71 0.11 0.28 0.01 0.30 0.01 
DBA/2J 0.15 0.01 0.17 0.01 1.55 0.07 1.69 0.06 0.27 0.00 0.33 0.01 
FVB/NJ 0.18 0.01 0.17 0.01 2.07 0.06 1.91 0.05 0.30 0.01 0.40 0.02 
I/LnJ 0.16 0.00 0.16 0.01 1.63 0.05 2.07 0.07 0.28 0.01 0.29 0.01 
LG/J 0.18 0.01 0.20 0.01 1.96 0.03 2.14 0.05 0.33 0.01 0.35 0.02 
LP/J 0.19 0.01 0.13 0.00 2.11 0.03 1.22 0.06 0.34 0.01 0.23 0.01 
MA/MyJ 0.17 0.01 0.18 0.01 1.77 0.05 1.74 0.02 0.24 0.01 0.32 0.01 
MRL/MpJ 0.17 0.01 0.20 0.01 1.63 0.03 1.76 0.05 0.31 0.01 0.34 0.01 
NOD/ShiLtJ 0.19 0.01 0.19 0.01 1.89 0.06 2.00 0.04 0.30 0.01 0.33 0.02 
NOR/LtJ 0.17 0.00 0.17 0.01 1.69 0.08 1.53 0.04 0.25 0.01 0.32 0.01 
NZB/BINJ 0.21 0.01 0.19 0.01 1.79 0.04 1.83 0.04 0.36 0.02 0.35 0.01 
NZW/LacJ 0.22 0.01 0.14 0.01 2.13 0.06 1.37 0.08 0.40 0.01 0.29 0.01 
P/J 0.18 0.01 0.19 0.01 2.13 0.05 1.70 0.02 0.34 0.01 0.32 0.01 
PL/J 0.17 0.01 0.21 0.01 1.82 0.03 1.90 0.05 0.33 0.01 0.34 0.02 
RIIIS/J 0.19 0.01 0.211 0.013 2.2 0.051 2.041 0.052 0.368 0.017 0.362 0.014 
SJL/J 0.174 0.01 0.195 0.011 2.065 0.044 1.887 0.043 0.305 0.011 0.29 0.008 
SM/J 0.181 0.01 0.217 0.009 1.939 0.055 2.019 0.034 0.31 0.01 0.311 0.012 
SWR/J 0.189 0.01 0.224 0.01 1.931 0.041 2.105 0.069 0.299 0.01 0.351 0.017 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains CREB
#
 STD CREB* STD PPP1R1B
#
 STD PPP1R1B* STD GAD67
#
 STD GAD67* STD 
129S1/SvImJ 0.69 0.03 0.62 0.02 1.08 0.03 0.76 0.03 1.3 0.09 1.13 0.06 
A/J 0.73 0.03 0.72 0.01 1.02 0.03 0.88 0.03 1.38 0.05 1.4 0.06 
AKR/J 0.75 0.07 0.7 0.02 1.17 0.04 0.87 0.03 1.37 0.07 1.21 0.08 
C57BL/6J 0.76 0.06 0.77 0.03 1.07 0.09 0.89 0.02 1.27 0.11 1.7 0.05 
BALB/cByJ 0.75 0.04 0.71 0.03 1.17 0.04 0.97 0.02 1.56 0.09 1.57 0.06 
C57BLKS/J 0.78 0.03 0.69 0.02 0.94 0.05 0.93 0.04 1.66 0.04 1.87 0.08 
C57BR/cdJ 0.81 0.02 0.78 0.03 1.23 0.03 1.07 0.05 1.73 0.02 1.72 0.07 
BTBRT+tf/J 0.82 0.04 0.75 0.03 1.38 0.04 1.13 0.05 2.09 0.06 1.41 0.06 
BUB/BnJ 0.83 0.02 0.77 0.03 1.17 0.04 1.21 0.09 1.97 0.06 1.87 0.1 
C3H/HeJ 0.82 0.03 0.76 0.02 1.23 0.05 0.76 0.01 1.85 0.1 1.21 0.04 
C58/J 0.76 0.02 0.8 0.04 0.87 0.04 1.12 0.04 1.72 0.05 2.07 0.09 
CBA/J 0.88 0.04 0.82 0.03 1.28 0.05 1.25 0.06 2.08 0.08 2.06 0.06 
CE/J 0.78 0.04 0.77 0.02 0.95 0.02 0.82 0.03 1.23 0.03 1.58 0.06 
DBA/2J 0.71 0.03 0.76 0.02 0.91 0.02 1.03 0.04 1.66 0.05 1.41 0.07 
FVB/NJ 0.82 0.04 0.83 0.04 1.17 0.09 1.21 0.08 1.72 0.14 1.58 0.09 
I/LnJ 0.79 0.02 0.7 0.03 1.02 0.03 0.91 0.05 1.57 0.03 1.26 0.06 
LG/J 0.85 0.03 0.85 0.05 1.22 0.04 0.87 0.05 1.6 0.06 1.5 0.08 
LP/J 0.84 0.03 0.47 0.03 1.28 0.07 0.52 0.02 1.88 0.07 0.72 0.05 
MA/MyJ 0.7 0.02 0.83 0.04 1.04 0.03 1.17 0.05 1.67 0.06 1.81 0.07 
MRL/MpJ 0.82 0.02 0.85 0.03 0.82 0.05 0.8 0.04 1.85 0.07 1.31 0.05 
NOD/ShiLtJ 0.83 0.04 0.78 0.02 1.17 0.05 1.16 0.07 1.84 0.08 1.41 0.06 
NOR/LtJ 0.65 0.03 0.73 0.02 1.05 0.03 0.98 0.03 1.5 0.04 1.5 0.06 
NZB/BINJ 0.89 0.03 0.8 0.03 1.27 0.06 1 0.05 1.18 0.03 1.23 0.05 
NZW/LacJ 0.95 0.04 0.53 0.03 1.29 0.08 0.8 0.02 1.4 0.05 1.11 0.04 
P/J 0.82 0.02 0.79 0.03 1.05 0.03 1.3 0.05 1.51 0.08 1.64 0.07 
PL/J 0.88 0.03 0.73 0.03 1.37 0.06 0.83 0.04 1.81 0.08 1.28 0.05 
RIIIS/J 0.96 0.05 0.7 0.03 1.2 0.08 0.92 0.05 1.82 0.08 1.72 0.05 
SJL/J 0.81 0.03 0.7 0.03 1.25 0.04 0.86 0.03 1.73 0.05 1.64 0.07 
SM/J 0.84 0.03 0.78 0.03 1.05 0.06 0.84 0.04 1.47 0.09 1.99 0.13 
SWR/J 0.82 0.02 0.8 0.02 1.32 0.06 1.08 0.06 1.76 0.05 1.75 0.06 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains Galanin
#
 STD 
Galanin
* STD 
GFAP
#
 STD 
GFA
P* STD 
Ghrelin
#
 STD Ghrelin* STD 
129S1/SvImJ 1.41 0.03 0.98 0.02 2.25 0.03 1.51 0.03 0.35 0.01 0.24 0.02 
A/J 1.40 0.02 1.19 0.02 2.11 0.08 2.41 0.06 0.38 0.01 0.42 0.03 
AKR/J 1.51 0.03 0.99 0.03 3.05 0.05 1.51 0.06 0.39 0.02 0.39 0.03 
C57BL/6J 1.14 0.08 1.42 0.03 1.83 0.19 2.06 0.03 0.31 0.04 0.38 0.01 
BALB/cByJ 1.37 0.04 1.06 0.04 3.81 0.13 3.32 0.30 0.37 0.02 0.35 0.03 
C57BLKS/J 1.40 0.02 1.48 0.04 1.97 0.06 1.97 0.05 0.35 0.02 0.23 0.02 
C57BR/cdJ 1.30 0.03 1.01 0.02 2.31 0.12 2.22 0.07 0.35 0.01 0.32 0.02 
BTBRT+tf/J 1.54 0.05 1.05 0.02 1.92 0.03 2.18 0.14 0.42 0.02 0.32 0.02 
BUB/BnJ 1.52 0.04 1.06 0.03 2.69 0.13 2.23 0.14 0.44 0.01 0.34 0.01 
C3H/HeJ 1.49 0.06 1.04 0.03 2.13 0.04 2.22 0.10 0.41 0.02 0.30 0.02 
C58/J 1.51 0.03 1.13 0.03 2.11 0.08 7.94 0.15 0.40 0.01 0.35 0.02 
CBA/J 1.58 0.04 1.21 0.02 2.63 0.08 5.02 0.11 0.45 0.01 0.34 0.02 
CE/J 1.51 0.04 1.06 0.03 1.96 0.03 1.77 0.06 0.38 0.02 0.30 0.02 
DBA/2J 1.30 0.04 0.96 0.02 1.74 0.08 6.81 0.18 0.37 0.02 0.33 0.01 
FVB/NJ 1.43 0.05 1.20 0.03 2.67 0.10 3.07 0.16 0.44 0.03 0.35 0.02 
I/LnJ 1.53 0.04 0.78 0.01 1.70 0.06 1.72 0.11 0.41 0.03 0.30 0.02 
LG/J 1.37 0.02 1.01 0.05 2.53 0.11 2.86 0.14 0.46 0.02 0.38 0.01 
LP/J 1.30 0.03 0.78 0.03 2.15 0.06 1.21 0.07 0.49 0.03 0.15 0.01 
MA/MyJ 1.50 0.03 0.89 0.01 2.47 0.11 3.74 0.13 0.39 0.01 0.35 0.01 
MRL/MpJ 2.77 0.12 1.03 0.03 2.60 0.03 3.06 0.20 0.46 0.01 0.32 0.01 
NOD/ShiLtJ 2.35 0.09 1.05 0.03 2.87 0.04 2.93 0.20 0.47 0.01 0.33 0.01 
NOR/LtJ 1.15 0.02 0.95 0.02 2.20 0.15 2.22 0.12 0.40 0.01 0.31 0.01 
NZB/BINJ 1.13 0.03 0.96 0.02 3.08 0.17 2.56 0.13 0.50 0.01 0.31 0.01 
NZW/LacJ 1.77 0.07 0.93 0.03 3.48 0.09 1.34 0.10 0.53 0.02 0.21 0.01 
P/J 1.27 0.06 0.88 0.02 2.56 0.04 6.50 0.17 0.49 0.02 0.38 0.02 
PL/J 1.32 0.02 0.98 0.02 2.09 0.05 2.42 0.09 0.49 0.02 0.33 0.01 
RIIIS/J 1.41 0.05 1.08 0.02 5.47 0.14 3.13 0.18 0.45 0.01 0.34 0.01 
SJL/J 1.34 0.04 1.05 0.02 3.16 0.04 3.04 0.20 0.47 0.01 0.31 0.01 
SM/J 1.48 0.05 1.19 0.03 2.08 0.02 3.17 0.09 0.46 0.02 0.37 0.01 
SWR/J 1.47 0.02 1.15 0.02 2.87 0.18 3.50 0.36 0.39 0.01 0.38 0.01 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains KCNJ9
#
 STD KCNJ9* STD GSR
#
 STD GSR* STD GLO1
#
 STD GLO1* STD 
129S1/SvImJ 0.36 0.01 0.33 0.01 0.85 0.03 0.53 0.04 3.49 0.18 1.77 0.26 
A/J 0.36 0.01 0.35 0.01 0.72 0.01 0.66 0.02 6.21 0.16 3.61 0.46 
AKR/J 0.35 0.01 0.33 0.01 0.87 0.02 0.62 0.03 5.93 0.20 3.83 0.28 
C57BL/6J 0.35 0.02 0.34 0.01 0.59 0.02 0.66 0.02 2.96 0.40 2.21 0.15 
BALB/cByJ 0.37 0.01 0.33 0.01 0.76 0.03 0.72 0.02 4.04 0.31 2.99 0.27 
C57BLKS/J 0.30 0.01 0.33 0.01 0.65 0.02 0.64 0.03 5.02 0.19 3.57 0.14 
C57BR/cdJ 0.33 0.01 0.34 0.01 0.76 0.01 0.61 0.02 3.10 0.10 3.35 0.15 
BTBRT+tf/J 0.37 0.01 0.36 0.01 0.83 0.02 0.65 0.02 4.17 0.13 3.22 0.12 
BUB/BnJ 0.34 0.01 0.36 0.02 0.87 0.01 0.78 0.04 4.34 0.19 3.67 0.12 
C3H/HeJ 0.38 0.01 0.37 0.01 0.87 0.03 0.61 0.02 4.38 0.25 3.71 0.16 
C58/J 0.37 0.01 0.37 0.01 0.75 0.02 0.67 0.03 3.78 0.14 3.27 0.06 
CBA/J 0.37 0.01 0.38 0.01 0.91 0.03 0.81 0.04 5.70 0.15 4.64 0.18 
CE/J 0.34 0.01 0.32 0.01 0.78 0.02 0.67 0.02 4.84 0.12 4.43 0.29 
DBA/2J 0.28 0.01 0.31 0.01 0.80 0.02 0.62 0.01 4.04 0.21 4.17 0.15 
FVB/NJ 0.34 0.02 0.35 0.02 0.74 0.05 0.71 0.04 4.61 0.21 3.57 0.27 
I/LnJ 0.35 0.01 0.35 0.01 0.68 0.01 0.63 0.02 4.11 0.16 3.60 0.31 
LG/J 0.36 0.01 0.39 0.01 0.76 0.01 0.77 0.03 4.27 0.18 4.11 0.14 
LP/J 0.38 0.01 0.26 0.01 0.93 0.02 0.40 0.02 6.51 0.17 2.09 0.21 
MA/MyJ 0.36 0.01 0.32 0.02 0.82 0.03 0.76 0.03 2.88 0.11 3.73 0.10 
MRL/MpJ 0.36 0.01 0.33 0.01 0.82 0.03 0.72 0.02 4.91 0.18 5.31 0.14 
NOD/ShiLtJ 0.35 0.01 0.36 0.01 0.85 0.02 0.77 0.02 4.34 0.21 4.22 0.16 
NOR/LtJ 0.32 0.01 0.32 0.01 0.80 0.03 0.76 0.02 2.66 0.16 3.43 0.14 
NZB/BINJ 0.40 0.01 0.33 0.01 0.65 0.02 0.64 0.02 4.98 0.18 4.09 0.10 
NZW/LacJ 0.41 0.02 0.27 0.01 0.75 0.01 0.45 0.02 5.37 0.16 2.75 0.22 
P/J 0.40 0.02 0.35 0.01 0.93 0.02 0.61 0.02 4.01 0.21 4.66 0.12 
PL/J 0.36 0.01 0.36 0.01 0.84 0.02 0.71 0.02 4.35 0.10 4.17 0.10 
RIIIS/J 0.37 0.01 0.38 0.02 0.83 0.03 0.80 0.03 4.98 0.18 4.07 0.18 
SJL/J 0.36 0.01 0.33 0.01 0.93 0.02 0.84 0.03 3.86 0.19 3.41 0.14 
SM/J 0.39 0.01 0.33 0.02 0.79 0.02 0.84 0.05 4.39 0.20 3.63 0.14 
SWR/J 0.35 0.01 0.38 0.01 0.78 0.02 0.84 0.04 4.26 0.12 4.72 0.27 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains 
GNB1
# STD 
GNB1
* STD 
GSK3β
# STD 
GSK3β
* STD HDAC5# STD HDAC5* STD 
129S1/SvImJ 7.79 0.78 8.43 0.65 0.87 0.05 0.67 0.04 2.04 0.09 1.63 0.10 
A/J 7.04 1.02 8.57 1.04 0.93 0.04 0.46 0.02 2.52 0.05 1.67 0.07 
AKR/J 8.02 0.94 8.39 0.61 0.71 0.04 0.67 0.03 2.01 0.08 2.12 0.10 
C57BL/6J 7.98 0.19 8.93 0.46 0.72 0.10 0.69 0.02 2.65 0.14 1.86 0.07 
BALB/cByJ 5.48 0.55 7.90 0.87 0.74 0.05 0.65 0.05 2.37 0.07 2.16 0.06 
C57BLKS/J 6.58 0.66 6.76 0.78 0.72 0.01 1.15 0.04 2.13 0.10 2.52 0.13 
C57BR/cdJ 6.35 0.50 6.03 0.22 1.09 0.06 0.88 0.03 2.36 0.06 2.45 0.11 
BTBRT+tf/J 9.31 0.30 5.99 0.41 0.83 0.02 1.57 0.05 2.55 0.08 3.30 0.16 
BUB/BnJ 9.14 0.66 11.55 0.94 0.77 0.04 1.13 0.02 2.24 0.05 2.53 0.17 
C3H/HeJ 7.24 0.38 9.70 0.86 1.01 0.03 0.55 0.03 2.87 0.18 2.13 0.06 
C58/J 5.68 0.44 7.71 0.41 0.92 0.03 0.82 0.02 2.57 0.10 2.42 0.11 
CBA/J 10.55 0.48 8.31 0.20 0.89 0.01 1.01 0.03 2.78 0.15 2.68 0.12 
CE/J 8.51 0.58 7.64 0.62 0.68 0.01 0.51 0.04 2.21 0.06 1.96 0.08 
DBA/2J 7.52 0.71 7.09 0.45 0.68 0.03 0.81 0.03 1.98 0.05 2.17 0.07 
FVB/NJ 6.89 0.63 8.60 1.06 0.91 0.03 0.70 0.04 2.64 0.20 2.59 0.17 
I/LnJ 10.23 1.26 8.07 1.05 0.53 0.03 0.88 0.10 1.86 0.03 2.32 0.18 
LG/J 7.45 0.26 8.15 0.19 1.20 0.02 0.93 0.05 2.76 0.10 2.53 0.10 
LP/J 10.81 0.61 7.10 0.40 0.78 0.02 0.26 0.02 2.80 0.11 1.31 0.07 
MA/MyJ 6.59 0.73 8.47 0.20 0.86 0.03 1.03 0.02 2.13 0.08 2.47 0.12 
MRL/MpJ 9.11 0.69 7.20 0.45 0.72 0.02 0.47 0.03 2.12 0.07 1.80 0.07 
NOD/ShiLtJ 9.85 0.88 8.91 0.62 1.59 0.04 1.37 0.04 2.98 0.06 3.05 0.16 
NOR/LtJ 6.69 0.75 10.40 0.61 0.83 0.06 0.83 0.04 2.02 0.06 2.57 0.09 
NZB/BINJ 14.23 1.11 7.96 0.33 1.45 0.05 0.96 0.03 3.51 0.16 2.65 0.11 
NZW/LacJ 11.73 0.66 8.25 0.19 0.58 0.02 0.69 0.05 2.61 0.12 2.14 0.10 
P/J 9.02 0.26 11.10 0.37 1.01 0.03 1.68 0.05 2.70 0.10 3.94 0.09 
PL/J 10.29 0.56 9.01 0.28 1.11 0.02 0.76 0.03 2.88 0.09 2.35 0.10 
RIIIS/J 8.49 0.41 10.41 0.66 1.05 0.02 0.57 0.02 2.62 0.13 2.04 0.11 
SJL/J 7.01 0.36 9.86 0.66 1.13 0.02 0.60 0.03 2.63 0.11 2.23 0.11 
SM/J 8.31 0.34 7.84 0.39 0.81 0.02 0.60 0.02 2.13 0.07 1.86 0.09 
SWR/J 9.77 0.72 12.10 0.34 1.61 0.05 1.15 0.05 3.06 0.11 2.87 0.14 
 
 
  
169 
 
Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains MCH
#
 STD MCH* STD NGF
#
 STD NGF* STD NPY
#
 STD NPY* STD 
129S1/SvImJ 0.002 0.008 0.008 0.006 1.78 0.03 1.66 0.04 0.91 0.02 0.47 0.02 
A/J 0.012 0.004 0.029 0.008 1.66 0.03 1.94 0.05 0.69 0.02 0.55 0.02 
AKR/J 0.015 0.004 0.026 0.006 1.83 0.05 1.88 0.06 0.94 0.03 0.49 0.03 
C57BL/6J -0.004 0.004 0.01 0.005 1.60 0.06 1.62 0.03 0.76 0.05 0.77 0.01 
BALB/cByJ 0.009 0.005 0.01 0.004 1.65 0.04 1.82 0.03 0.81 0.03 0.64 0.02 
C57BLKS/J 0.014 0.003 0.007 0.005 1.75 0.03 1.83 0.13 0.76 0.02 0.71 0.02 
C57BR/cdJ 0.002 0.003 0.009 0.004 1.67 0.03 1.53 0.02 0.97 0.02 0.66 0.03 
BTBRT+tf/J -0.003 0.006 -0.005 0.003 1.52 0.05 1.86 0.02 0.87 0.02 0.63 0.02 
BUB/BnJ 0.006 0.005 -0.006 0.005 1.69 0.04 1.65 0.02 0.91 0.03 0.65 0.03 
C3H/HeJ 0.01 0.003 0.005 0.004 1.72 0.03 1.54 0.02 0.85 0.03 0.64 0.03 
C58/J 0.01 0.003 0.004 0.006 1.65 0.03 1.54 0.04 0.73 0.02 0.67 0.02 
CBA/J 0.008 0.004 0 0.002 1.55 0.02 1.87 0.02 0.81 0.02 0.72 0.02 
CE/J 0.012 0.002 0.008 0.002 1.62 0.02 1.50 0.04 0.70 0.02 0.57 0.02 
DBA/2J 0.012 0.003 0.015 0.004 1.44 0.04 1.54 0.03 0.67 0.03 0.66 0.01 
FVB/NJ 0.014 0.004 0.008 0.005 1.75 0.02 1.69 0.13 0.77 0.04 0.64 0.04 
I/LnJ 0.02 0.004 0.025 0.003 1.54 0.02 1.48 0.04 0.69 0.03 0.56 0.03 
LG/J 0.016 0.004 0.021 0.004 1.69 0.04 1.61 0.02 0.69 0.03 0.60 0.02 
LP/J 0.029 0.003 0.001 0.004 1.83 0.02 1.52 0.04 0.70 0.03 0.32 0.02 
MA/MyJ 0.03 0.003 0.013 0.004 1.64 0.04 1.39 0.01 0.74 0.02 0.71 0.02 
MRL/MpJ 0.011 0.003 -0.005 0.004 1.57 0.02 1.56 0.04 0.91 0.03 0.58 0.01 
NOD/ShiLtJ 0.022 0.003 0.006 0.002 1.62 0.02 1.75 0.04 0.98 0.02 0.70 0.02 
NOR/LtJ 0.011 0.002 0.003 0.003 1.55 0.04 1.44 0.02 0.69 0.03 0.59 0.02 
NZB/BINJ 0.003 0.006 0.001 0.003 1.71 0.02 1.62 0.02 0.66 0.02 0.59 0.01 
NZW/LacJ 0.015 0.006 -0.008 0.003 1.71 0.03 1.43 0.04 0.80 0.03 0.43 0.02 
P/J 0.001 0.004 0.007 0.004 1.73 0.03 1.41 0.02 0.78 0.02 0.57 0.02 
PL/J 0.017 0.004 -0.001 0.003 1.56 0.02 1.63 0.02 0.80 0.02 0.59 0.02 
RIIIS/J 0.022 0.003 -0.004 0.005 1.73 0.04 1.68 0.02 0.84 0.03 0.64 0.01 
SJL/J 0.021 0.003 -0.003 0.003 1.62 0.02 1.57 0.02 0.80 0.03 0.55 0.02 
SM/J 0.019 0.004 0.001 0.002 1.67 0.03 1.57 0.03 0.81 0.03 0.72 0.03 
SWR/J 0.006 0.002 0.004 0.003 1.64 0.03 1.81 0.02 0.74 0.01 0.65 0.02 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains NMDA1
#
 STD NMDA1* STD NET
#
 STD NET* STD P2X7
#
 STD P2X7* STD 
129S1/SvImJ 1.04 0.06 0.73 0.05 0.49 0.02 0.40 0.01 2.76 0.06 2.22 0.11 
A/J 0.96 0.04 0.92 0.05 0.40 0.01 0.46 0.01 3.55 0.09 2.67 0.08 
AKR/J 1.15 0.05 0.89 0.04 0.46 0.01 0.47 0.02 3.20 0.06 2.81 0.07 
C57BL/6J 0.80 0.02 1.09 0.03 0.42 0.03 0.53 0.02 3.43 0.16 2.61 0.05 
BALB/cByJ 0.88 0.05 0.98 0.03 0.44 0.02 0.47 0.01 3.73 0.13 2.99 0.07 
C57BLKS/J 0.98 0.04 0.99 0.04 0.44 0.01 0.49 0.03 3.21 0.06 2.84 0.10 
C57BR/cdJ 0.93 0.02 0.87 0.03 0.46 0.02 0.53 0.02 3.07 0.05 3.28 0.10 
BTBRT+tf/J 1.19 0.02 0.89 0.03 0.50 0.01 0.48 0.01 3.93 0.09 3.42 0.08 
BUB/BnJ 1.03 0.04 1.04 0.05 0.47 0.01 0.52 0.04 3.49 0.12 2.79 0.12 
C3H/HeJ 0.93 0.04 0.60 0.03 0.41 0.02 0.48 0.02 3.62 0.14 3.38 0.08 
C58/J 0.84 0.02 0.94 0.04 0.43 0.02 0.48 0.02 3.62 0.13 3.10 0.09 
CBA/J 1.08 0.04 1.01 0.04 0.45 0.01 0.52 0.03 3.61 0.11 3.07 0.09 
CE/J 0.72 0.02 0.80 0.03 0.39 0.01 0.43 0.01 3.42 0.05 2.98 0.07 
DBA/2J 0.81 0.03 0.84 0.04 0.40 0.01 0.45 0.01 3.01 0.07 2.65 0.05 
FVB/NJ 0.91 0.06 0.96 0.06 0.42 0.03 0.50 0.04 3.65 0.14 3.32 0.15 
I/LnJ 0.87 0.03 0.72 0.06 0.39 0.01 0.37 0.01 3.07 0.08 3.00 0.08 
LG/J 0.85 0.02 0.98 0.04 0.44 0.02 0.47 0.02 3.63 0.07 3.74 0.13 
LP/J 1.10 0.03 0.45 0.02 0.45 0.02 0.29 0.01 4.12 0.10 2.32 0.08 
MA/MyJ 0.86 0.03 0.98 0.06 0.40 0.02 0.49 0.01 3.28 0.08 2.97 0.09 
MRL/MpJ 1.13 0.03 0.80 0.02 0.51 0.02 0.47 0.02 3.19 0.07 3.15 0.08 
NOD/ShiLtJ 1.13 0.06 0.90 0.03 0.53 0.02 0.50 0.02 3.18 0.12 3.31 0.09 
NOR/LtJ 0.91 0.03 0.93 0.05 0.38 0.01 0.42 0.02 3.03 0.08 3.05 0.05 
NZB/BINJ 0.90 0.04 0.81 0.03 0.49 0.02 0.45 0.02 4.25 0.13 3.26 0.12 
NZW/LacJ 1.20 0.05 0.65 0.02 0.54 0.03 0.35 0.01 4.27 0.13 2.35 0.10 
P/J 0.94 0.04 1.08 0.03 0.50 0.03 0.44 0.03 4.04 0.14 3.69 0.10 
PL/J 1.18 0.05 0.81 0.04 0.48 0.02 0.49 0.02 3.27 0.10 3.53 0.10 
RIIIS/J 1.15 0.05 0.91 0.04 0.53 0.03 0.50 0.02 3.54 0.12 3.33 0.13 
SJL/J 1.03 0.04 0.97 0.03 0.48 0.03 0.45 0.02 3.45 0.09 3.45 0.10 
SM/J 1.04 0.04 1.17 0.05 0.47 0.02 0.52 0.03 3.00 0.08 2.72 0.11 
SWR/J 0.99 0.04 0.94 0.02 0.46 0.01 0.50 0.02 2.98 0.07 3.67 0.09 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one neurobiochemical 
analytes measured in the cortex of thirty mouse inbred strains   
Strains PTH
#
 STD PTH* STD PAQR8
#
 STD PAQR8* STD S100β# STD S100β* STD 
129S1/SvImJ 0.72 0.07 0.78 0.08 0.48 0.04 0.32 0.03 3.58 0.31 1.85 0.15 
A/J 0.62 0.03 0.61 0.03 0.28 0.02 0.47 0.02 2.91 0.14 3.84 0.33 
AKR/J 0.80 0.04 0.72 0.06 0.47 0.03 0.39 0.01 4.30 0.22 2.41 0.29 
C57BL/6J 0.79 0.09 0.86 0.09 0.48 0.04 0.55 0.04 1.18 0.20 4.47 0.21 
BALB/cByJ 0.65 0.03 0.52 0.02 0.36 0.06 0.47 0.02 3.17 0.39 3.35 0.30 
C57BLKS/J 0.77 0.02 0.70 0.05 0.45 0.02 0.42 0.02 3.67 0.12 4.08 0.46 
C57BR/cdJ 0.84 0.05 0.90 0.05 0.59 0.03 0.58 0.01 5.06 0.22 3.99 0.21 
BTBRT+tf/J 0.73 0.01 0.58 0.01 0.50 0.01 0.51 0.02 3.96 0.16 3.97 0.23 
BUB/BnJ 0.81 0.01 0.67 0.06 0.50 0.04 0.49 0.02 4.48 0.48 4.65 0.30 
C3H/HeJ 0.90 0.03 0.79 0.05 0.46 0.02 0.49 0.03 2.96 0.10 2.28 0.08 
C58/J 0.71 0.02 0.55 0.01 0.41 0.03 0.46 0.02 2.70 0.14 3.69 0.23 
CBA/J 0.83 0.01 0.68 0.02 0.46 0.02 0.53 0.03 3.45 0.15 4.21 0.41 
CE/J 0.82 0.04 0.70 0.06 0.39 0.02 0.40 0.04 2.50 0.18 3.23 0.37 
DBA/2J 0.58 0.02 0.50 0.01 0.31 0.03 0.43 0.04 2.09 0.31 3.18 0.35 
FVB/NJ 0.78 0.03 0.80 0.05 0.46 0.02 0.47 0.02 3.08 0.16 3.27 0.11 
I/LnJ 0.81 0.05 0.65 0.05 0.41 0.04 0.37 0.03 2.47 0.36 1.66 0.27 
LG/J 0.66 0.01 0.58 0.01 0.41 0.02 0.51 0.02 2.54 0.16 3.40 0.20 
LP/J 0.83 0.01 0.43 0.01 0.47 0.02 0.23 0.01 2.92 0.11 1.03 0.08 
MA/MyJ 0.80 0.04 0.64 0.01 0.41 0.02 0.40 0.01 2.60 0.14 4.12 0.28 
MRL/MpJ 0.65 0.03 0.50 0.01 0.39 0.02 0.41 0.05 4.47 0.15 2.67 0.24 
NOD/ShiLtJ 0.68 0.06 0.70 0.02 0.46 0.03 0.44 0.02 3.75 0.35 2.47 0.09 
NOR/LtJ 0.68 0.04 0.64 0.02 0.45 0.02 0.32 0.03 2.03 0.23 1.03 0.33 
NZB/BINJ 0.79 0.02 0.51 0.01 0.51 0.03 0.38 0.02 1.96 0.08 2.70 0.13 
NZW/LacJ 0.96 0.02 0.50 0.01 0.66 0.04 0.28 0.01 2.49 0.11 1.86 0.22 
P/J 0.89 0.02 0.66 0.01 0.60 0.03 0.38 0.01 2.85 0.10 3.00 0.16 
PL/J 0.68 0.01 0.53 0.02 0.52 0.03 0.42 0.02 3.58 0.19 3.07 0.13 
RIIIS/J 0.79 0.01 0.68 0.03 0.61 0.05 0.46 0.02 4.05 0.23 3.92 0.28 
SJL/J 0.77 0.02 0.66 0.02 0.58 0.03 0.41 0.03 3.91 0.32 2.69 0.18 
SM/J 0.69 0.02 0.62 0.02 0.55 0.04 0.53 0.03 3.73 0.22 4.66 0.21 
SWR/J 0.84 0.03 0.89 0.04 0.45 0.03 0.49 0.03 2.81 0.28 3.44 0.09 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one 
neurobiochemical analytes measured in the cortex of thirty mouse inbred strains   
Strains SGNE
#
 STD SGNE* STD SERT
#
 STD SERT* STD 
129S1/SvImJ 0.50 0.01 0.35 0.01 1.08 0.02 0.81 0.05 
A/J 0.40 0.01 0.40 0.01 0.85 0.02 0.84 0.03 
AKR/J 0.57 0.02 0.30 0.01 1.08 0.03 0.57 0.02 
C57BL/6J 0.46 0.02 0.51 0.01 0.95 0.08 1.01 0.02 
BALB/cByJ 0.47 0.01 0.42 0.01 1.08 0.06 0.93 0.03 
C57BLKS/J 0.43 0.01 0.38 0.01 0.96 0.03 0.93 0.02 
C57BR/cdJ 0.57 0.01 0.47 0.01 1.17 0.03 1.03 0.02 
BTBRT+tf/J 0.49 0.01 0.44 0.01 1.10 0.02 1.06 0.02 
BUB/BnJ 0.49 0.01 0.38 0.01 1.12 0.03 0.93 0.03 
C3H/HeJ 0.49 0.01 0.38 0.01 1.14 0.03 0.84 0.03 
C58/J 0.42 0.01 0.46 0.01 0.97 0.02 0.97 0.02 
CBA/J 0.48 0.01 0.44 0.01 1.08 0.02 0.97 0.03 
CE/J 0.57 0.01 0.38 0.01 0.95 0.02 0.85 0.04 
DBA/2J 0.46 0.01 0.43 0.01 0.92 0.06 0.87 0.02 
FVB/NJ 0.44 0.02 0.38 0.01 0.97 0.04 0.90 0.02 
I/LnJ 0.45 0.01 0.36 0.01 1.02 0.05 0.97 0.03 
LG/J 0.48 0.01 0.41 0.01 1.09 0.02 0.87 0.03 
LP/J 0.44 0.01 0.26 0.01 1.17 0.02 0.49 0.02 
MA/MyJ 0.47 0.01 0.44 0.01 1.00 0.02 1.05 0.02 
MRL/MpJ 0.57 0.01 0.41 0.01 1.14 0.03 0.77 0.02 
NOD/ShiLtJ 0.50 0.01 0.35 0.01 1.34 0.04 0.88 0.02 
NOR/LtJ 0.42 0.01 0.40 0.01 0.92 0.04 0.88 0.02 
NZB/BINJ 0.45 0.01 0.44 0.01 1.06 0.03 0.85 0.02 
NZW/LacJ 0.40 0.01 0.30 0.01 1.32 0.04 0.62 0.03 
P/J 0.46 0.02 0.43 0.01 1.01 0.03 0.91 0.01 
PL/J 0.51 0.02 0.40 0.01 1.08 0.03 0.84 0.02 
RIIIS/J 0.39 0.01 0.34 0.01 1.16 0.03 0.95 0.02 
SJL/J 0.52 0.01 0.37 0.01 1.14 0.03 0.80 0.02 
SM/J 0.51 0.01 0.43 0.01 1.07 0.04 0.97 0.02 
SWR/J 0.38 0.01 0.34 0.01 1.10 0.04 0.90 0.03 
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Supplementary Table 4.4 Mean relative flourescence intensity (RFI) values for thirty-one 
neurobiochemical analytes measured in the cortex of thirty mouse inbred strains   
Strains 
TNF-α# STD TNF-α* STD VEGF# STD VEGF* STD 
129S1/SvImJ 0.811 0.021 0.393 0.016 0.187 0.010 0.173 0.007 
A/J 0.763 0.017 0.531 0.011 0.250 0.008 0.201 0.009 
AKR/J 0.821 0.021 0.477 0.015 0.217 0.008 0.183 0.009 
C57BL/6J 0.710 0.057 0.555 0.021 0.245 0.010 0.178 0.007 
BALB/cByJ 0.729 0.033 0.546 0.018 0.242 0.012 0.220 0.008 
C57BLKS/J 0.730 0.016 0.592 0.010 0.202 0.009 0.168 0.010 
C57BR/cdJ 0.723 0.018 0.608 0.027 0.202 0.008 0.225 0.014 
BTBRT+tf/J 0.815 0.015 0.633 0.012 0.253 0.011 0.228 0.009 
BUB/BnJ 0.835 0.030 0.586 0.015 0.221 0.009 0.197 0.012 
C3H/HeJ 0.749 0.031 0.609 0.018 0.246 0.015 0.232 0.006 
C58/J 0.758 0.023 0.654 0.014 0.249 0.009 0.232 0.010 
CBA/J 0.829 0.038 0.610 0.017 0.230 0.008 0.209 0.008 
CE/J 0.766 0.019 0.541 0.019 0.285 0.016 0.213 0.006 
DBA/2J 0.681 0.035 0.527 0.020 0.232 0.006 0.212 0.007 
FVB/NJ 0.718 0.033 0.584 0.029 0.231 0.016 0.209 0.015 
I/LnJ 0.754 0.035 0.573 0.024 0.252 0.010 0.227 0.009 
LG/J 0.790 0.021 0.687 0.027 0.291 0.011 0.261 0.014 
LP/J 0.828 0.021 0.364 0.017 0.261 0.014 0.152 0.003 
MA/MyJ 0.750 0.026 0.595 0.018 0.238 0.011 0.254 0.011 
MRL/MpJ 0.975 0.014 0.578 0.019 0.276 0.011 0.234 0.008 
NOD/ShiLtJ 1.085 0.029 0.597 0.009 0.245 0.009 0.225 0.011 
NOR/LtJ 0.716 0.015 0.591 0.011 0.236 0.006 0.240 0.009 
NZB/BINJ 0.902 0.021 0.623 0.016 0.332 0.013 0.245 0.015 
NZW/LacJ 1.009 0.029 0.439 0.017 0.302 0.014 0.187 0.006 
P/J 0.876 0.023 0.633 0.025 0.292 0.012 0.279 0.013 
PL/J 0.822 0.016 0.632 0.016 0.289 0.012 0.259 0.013 
RIIIS/J 0.877 0.035 0.580 0.018 0.274 0.014 0.206 0.012 
SJL/J 0.864 0.019 0.584 0.012 0.273 0.014 0.235 0.016 
SM/J 0.803 0.028 0.623 0.018 0.265 0.014 0.219 0.009 
SWR/J 0.756 0.022 0.636 0.015 0.236 0.010 0.228 0.010 
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Supplementary Table 4.5 Pairwise comparisons of behavioral scores between treatment groups 
 
Supplementary Table 4.5 Pairwise comparisons of behavioral scores between treatment groups.   
Strain 
U-Statistic for 
Percent Time 
Spent 
Immobile in 
the TST 
Adjusted p-
values*** 
U-Statistic for 
Percent Time Spent 
in the Center of the 
OF 
Adjusted p-
values*** 
129S1/SvImJ 96 0.537 111.5 0.294 
A/J 114 0.264 115 0.917 
AKR/J 41 0.345 40 0.965 
BALB/cJ 249.5 0.001** 47.5 0.879 
BTBRT<t>tf/J 45 0.386 61 0.619 
BUB/BnJ 62 0.012* 51.5 0.136 
C3H/HeJ 121 0.291 117.5 0.836 
C57BL/6J 57 0.007** 63.5 0.5 
C57BLKS/J 71 0.26 63 0.843 
C57BR/cdJ 95 0.023* 124 0.097 
C58/J 42 0.895 53 0.27 
CBA/J 190.5 0.00002** 117 0.369 
CE/J 69 0.286 70 0.256 
DBA/2J 131.5 0.094^ 262.5 0.014* 
FVB/NJ 43 0.248 64 0.038 
I/LnJ 24 0.427 66.5 0.063 
LG/J 61 0.070^ 77 0.037 
LP/J 41.5 0.826 115 0.147 
MA/MyJ 63 0.047* 68 0.015* 
MRL/MpJ 37 0.923 57.5 0.265 
NOD/LtJ 81 0.067^ 61 0.974 
NOR/LtJ 48 0.205 55.5 0.973 
NZB/BlNJ 46 0.594 95.5 0.022 
NZW/LacJ 50 0.178 39 0.895 
P/J 90 0.001** 79 0.025 
PL/J 94 0.025* 102.5 0.078 
RIIIS/J 66 0.394 73 0.177 
SJL/J 50 0.97 100.5 0.009** 
SM/J 49 0.002** 64 0.007** 
SWR/J 93 0.225 83 0.525 
*** Following Mann-Whitney U test for post-hoc pairwise comparisons of behavioral scores between 
treatment groups, p-values were adjusted for multiple comparisons using the Benjamini-Hochberg 
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correction for multiple testing; *** denotes p-values p<0.009; ** denotes p-values p<0.05; ^denotes p-
values p<0.10  
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Supplementary Table 4.6 Covariance of behavior and neurobiochemical levels explained by 
partial least squares (PLS) latent vectors 
Supplementary Table 4.6  Covariance  of behavior and neurobiochemical levels explained by partial 
least squares (PLS) latent vectors  
  
Percent covariance explained for behavior 
and biochemical levels  
Cumulative percent covariance explained 
for behavior and biochemical levels  
Vehicle 
 
  
Vector 1 59 59 
Vector 2 29 88 
Vector 3 12 100 
  
 
  
Fluoxetine 
 
  
Vector 1 56 56 
Vector 2 33 89 
Vector 3 11 100 
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Supplementary Table 4.7 Informative genes used to predict treatment groups in the k-NN leave-
one-out cross-validation test 
Supplementary Table 4.7 Informative genes used to predict treatment groups in the kNN leave-one-
out cross-validation test 
Genes Description 
Gm129 gene model 129 
Lgi2 leucine-rich repeat LGI family, member 2 
Erf Ets2 repressor factor 
Gnb4 guanine nucleotide binding protein (G protein), beta 4 
Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3 
Anp32a acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 
2400009B08Rik RIKEN cDNA 2400009B08 gene,  
Sema4a 
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4A,  
 Gpc1 glypican 1 
Inhba inhibin beta-A 
C030003D03Rik RIKEN cDNA C030003D03 gene 
Sgsm1 small G protein signaling modulator 1 
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Supplementary Table 4.8 Informative genes used to predict response groups in the k-NN leave-
one-out cross-validation test. 
Supplementary Table 4.8 Informative genes used to predict  response groups in the kNN leave-one-out 
cross-validation test 
Genes Description 
Copg2as2 coatomer protein complex, subunit gamma 2, antisense 2 
Prcp prolylcarboxypeptidase (angiotensinase C)  
Gpr115 G protein-coupled receptor 115 
Gxylt2 glycosyltransferase 8 domain containing 4  
Plb1 phospholipase B1 
Txndc9 thioredoxin domain containing 9 
Mum1l1 melanoma associated antigen (mutated) 1-like 1 
EG545391 predicted gene 
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Supplementary Table 4.9 Baseline genetic markers that influence variable antidepressant 
response 
Supplementary Table 4.9 List of candidate baseline genetic markers that account for variable fluoxetine 
response 
Gene Gene Name p-value  R
2
 Adjusted R
2
 
9230108I15Rik RIKEN cDNA 9230108I15 gene 0.00014 0.61 0.58 
Gm16432 Predicted gene 16432 0.00057 0.53 0.51 
C78760 Expressed sequence C78760 0.00069 0.52 0.49 
Smurf2 SMAD specific E3 ubiquitin protein ligase 2 0.00086 0.51 0.48 
2610005L07Rik Cadherin 11 pseudogene 0.00113 0.49 0.46 
Lmo3 LIM domain only 3 0.00156 0.47 0.44 
Tcrb-J T-cell receptor beta, joining region 0.00206 0.46 0.42 
LOC665506 T-cell receptor beta, joining region 0.00278 0.44 0.40 
Pabpc1 Poly(A) binding protein, cytoplasmic 1 0.00431 0.41 0.37 
Ern1 Endoplasmic reticulum (ER) to nucleus signalling 1 0.00461 0.40 0.37 
LOC627901 Similar to zinc finger protein 14 0.00533 0.39 0.36 
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8. Supplementary Figure  
 
Supplementary Figure 4.1 Cellular adhesion and proliferation pathway links candidate 
antidepressant biochemical markers S100β GFAP, GSK3β, and HDAC5 
Supplementary Figure 4.1. Cellular adhesion and proliferation pathway links candidate 
antidepressant biochemical markers S100β, GFAP, HDAC5, and GSK3β. Molecular connections 
between candidate antidepressant biomarkers were evaluated using Ingenuity Pathway Analysis (IPA) 
software. Results indicate that all candidate antidepressant markers are linked either directly or 
indirectly. S100β, GFAP, HDAC5, and GSK3β connect within a common cellular growth and 
proliferation network, indicating the importance of cellular genesis in mediating response to chronic 
fluoxetine treatment 
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CHAPTER 5 
TAKING THE YELLOW BRICK ROAD TO BIOMARKER VALIDATION 
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1. Summary 
 
We collected genome-wide gene expression data and measured the levels of 40 biochemical 
molecules that have been implicated in anxiety and depression, including neurotransmitters, 
neurotrophic factors, neuropeptides, and neuroamine regulators . We quantified these biochemical 
molecules under control, fluoxetine, and treatment-naïve conditions. In addition, we recorded several 
baseline anxiety and depressive behavioral measures, as well as depressive-like responses, in multiple 
inbred strains after administration of fluoxetine or water. Our goal is to identify genetic and 
biochemical markers that can assess SSRI drug response and risk for poor treatment outcome.  
2. Translating Genetic Findings from Murine to Humans  
 
Haplotype-behavioral associations were performed, and the locations of the candidate QTLs 
were examined for previous association with behavioral responses related to anxiety and depression.  
We identified two anxiety-like QTLs, Chr 5: 108.2 – 110.9 and Chr 17: 18.7 – 23.7, that have 
been previously reported for anxiety-related responses and circadian photosensitivity, respectively 
(Cohen et al. 2001; Yoshimura et al. 2002). Investigation of genes within the anxiety-like behavior loci 
on Chrs 5 and 7 reveal three genes (Fpr1, Pde6b, and Pxmp2) with previous association with anxiety or 
depression (Cohen et al. 2001; Yoshimura et al. 2002). Interestingly, we identified a behavioral despair 
locus on Chr 4 that has been previously linked with anxiety behavior and responses to thermal pain 
(Mogil et al. 1997; Nakamura et al. 2003). Two genes within the despair locus on Chr 4, Hcrtr1 and 
Oprd1, were previously correlated with depressive and/or anxiety behavior (Filliol et al. 2000; Scott et 
al. 2011; van Rijn et al. 2010). Our study demonstrates the power of QTL mapping analysis for the 
detection of genetic loci that influence complex behavioral phenotypes.  
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Detecting susceptibility loci for mental health disorders is challenging for human studies given 
the limited ability to control and account for environmental effects and the need for larger sample sizes 
to detect genes with moderate effects. Although the use of mouse models can overcome these 
limitations, depression is challenging to model in animals given that diagnosis and prognosis are based 
on empirical clinical observations and patients‟ phenomenological accounts. As a result, rodent 
behavioral tests for depression often lack face and construct validity and are unable to model certain 
symptoms, like suicidality. Therefore, an important future direction for mouse QTL behavioral 
mapping studies is the assessment of candidate genes for depressive disorder. To establish association 
of murine candidate genes with major depression, we propose a cross-species association analysis 
approach.  
Cross-species association analysis utilizes mouse QTL mapping studies for candidate gene 
identification and human candidate gene association studies for gene validation. Ease in sample and 
subject accessibility, reduced genomic complexity, and the ability to control for the effects of 
environment on behavior makes mouse QTL mapping analysis an effective and efficient method for 
candidate gene identification, while the use of human samples and data for candidate gene validation 
provides further information regarding the clinical relevance of genetic biomarkers.   
Stage 1: Following identification of loci associated with anxiety-like and depressive-like 
phenotypes (chapter 2), genes within behavioral QTLs can be prioritized by examining gene expression 
and biochemical data. Genes with expression levels that correlate with behavioral phenotypes or 
neurobiochemical levels will be further examined for association with clinical anxiety and depression.     
Stage 2: We will perform candidate gene analysis study on the known human homologues of 
the murine candidate genes identified in Stage 1. Genes that exhibit empirical pointwise p-values of 
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<0.05 from an allelic association test or haplotype-phenotype association analysis for association with 
MDD will be selected for further validation. Genotype and clinical information from the Genetic 
Association Information Network (GAIN) trial are available at http://www.ncbi.nlm.nih.gov/.  Details 
on the methods and study participants have been previously described (Boomsma et al. 2008). 
Stage 3: Genotyping experiments will be performed on additional markers within genes that 
correlate with major depression in stage 2. These markers include haplotype tagging SNPs and SNPs 
projected to alter gene function (nonsynonymous SNPs and variants for polymorphic microRNA 
(miRNA) binding sites). Genetic data, clinical information, and biological materials will be obtained 
from the National Institute of Mental Health Center (NIMH) for Genomic Studies.  
It is possible that some genes identified in our mouse QTL mapping analysis may not correlate 
with major depression. In this case, we will look for similar connections or similar downstream 
pathways that are shared among candidate behavioral despair genes. We can also compare our pre-
clinical findings to human studies that have examined a more homogenous patient population (e.g., 
patients with recurrent depression or early-onset major depressive disorder).  
3. Candidate Gene Validation 
 
3.1 Oprd1 in comorbid anxiety and depression 
 
 
The locus on Chr 4 for depressive-like behavior has been previously linked with anxiety 
behavior and responses to thermal pain. Of particular interest is the Oprd1 gene, which encodes for the 
opioid receptor, delta1. The Oprd1 null mice display increased behavioral despair and anxiety-like 
behavior, indicating that delta1 opioid receptor activity is critical for mediating both anxiety and mood 
disorder (Filliol et al. 2000). Importantly, this result suggests that similar genetic mechanisms underlie 
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anxiety and major depression. To further examine the role of Oprd1 in comorbid anxiety and 
depression, we can compare the behavioral effects of a delta-selective opioid agonist, selective 
serotonin reuptake inhibitor (SSRI), and benzodiazepine in attenuating anxiety-like and depressive-like 
responses. This study can be performed in strains with a) high anxiety-like and minimal depressive-like 
behavior, b) low anxiety-like and high depressive-like behavior, and c) high anxiety-like and high 
depressive-like behavior. Strains will be chosen following an exhaustive analysis of our behavioral data 
and the data from other studies that have assessed several anxiety-like and depressive-like responses 
between strains. 
 
3.2 Dpp4 in depression 
From our QTL mapping analysis, we identified a significant association between Dpp4 and 
depressive-like responses. DPP4 is an ectoenzyme that cleaves polypeptides with proline and, to a 
lesser extent, alanine at the penultimate position. In this study, we found that higher baseline 
immobility scores are linked with reduced DPP4 protein levels. Compared to D2 mice, B6 mice have 
higher immobility scores and higher plasma and brain DPP4 protein levels. There are six different 
Dpp4 transcript variants that have been reported for B6. One of these isoforms leads to an alternative 
protein product, which may explain the difference in DPP4 protein levels between B6 and D2 mice. 
There was no difference in enzymatic activity between B6 and D2, which suggest that baseline inter-
strain behavioral differences are likely due to difference in DPP4 protein levels. This result concurs 
with a mouse knockout study that showed Dpp4
-/-
 mice have lower immobility scores compared to 
wild-type.   
Treatment with sitagliptin resulted in greater than 80% inhibition of plasma DPP4 enzymatic 
activity. However, no significant difference in depressive-like responses was observed between 
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vehicle- and sitagliptin-treated mice of either strain. It is likely that prolonged DPP4 inhibition is 
required to mediate depressive-like responses. To assess the direction of the correlation between DPP4 
and depressive behavior, we will evaluate the relationship between behavioral responses and DPP4 
transcript levels, protein expression, and activity after long-term inhibition of sitagliptin.  We will also 
measure depressive-like responses in mice following intracranial administration of sitagliptin or 
placebo to ascertain if reduction in brain DPP4 activity is required to affect behavior.  
In agreement with this finding, strains that were less immobile or less “depressed-like” after 
fluoxetine treatment exhibited lower mRNA expression of Dpp4 after fluoxetine administration (data 
not reported), indicating a potential role of DPP4 in antidepressant therapy. Reduction in Dpp4 gene 
expression after fluoxetine treatment corresponds with lower immobility. This result suggests a 
potential role of DPP4 in antidepressant therapy.  After the direction of the association between Dpp4 
and depressive-like behavior has been established, we will examine the relationship between Dpp4 and 
fluoxetine response. In this study, we will assess behavioral responses following administration of 
water, fluoxetine, and fluoxetine plus sitagliptin. 
4. Biochemical Marker Validation 
 
Overall differences in neurobiochemical levels were observed for positive and negative 
responders. Biochemical alterations following chronic fluoxetine treatment identified positive 
responders, while baseline neurobiochemical differences differentiated negative responders. Results 
show that glial fibrillary acidic protein (GFAP), S100 beta protein (S100β), GLO1, and histone 
deacytelase 5 (HDAC5) contributed the most to fluoxetine response. These proteins are linked within a 
cellular growth/proliferation pathway, suggesting the involvement of cellular genesis in fluoxetine 
response. 
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Our research approach, if validated, provides an unprecedented and feasible means in which we 
can investigate the effectiveness and clinical utility of new agents in non-responsive lines and strains 
susceptible to depressive-like phenotypes, ultimately facilitating research efforts towards 
antidepressant drug development. Unlike other mouse models, our treatment-resistant and depressive-
like prone strains were not habituated to exhibit more depressive-like features, nor were their genomes 
manipulated. Our forward genetic approach uses multiple inbred mouse strains, thereby taking 
advantage of the naturally-occurring genetic and phenotypic variation extant across inbred mouse 
strains, which more closely parallels the genetic and phenotypic complexities in the heterogeneous 
human population.  Therefore, our mouse models more closely mimic the conditions of depressed 
individuals and are powerful pre-clinical models for in vivo antidepressant screening and comparative 
drug studies. For independent validation, we are using a different, but more robust, mouse model of 
depression, as well as evaluating the antidepressive-like effects of other mood-altering agents.  
Study 1: Strains previously shown to have differential depressive-like and anxiety-like 
behavior at baseline will be selected for this study. We will assess baseline and chronic mild stress 
(CMS)-induced hedonic responsiveness, behavioral despair, and anxiety-like behavior in the strains 
that were previously shown to have variable depressive-like and anxiety-like behavior at baseline. The 
chronic mild stress (CMS) behavioral paradigm presents several advantages. First, CMS is sensitive to 
chronic antidepressant treatment, thereby providing predictive validity. CMS also reduces hedonic 
responsiveness to pleasurable items, modeling anhedonia observed in depressed patients. Finally, CMS 
elicits many of the depressive symptoms commonly found in humans, including reduction in sexual 
behavior, increased HPA axis activity, and abnormal EEG measures, thereby providing good face 
validity (Willner 1997; Willner et al. 1992) and making this test a robust animal model of depression 
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(Nestler and Hyman 2010). The first study will examine baseline responses to chronic mild stress 
(CMS) to identify depressive-like prone strains, thus providing an independent validation of our 
previous findings.   
Study 2: Upon completion of the first study, the mice will be randomized to receive vehicle, 
citalopram (20 mg/kg), or novel antidepressant agent UNC1 for 28 days. Mice will be exposed to 
various stressors for 5 days during the second and third week of the treatment study to maintain stress-
induced hedonic state in the mice (Strekalova et al. 2006). After chronic treatment, the mice will be 
tested in the open field, light/dark test, tail suspension test, and forced swim test. Preference and 
consumption of sucrose-flavored water will be measured weekly using previously published protocols 
(Strekalova et al. 2006). The goal of study 2 is to investigate the ability of citalopram and UNC1 to 
reverse stress-induced depressive-like and anxiety-like response in susceptible and non-susceptible 
strains, previously identified in study1. In this study, we will investigate if the same genetic and 
biochemical markers of fluoxetine response can delineate treatment responders to other antidepressant 
agents (citalopram and novel agent UNC1), providing an independent validation of predictive 
biomarkers, which has not been done before in pre-clinical models of depression. Furthermore, we plan 
to collectively assess molecular, biochemical, and behavioral parameters in order to establish a 
composite measure of drug response.  
Another important avenue for future study is the assessment of these biomarkers in easily 
accessible samples, like plasma or serum, thus facilitating translation of pre-clinical findings in mice to 
human studies. Current work in the lab aims to evaluate the relationship between behavioral responses 
and serum levels of neurobiochemical markers across multiple inbred strains.  
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5. Conclusion 
 
We conducted a comprehensive analysis of behavioral, neurobiochemical, and transcriptome 
data across thirty mouse inbred strains, which has not been accomplished previously. We identified 
biomarkers that influence fluoxetine response, which altogether, implicate the importance of cellular 
genesis in fluoxetine treatment. More broadly, this approach can be used to assess a wide range of drug 
response phenotypes that remain challenging to address using human samples. 
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